{"title": "PDF", "author": "PDF", "url": "https://ranf.com/wp-content/uploads/academicos/documentacion/numero/esteban_cv2018.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " 1                         Curriculum vitae           Nombre: Mariano Esteban Rodr\u00edguez     Fecha: Febrero 2018                                      2 Apellidos: ESTEBAN RODR\u00cdGUEZ           Nombre: MARIANO DNI:   12.666.094-V Fecha de nacimiento :   26/7/1944 Sexo:   V   SITUACI\u00d3N PROFESIONAL ACTUAL       Organismo: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS  Facultad, Escuela o Instituto: CENTRO NACIONAL DE BIOTECNOLOGIA Depto./Secc./Unidad estr.: Departamento de Biolog\u00eda Molecular y Celular Direcci\u00f3n postal: Campus Universidad Aut\u00f3noma. Darwin 3. 28049-Madrid Tel\u00e9fono (indicar prefijo, n\u00famero y extensi\u00f3n): (91) 585.45.53 Fax: (91) 585.4506     Correo electr\u00f3nico: mesteban@cnb.csic.es  Especializaci\u00f3n (C\u00f3digos UNESCO): 242007 Categoria profesional: Profesor de Investigaci\u00f3n Fecha de inicio: 1987 Situaci\u00f3n administrativa  X     Plantilla   Contratado   Interino   Becario   Otras situaciones  especificar:      \n  Dedicaci\u00f3n A tiempo completo X     A tiempo parcial     L\u00cdNEAS DE INVESTIGACI\u00d3N   Biolog\u00eda molecular y celular de poxvirus, interacci\u00f3n virus-c\u00e9lula, expresi\u00f3n g\u00e9nica, biolog\u00eda de sistemas, respuesta inmune, inmunomoduladores, citoquinas, interferones, vacunas, VIH/sida, malaria, leishmania, hepatitis C, chikungunya, ebola, c\u00e1ncer de pr\u00f3stata.     FORMACI\u00d3N ACAD\u00c9MICA    Titulaci\u00f3n Superior     Centro        Fecha Licenciatura en Farmacia Universidad de Santiago de Compostela 1967 Licenciatura en C. Biol\u00f3gicas Universidad de Santiago de Compostela 1972     Doctorado     Centro        Fecha  Dr. en Farmacia (Microbiolog\u00eda) Universidad de Santiago de Compostela 1970  3 ACTIVIDADES ANTERIORES DE CAR\u00c1CTER CIENT\u00cdFICO PROFESIONAL  Puesto Instituci\u00f3n Fechas Investigador Asociado National Inst. for Medical Research, Londres (UK) 1970-74 Instructor Rutgers Medical School (NJ) USA 1974-77 Profesor visitante Mol. Biol.Institut, University of Gent (B\u00e9lgica) 1978 Assistant Professor State University of New York, Medical School, NY 1979-1982 Associate Professor State University of New York, Medical School, NY  1982-1985 Professor State University of New York, Medical School, NY  1985-1992 A\u00f1o S\u00e1batico National Inst. for Medical Research, Londres (UK)  1987-1988 Director Centro Nacional de Biotecnolog\u00eda, CSIC, Madrid 1992-2003 Presidente Real Academia Nacional de Farmacia (RANF), Spain 2012-   Idiomas (R = regular,  B = bien,  C = correctamente)  Idioma Habla Lee Escribe Ingl\u00e9s  C C R  C C C  Franc\u00e9s R B R    PARTICIPACI\u00d3N EN PROYECTOS DE I+D FINANCIADOS EN CONVOCATORIAS P\u00daBLICAS     T\u00edtulo del proyecto: Mechanism of action of interferon Entidad financiadora: National Institutes of Health (NIH), USA Duraci\u00f3n,  desde: 1983  hasta: 1986 Investigador responsable: Mariano Esteban  T\u00edtulo del proyecto: Thymidine kinase and interferon action.  Entidad financiadora:  NIH (USA) Duraci\u00f3n,  desde:   1983 hasta:   1986 Investigador responsable:  Co-Principal Mariano Esteban  T\u00edtulo del proyecto: Mechanism of Antiviral Activity of Human Interferon Entidad financiadora:  Science and Technological Cooperation, Spain-USA Duraci\u00f3n,  desde: 1986   hasta:  1988 Investigador responsable: Mariano Esteban    T\u00edtulo del proyecto: Mechanism of action of interferon  Entidad financiadora:  NIH (USA) Duraci\u00f3n,  desde:  1986 hasta:   1992 Investigador responsable:   Mariano Esteban  4  T\u00edtulo del proyecto: Genetic variability and virulence of poxviruses  Entidad financiadora:  National Science Foundation (NSF), USA Duraci\u00f3n,  desde:  1987  hasta:  1991  Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Genetic markers and attenuation of vaccinia virus  Entidad financiadora:  Health Research Council of New York (USA) Duraci\u00f3n,  desde:  1986  hasta:  1987  Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Role of Poly A on virus induced inhibition of protein synthesis  Entidad financiadora:  NIH (USA) Duraci\u00f3n,  desde:  1987  hasta:   1990 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Pathogenesis of vaccinia virus  Entidad financiadora:  HSC (USA) Duraci\u00f3n,  desde:   1991 hasta:   1992 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Fusion proteins as immunogens against HIV infection Entidad financiadora:  NIH (USA) Duraci\u00f3n,  desde:   1992 hasta:   1995 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Prote\u00ednas de fusi\u00f3n como vacunas recombinantes contra el SIDA  Entidad financiadora:  CICYT Duraci\u00f3n,  desde:   1992 hasta:   1995 Investigador responsable:  Mariano Esteban  T\u00edtulo del proyecto: Uso de recombinantes atenuados de vaccinia como posible vacuna  contra Leishmaniasis  Entidad financiadora:  CAM Duraci\u00f3n,  desde:   1992 hasta:   1993 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Obtenci\u00f3n de vacunas recombinantes del virus vaccinia que  expresan prote\u00ednas (gp46 y gp63) protectoras a la infecci\u00f3n por Leishmania infantum. Entidad financiadora:  FIS Duraci\u00f3n,  desde:   1994 hasta:   1996 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: The role of intracellular membrane compartments in the assembly of viruses Entidad financiadora:  CE Human Capital and Mobility Duraci\u00f3n,  desde:   1994 hasta:   1997 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Desarrollo de estrategias para controlar la infecci\u00f3n por el virus de inmunodeficiencia human (VIH-1) Entidad financiadora:  CICYT Duraci\u00f3n,  desde:   1995 hasta:   1998 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Mecanismos reguladores de crecimiento y muerte celular por interferones  5 Entidad financiadora:  CICYT Duraci\u00f3n,  desde:   1996 hasta:   1999 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: European Action Progamme Against AIDS Entidad financiadora: CE Biomed Duraci\u00f3n,  desde:   1996 hasta:   1997 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: European vaccine against AIDS Entidad financiadora:  CE biomed 2. Programme PL 96-2515 Duraci\u00f3n,  desde:   1996 hasta:   1998 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Molecular and cellular principles of membrane virus biosynthesis and infection Entidad financiadora: European Union,  FMRX-CT98-0225  Duraci\u00f3n,  desde: 1998 hasta: 2001   Investigador responsable: Mariano Esteban    T\u00edtulo del proyecto: Malaria vaccine: attenuated influenza and vaccinia vectors Entidad financiadora:  NIH (USA). AI36526.05 Duraci\u00f3n,  desde:   1998 hasta:   2003 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Estrategias de terapia g\u00e9nica en las infecciones por VIH Entidad financiadora:  Comunidad de Madrid. 08.6/0020/1997 Duraci\u00f3n,  desde:   1998 hasta:   2001 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Mecanismo de inducci\u00f3n de apoptosis por los interferones: pap\u00e9l de las enzimas proteina quinasa (PKR) y sistema 2-5A sintetasa/RnasaL. Entidad financiadora: Ministerio de Educaci\u00f3n y Cultura, PM-98-0112 Duraci\u00f3n,  desde: 1999 hasta:2002    Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Modulaci\u00f3n de la respuesta inmune frente a ant\u00edgenos del virus de la inmunodeficiencia humana (VIH) Entidad financiadora: Comisi\u00f3n Interministerial de Ciencia y Tecnologia (CICYT), SAF98-0056, Duraci\u00f3n,  desde: 1998 hasta:   2001 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Development of immunogenic and safe vaccinia virus vaccines. Entidad financiadora: European Union. BIOTECH  Program . PL970456 Duraci\u00f3n,  desde:    1998 hasta:   2001 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: . Effector and memory anti-malaria CD8+ cell responses. Entidad financiadora: National Institutes of Health (NIH), 1 RO1  AI44375-01 Duraci\u00f3n,  desde:  1999 hasta:   2003 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Project Leader of the EuroVac Cluster, European Vaccine Effort Against HIV/AIDS Entidad financiadora: Fifth Framework Programme, QLRT-PL1999-01321 Duraci\u00f3n,  desde:2000 hasta:   2003 Investigador responsable:   Mariano Esteban   6 T\u00edtulo del proyecto: European Vaccine against AIDS Entidad financiadora: Programme EVA CFAR, QLRT-PL1999-00609 Duraci\u00f3n,  desde:  2000 hasta:   2003 Investigador responsable:   Mariano Esteban  T\u00edtulo del proyecto: Visceral Leishmaniasis Vaccine-Murine Model Studies Entidad financiadora: National Institutes of Health (NIH),  5R01AI45044-02 Duraci\u00f3n,  desde: 1999                             hasta: 2003   Investigador responsable: Mariano Esteban  T\u00edtulo del proyecto: Desarrollo de una vacuna contra Leishmaniasis Entidad financiadora: Comunidad Autonoma de Madrid (CAM),  08.2/0057/2000  Duraci\u00f3n,  desde: 2001 hasta: 2003   Investigador responsible: Mariano Esteban  T\u00edtulo del proyecto: Desarrollo de una vacuna contra Leishmaniasis Entidad financiadora: Comunidad Autonoma de Madrid (CAM),  08.2/0057/2000  Duraci\u00f3n,  desde: 2001 hasta: 2003   Investigador responsible: Mariano Esteban  Principal investigator. Desarrollo de una vacuna contra leishmaniasis. Comunidad Aut\u00f3noma de Madrid (CAM) 08.2/0057/2000-2001.   Project Leader of the EuroVac Cluster, European Vaccine Effort Against HIV/AIDS, Fifth Framework Programme, QLRT-PL1999-01321, Euros 500.000, 2000-2005   Concerted Action, Fifth Framework Programme, European Vaccine against Aids (EVA) CFAR, QLRT-PL1999-00609, 2000-2003.  Principal investigator. Contract with MOLOGEN, Germany, 2000-2001  Principal investigator. Contract with ITALFARMACO, Spain, 2001  Principal investigator. Premio IBERDROLA Ciencia y Tecnolog\u00eda, Profesores Visitantes, 2000-2003  Principal Investigator. Desarrollo de nuevas herramientas moleculares para el estudio del virus de la hepatitis C y su aplicaci\u00f3n a morfog\u00e9nesis, estructura, resistencia del virus a interferon y caracterizaci\u00f3n de la respuesta inmune al virus. BIO2000-0340-P4, 2001-2003. 171.649 Euros.  Principal investigator. Dise\u00f1o y utilizaci\u00f3n del virus vaccinia como vacuna contra distintas enfermedades: an\u00e1lisis de la interacci\u00f3n virus-c\u00e9lula y modulaci\u00f3n de la respuesta inmune. BIO2001-2269, 2001-2003, 170.000 Euros   Principal investigator. Analysis of the molecular mechanism of hepatitis C virus (HCV) resistance to antiviral therapy. EU QLK2-CT-2002-00954. 2002-2005, 124.313 Euros  Coordinator. Increasing the potency of vaccinia MVA vaccines. EU QLK2-CT-2002-01867. 2002-2006. 220.000 Euros  Principal investigator. European vaccine effort against HIV/AIDS (EuroVac III). QLK2-CT-2002-01431. 2002-2007. 50.000 euros  Principal investigator. Potenciaci\u00f3n de la respuesta inmune (sist\u00e9mica y de mucosas) frente al virus de la inmunodeficiencia humana (VIH-1). FIPSE, 2002-2006, 209.365 Euros  Principal Investigator. Vaccine strategies for combined targeting of innate and adaptive immune pathways  7 (VaccTIP). EU-2004-012161. 2005-2007. 177.000 euros  Principal Investigator. Host immune activation optimised vaccinia virus vectors for vaccine development (MVACTOR). LSHP-CT-2006-037536. 2006-2009. 175.000 euros  Principal investigator. Dise\u00f1o de nuevas vacunas tanto preventivas como terap\u00e9uticas para las enfermedades de mayor prevalencia: sida, hepatitis C y c\u00e1ncer de pr\u00f3stata. BIO2004-03954. 2004-2007. 180.000 euros.  Principal Investigator. Desarrollo de vacunas contra enfermedades prevalentes. Fundaci\u00f3n Bot\u00edn  2005-2010. 1.100.000 euros.  Principal Investigator. Caracterizaci\u00f3n funcional y utilizaci\u00f3n de la prote\u00edna quinasa (PKR) inducida por los interferones como mediador de apoptosis e inhibidor tumoral. 2005-2008. 150.000 euros.  Principal Investigator. Pox T cell vaccine Discovery Consortium (PTVDC). Foundation Bill y Melinda Gates. $1.500.000. 2006-2013.  Principal Investigator. Red de SIDA, ISCIII-RETIC-RD06/006. 2007-2010. 248.000 euros.  Principal Investigator. Modificaci\u00f3n genetica y optimizaci\u00f3n inmunol\u00f3gica de una vacuna (MVA-B) contra el VIH-1 subtipo B. Fundaci\u00f3n para la Investigaci\u00f3n y la Prevenci\u00f3n del Sida (FIPSE). 2007-2009. 172.374 euros  Principal Investigator. Biolog\u00eda del virus vaccinia y su aplicaci\u00f3n como vacuna contra enfermedades prevalentes. SAF2008-02036. 2008-2013. 654.000 euros  Principal Investigator. Optimizaci\u00f3n de la vacuna espa\u00f1ola (MVA-B) contra el VIH/SIDA. Fundacion para la Investigaci\u00f3n y la Prevenci\u00f3n del Sida (FIPSE). 36-0731-09. 2010-2013. 259.391 euros  Co-Principal Investigator. Estudio en fase I abierto para evaluar la seguridad e inmunogenicidad de la vacuna frente al VIH-1 MVA-B en pacientes infectados por VIH cr\u00f3nicos en tratamiento antirretroviral (RISVAC03). EudraCT 2099-016578-34.  2010-2011. 411.000 euros  Co-Principal Investigator. Desarrollo de una vacuna frente al VIH: Estudio de los cambios en la biolog\u00eda de c\u00e9lulas dendr\u00edticas humanas tras interacci\u00f3n con distintos inmun\u00f3genos. Fondo de Investigaciones Sanitarias (FIS). 2010-2013. 227.000 euros  Principal Investigator. Desarrollo y optimizaci\u00f3n de vectores virales vacunales contra subtipos B/F de VIH-1 circulantes en Argentina y pa\u00edses lim\u00edtrofes.  Cooperaci\u00f3n Interuniversitaria en Investigaci\u00f3n Cient\u00edfica con Argentina. A/025293/09. 2010-2011. 23.000 euros  Coinvestigator. Red Tem\u00e1tica en SIDA. ISCIII-RETIC, RD12/0017/0038. 2013\u20142017. 178.250 euros  Principal Investigator. A Novel Replication Competent Flavivirus-based HIV Vaccine Platform, ie RepliVax\u00ae, as a Priming Component for Improving Antibody Response. Foundation Bill and Melinda Gates. 2012-2017. 510.000 euros.  Principal Investigator. ICRES: Integration of Chikungunya Research. EU 7th Framework Program. Grant agreement 261202. 2011-2014. 50.000 euros.  Principal Investigator. Mecanismo de acci\u00f3n de vacunas. CSIC-201420E064. 2014-2017. 135.000 euros  Principal Investigator. Vacunas frente a enfermedades humanas prevalentes y optimizaci\u00f3n de la respuesta immune humoral y cellular. 2014-2017. SAF2013-45232-R. 592.900 euros   8 Principal Investigator. European HIV Vaccine Alliance (EHVA): an EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates. EU H2020. 2016-2020. 415.000 euros  Principal Investigator. Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en Salud: Red Espa\u00f1ola de Investigaci\u00f3n en Sida (RIS). RD16/0025/0014. 2017-2021. 132.000 euros.  Principal investigator. Evaluating a combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection (HIVACAR). H2020-73126. 2017-2021. 408.000 euros  Principal investigator. Vacunas frente a enfermedades humanas prevalentes: papel de ISG15. SAF2017-88089-R. 2017-2020. 332.000 euros.         PUBLICACIONES  1. Kerr, I.M., Dobos, P., Martin, E.M., Metz, D.H. and Esteban, M. (1972). Protein synthesis in interferon-treated and virus infected cells.  Federation of European Biochemical Societies Academic Press. Vol. 22:45-64.  2. Metz, D.H. and Esteban, M. (1972). Interferon inhibits viral protein synthesis in L-cells infected with vaccinia virus.  Nature 238:385-388   3. Friedman, R.M.; Esteban, M., Metz, D.H., Tovell, D.R. and Kerr, I.M. (1972). Translation of RNA by L-cell extracts:  Effect of interferon.  FEBS Letters 24:273-77.  4. Friedman, R.M., Metz, D.H. Esteban, R.M., Tovell, D.R., Ball, L.A., and Kerr, I.M. (1973). Mechanism of interferon action.  Inhibition of viral messenger ribonucleic acid (RNA) translation in L-cell extracts.  J. Virol. 10: 1184-1198.  5. Esteban, M. and Metz, D.H.  (1973). Early viral protein synthesis in vaccinia infected L-cells. J. Gen. Virol. 19:201-216 .  6. Esteban, M. and Metz, D.H.(1973).  Inhibition of early vaccinia virus protein s y n t h e s i s  i n  interferon-treated chicken embryo fibroblasts. J. Gen. Virol. 20:111-115.  7. Fournier, F., Tovell, D.R., Esteban, M., Metz, D.H., Ball, L.A., and Kerr, I.M.  (1973). The translation of vaccinia mRNA in animal cell-free systems.  FEBS Letters 30:268-272 .  8. Kerr, I.M. Friedman, R.M., Esteban, M., Brown, R.E., Ball, L.A., Metz, D.H., Risby, D., Tovell, D.R., and Sonnabend, J.A.  (1973) The control of protein synthesis in interferon-treated infected cells.  In \"Advances in the Biosciences\" ll Pergamon Press. Vieweg, 109-126.   9. Esteban, M. and Kerr, I.M.  (1974) The synthesis of Encephalomyocarditis virus polypeptides in infected L-cell and cell-free systems.  Eur. J. Biochem. 45:567-576.  10. Metz, D.H., Esteban, M., and Danielescu, G.  (1975) The effect fo interferon on the formation of virus polyribosome in L-cell infected with vaccinia virus.  J. Gen. Virol. 27:197-209.  11. Metz, D.H., Esteban, M., and Danielescu, G.  (1975) The formation of polyribosomes in L-cells infected with vaccinia virus.  J. Gen. Virol. 27:181-195  9  12. Esteban, M. (1975). Interferon inhibits the translation of viral mRNA in animal cell-free systems.  In \"Effects of interferon on cells, viruses and the Immune System\", ed. Geraldes (Academic Press, London) 549-562.  13. Esteban, M.  (1977). Rifampicin and Vaccinia DNA.  J. Virol. 21:796-801.  14. Esteban, M. and Holowczak, J.A.  (1977). Replication of vaccinia DNA in mouse L cells.  I. In vivo DNA synthesis.  Virology 78:57-75.  15. Esteban, M.  and Holowczak, J.A.  (1977). Replication of vaccinia DNA in mouse L-cells.  I. In vitro DNA synthesis in cytoplasmic extracts.  Virology 78:76-86.  16. Esteban, M. and Holowczak, J.A.  (1977). Replication of vaccinia DNA in mouse L-cells. III. Intracellular forms of vaccinia DNA.  Virology 82: 308-322 .  17. Esteban, M., Flores, L. and Holowczak, J.A.  (1977)  Model for vaccinia virus DNA replication.  Virology 83: 467-473.  18. Esteban, M., Flores, L. and Holowczak, J.A.  (1977). Topography of vaccinia virus DNA. Virology 82; 163-181.  19. Esteban, M. and Holowczak, J.A.  (1978).  Replication of vaccinia DNA in mouse L-cells.  IV. Protein synthesis and viral DNA replication.  Virology 86:376-390 .  20. Cabrera, C.V. and Esteban, M.  (1978). A simple procedure to purify intact -DNA from vaccinia virus. J. Virol. 25: 442-445 .  21. Soloski, M.J., Esteban, M. and Holowczak, J.A.  (1978). DNA-binding proteins in the cytoplasm of vaccinia infected mouse L-cells. J. Virol. 25: 263-273.  22.  Mc Carron, R.J., Cabrera, C.V., Esteban, M., Mc Allister, W.T. and Holowczak, J.A.  (1978). Structure of vaccinia DNA: Analysis of the viral genome by restriction endonucleases. Virology 86: 88-101 .  23. Cabrera, C.V., Esteban, M., Mc Carron, R.J., Mc Allister, W.T and Holowczak, J.A. (1978). Vaccinia virus transcription:  Hybridization of mRNA to restriction fragments of vaccinia DNA.  Virology 86: 102-114.  24. Bablanian, R. Esteban,  M., Baxt, B. and Sonnabend, J.A.  (1978). Studies on the mechanism of vaccinia virus cytophatic effects: I.  Inhibition of protein synthesis in infected cell is associated with virus-induced RNA synthesis. J. Gen. Virol. 39: 39l-402 .  25. Bablanian, R., Baxt, B., Sonnabend, J.A., and Esteban, M.  (1978). Studies on the mechanism of vaccinia virus cytophatic effects: II.  Early cell rounding is associated with virus polypeptide synthesis.  J. Gen. Virol. 39: 403-413.  26. Esteban, M., Soloski, M., Cabrera, C.V. and Holowczak, J.A. (1979). Replication of vaccinia DNA and studies on the structure of the virus chromosome.  Cold Spring Harbor Symposia Quantitative Biology.  Vol. XLIII. DNA: Replication and recombination. 789-799.  27. Soloski, M.J., Cabrera, C.V., Esteban, M. and Holowczak, J.A.  (1979). Studies concerning the structure and organization of the vaccinia virus nucleoid. Virology 99, 209-217.  28. Esteban, M. and Holowczak, J.A.  Vaccinia virus DNA replication. (1980).  In \"Microbiology\" (ed. D. Schlesinger) ASM publication 275-280.  10  29. Bablanian, R., Coppola, G., Scribani, S. and Esteban, M.  (1981). Inhibition of p r o t e i n  synthesis by vaccinia virus.  The effect of UV-irradiated virus in the inhibition of protein synthesis. Virology 112, 1-12.  30. Bablanian, R., Coppola, G., Scribani S. and Esteban, M.  (1981). Inhibition of protein synthesis by vaccinia virus.  The role of low molecular weight viral, RNA in the inhibition of protein synthesis.  Virology 112, 13-24.  31. Carrasco, L. and Esteban, M. (1982). Modification of membrane permeability in vaccinia virus-infected cells.  Virology 117, 62-69 .  32. Pellicer, A. and Esteban, M.  (1982). Gene-transfer, stability and biochemical p r o p e r t i e s  o f  animal cells transformed with vaccinia DNA.  Virology 122, 363-380   33. Santoro, M.G., Jaffe, B.M., Garaci, E. and Esteban, M. (1982). Antiviral effect of prostaglandins of the A series:  Inhibition of vaccinia virus replication in cultured cells. J. Gen. Virol. 63, 435-440.  34. Lewis, J.A., Mengheri, E. and Esteban, M.  (1983). Induction of an antiviral state by interferon requires thymidine kinase.  Proc. Natl. Acad. Sci. USA 80, 26-30.  35. Mengheri, E., Esteban, M. and Lewis, J.A. (1983). Thymidine kinase genes and the induction of an antiviral response.  FEBS Letters 157, 301-305.  36. Esteban, M., Cabrera, C. and Holowczak, J.A. (1983).  Electron microscopic studies of transcriptional complexes released from vaccinia cores during RNA-synthesis in vitro: methods for fractionation of transcriptional complexes.  J. Virol. Methods 7, 73-92.  37. Santoro, G., Jaffe, B.M. and Esteban, M.  (1983). Prostaglandin A inhibits the replication of vesicular stomatitis virus: effect on virus glycoprotein. J. Gen. Virol. 64, 2797-2801.  38. Santoro, G.M., Jaffe, B., Paez, E. and Esteban, M.  T (1983). The relationship between the antiviral action of interferon and prostaglandins in virus-infected murine cells. Biochem. Biophys. Res. Commun. 116, 442-448.  39. Benavente, J., Esteban, M., Jaffe, B. and Santoro, G.M.  (1984). Selective inhibition of viral gene expression as the mechanism for the antiviral action of PGA1 in vaccinia virus-infected cells, J. Gen. Virol. 65, 599-608.  40. Esteban, M. (1984). Analysis of replicating vaccinia DNA in interferon treated, virus infected cells. J. Interferon Research 4, 179-192.  41. Esteban, M. (1984).  Defective vaccinia virus particles in interferon-treated, i n f e c ted cells. Virology 133, 220-227.  42. Boni, C., Esteban, M. and Pellicer, A.  (1984). Expression of cloned vaccinia DNA sequences introduced into animal cells.  J. Gen. Virol 65, 1245-1251.  43. Esteban, M., Benavente, J. and Paez, E. (1984). Effect of interferon on integrity of vaccinia virus and ribosomal RNAs in infected cells.  Virology 134, 40-51.  44. Paez, E. and Esteban, M. (1984). Resistance of vaccinia virus to interferon is r el at ed t o an interference phenomenon between the virus and the interferon system. Virology 134, 12-28.   11 45. Paez, E. and Esteban, M. (1984). Nature and mode of action of vaccinia virus products that block activation of the interferon-mediated ppp(A2'p)nA-synthetase.  Virology 134, 29-39.  46. Lewis, J.A. and Esteban, M. (1984).  Induction of an antiviral response and 2',5'oligo A synthetase by interferon in several thymidine kinase deficient cell-lines.  Virology 134, 464-469.  47. Benavente, J., Paez, E. and Esteban, M.  (1984). Indiscriminate degradation of R N A s  i n  interferon-treated, vaccinia virus infected mouse L cells.  J. Virol 51, 866-871.  48. Paez, E and Esteban, M. (1985).  Interferon inhibits marker rescue of vaccinia v i r u s .   J .  Interferon Research 5, 247-256.  49. Esteban, M. and Paez E.  (1985). Antiviral and antiproliferative properties of i n t e r f e r o n s :  Mechanism of action.  Progress in Medical Virology; ed. J. Melnick vol. 32, 159-173.  50. Perucho, M. and Esteban, M. (1985).  Inhibitory effect of interferon on the g e n e t i c  a n d  oncogenic transformation by viral and cellular genes.  J. Virol 54, 229-232.  51. Paez, E., Dallo, S. and Esteban, M. (1985). In vivo generation of a dominant 8 Md deletion at the left terminus of vaccinia DNA. Proc. Natl. Acad. Sci. U.S.A. 82, 3365-3369.  52. Paez, E. and Esteban, M.  (1985). Interferon prevents the generation of spontaneous deletions at the left terminus of vaccinia DNA.  J. Virol. 56, 75-84.  53. Esteban, M., C a b r e r a ,  C . V .  a n d  H o l o w c z a k ,  J . A .  ( 1 9 8 5 ) .   B i o c h e m i c a l  a n d e l e c t r o n  microscopic studies of the transcription of vaccinia DNA by RNA polymerase from E. coli:  Localization and characterization of trancriptional complexes.  J. Virol. Methods 12, 111-133.  54. Rodriquez, J.F., Janeczko, R. and Esteban, M. (1985).  Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J. Virol. 56, 482-488.  55. Esteban, M. and Paez, E. (1985).  The 2-5A system and vaccinia virus.  Prog. Clin. Biol Res 202, 25-34.   56. Esteban, M., Benavente, J. and Paez, E. (1986).  Mode of sensitivity and resistance of vaccinia virus replication to interferon.  J. Gen. Virol. 67, 801-808.  57. Rodriquez, J.F., Kahn, J. and Esteban, M. (1986).  Molecular cloning, e n c o d i n g s e q u e n c e s  and expression of the nucleic acid dependent phosphohydrolase gene of vaccinia virus.  Proc. Natl. Acad. Sci. USA 83, 9566-9570.  58. Esteban, M. and Paez, E. (1986).  Mechanism of antiproliferative action of i n t e r f e r o n :  prevention of DNA sequence alterations.  In \"Interferons as cell growth inhibitors and antitumor factors:  UCLA symposia on Molecular and Cellular Biology.  Alan R. Liss, Inc. New York pp 4-15.  59. Paez, E. and Esteban, M. (1987).  Inhibition of host protein synthesis by DNA viruses (Adenovirus, Herpesvirus and Poxvirus):  Mechanism of action. In \"Mechanisms of Viral Toxicity in Animal Cells.\" (ed. L. Carrasco).  CRC Press publication pp. 59-90.  60. Zabagno, G., Jaffe, B. and Esteban, M. (1987).  Role of Prostaglandins and Nonsteroidal Anti-Inflamatory Drugs in the Pathogenicity of Vaccinia Virus.  J. Gen. Virol. 68, 593-600.  61. Janeczko, R., Rodriguez, J.F. and Esteban, M. (1987).  Studies on the mechanism of entry of vaccinia virus in animal cells.  Archives of Virology 92, 135-150.   12 62. Rodriquez, J.F., Paez, E. and Esteban, M. (1987).  A 14,000 Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers.  J. Virol 61, 395-404.  63. Dallo, S., Esteban, M. (1987).  Isolation and characterization of attenuated mutants of vaccinia virus.  Virology 159, 408-422.  64. Dallo, S., Rodriguez, J.F. and Esteban, M. (1987).  A 14K envelope protein of vaccinia virus with an important role in virus-host cell interactions is altered during virus persistence and determines the plaque size phenotype of the virus.  Virology 159, 408-422.  65. Paez, E., Dallo, S. and Esteban, M. (1987).  Virus attenuation and identification of structural proteins of vaccinia virus that are selectively modified during virus persistence.  J. Virol. 61, 2642-2647.  66. Rodriguez, J.F. and Esteban, M. (1987).  Mapping and nucleotide sequence of the vaccinia virus gene that encodes a 14K fusion protein.  J. Virol. 61, 3550-3554.  67. Maa, J-S, and Esteban, M. (1987).  Structural and functional studies of a 39,000 Mr immunodominant protein of vaccinia virus. J. Virol. 61, 3910-3919.  68. Paez, E. and Esteban, M. (1987).  Resistance of vaccinia virus to interferons: Modulation of the 2-5A system in interferon-treated, vaccinia virus infected cells. Microbiologia SEM 3, 163-178.  69. Rodriguez, J.F., Rodriguez, D., Rodriguez, J-R., McGowan, E. and Esteban,M. (1988). Expression of the firefly luciferase gene in vaccinia virus: A highly sensitive gene marker to follow virus dissemination in tissues of infected animals.  Proc. Natl. Acad. Sci. USA 85, 1667-1671.  70. Paez, E. and Esteban, M. (1988).  Stability of vaccinia virus DNA during persistent infections:  Accumulation of left-end deletions and of tandem repeats at both ends of the viral genome and prevention by interferon. Virology 163 145-154.  71. Bablanian, AR., Goswani, S.K., Esteban, M. and Banerjee, A.K. (1988). Selective inhibition of protein synthesis by synthetic and vaccinia virus-core synthesized poly (riboadenylic acids).  Virology 161, 366-373.  72. Feduchi, E., Esteban, M. and Carrasco, L. (1988).  Reovirus Type 3 synthesizes proteins in interferon-treated Hela cells without reversing the antiviral state.  Virology 164, 420-426.  73. Santoro, G., Favalli, C., Mastino, A., Jaffe, B.M., Esteban, M. and Garaci, E. (1988). Antiviral activity of a synthetic analog of prostaglandin A in mice infected with influenza A virus.  Arch. Virology 99, 89-100.  74. Rodriguez, J.F. and Esteban, M. (1989).  The plaque size phenotype as a selectable marker in the selection of recombinants of vaccinia virus.  J. Virol. 63, 997-1001.  75. Rodriguez, D., Rodriguez, J-R., Rodriguez, J.F., Trauber, D. and Esteban, M. (1989). Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses Proc. Natl. Acad. Sci. USA 86, 1287-1291.  76. Portela, A., Rodriguez, J.R., Rodriguez, D., Rodriguez, J.F., Garcia-Barreno, B., Melero, J.A. and Esteban, M. (1989).  Expression of the fusion(F) protein of human respiratory syncytial virus using an attenuated strain of vaccinia virus.  In Genetics and Pathogenicity of Negative Strand Viruses. ( A. Flamand, D. Kolakofsky and B.W.J. Mahy, ed) pp 74-78.  Elsevier Science Pub. N.Y.  13  77. Dallo, S., Maa, J-S., Rodriguez, J.R., Rodriguez, D. and Esteban, M. (1989).  Humoral immune response elicited b y  h i g h l y  a t t e n u a t e d  v a r i a n t s  o f  v a c c i n i a  v i r u s  a n d  b y  a n  a t t e n u a t e d  recombinant expressing HIV-1 envelope protein.  Virology 173, 323-329.  78. Gong, S., Lai, C., Dallo, S. and Esteban, M. (1989).  A single point mutation Asp for Ala-25 in the 14KDa membrane p r o t e i n  o f  v a c c i n i a  v i r u s  i n d u c e s  a  s i z e  c h a n g e  t h a t  l e a d s  t o  s m a l l  plaque-size phenotype of the virus.  J. Virol. 63, 4507-4514.  79. Maa, J-S., Rodriguez, J-F. and Esteban, M. (1990).  Structural and functional characterization of a cell surface binding protein of vaccinia virus.  J. Biol. Chem. 265, 1569-1577.  80. Gong, S., Lai, C. and Esteban, M. (1990).  Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14 Kda virus envelope protein.  Virology 178, 81-91.  81. Lai, C., Gong, S. and Esteban, M. (1990).  Structural and functional properties of the 14 KDa envelope protein of vaccinia virus synthesized in Escherichia coli. J. Biol. Chem. 265, 22174-22180.  82. Rodriguez, D., Zhou, Y., Rodriguez, J.R., Durbin, R.K., Jimenez, V., McAllister, W.T. and Esteban, M. (1990).  Regulated expression of nuclear genes by T3 RNA polymerase and lac repressor using recombinant vaccinia virus vectors.  J. Virol. 64, 4851-4857.  83. Kahn, J. and Esteban, M. (1990).  Identification of the point mutation in two vaccinia virus nucleoside triphosphate phosphohydrolase 1 temperature-sensitive mutants and role of this DNA-dependent ATPase enzyme in virus gene expression.  Virology 74, 459-471.   84. Lai, C., Gong, S. and Esteban, M. (1991).  The 32 KDa envelope protein of vaccinia virus synthesized in Escherichia coli binds with specificity to cell surfaces.  J. Virol. 65, 499-504.  85. Rodriguez, D., Rodriguez, J.R., Ojakian, G.K. and Esteban, M. (1991).  Vaccinia virus preferentially enters polarized epithelial cells through the basolateral surface.  J. Virol. 65, 494-498.  86. Rodriguez, J.R., Rodriguez, D. and Esteban, M. (1991).  Structural properties of HIV-1 envelope fused with the 14 KDa vaccinia virus envelope protein. Virology 181, 742- 748.  87. Bablanian, R . ,  G o s w a m i ,  S . K . ,  Esteban, M., Banerjee, A.K. and Merrick, W.C. (1991). Mechanism of selective translation of vaccinia virus mRNAs:  Differential role of poly A and initiation factors in the translation of viral and cellular mRNAs.  J. Virol. 65, 4449-4460.  88. Lai, E., Gong, S. and Esteban, M. (1991).  The purified 14KDa envelope protein of vaccinia virus produced in E.coli induces virus immunity in animals.  J. Virol. 65, 5631-5635.  89. Rodriguez, J-R., Rodriguez, D. and Esteban, M. ( 1 9 9 1 ) .   Interferon treatment inhibits early events in vaccinia virus gene expression in infected mice.  Virology 185, 929- 933.  90. Demkowicz, W.E., Maa, J-S and Esteban, M. (1992).  Identification of vaccinia genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans.  J. Virol. 66, 386-398.  91. Rodriguez, D., Rodriguez, J-R and Esteban, M. (1992).  Insertional inactivation of the vaccinia virus 32-Kilodalton gene is associated with attenuation in mice and reduction of viral gene expression in polarized epithelial cells.  J. Virol. 66, 183-189.   14 92. Lee, S.B., Melkova, Z., Yan, W., Williams, B.R.G., Hovanessian, A. and Esteban, M. (1993).  The interferon-induced double-stranded RNA-activates human p68 protein kinase potently inhibits protein synthesis in cultured cells.  Virology 192., 380-385.  93. Lee, S.B. and Esteban, M. ( 1 9 9 3 ) .   T h e  i n t e r f e r o n-induced double-stranded RNA- a c t i v a t e d  human p68 protein kinase inhibits the replication of vaccinia virus.  Virology 193, 1037-1041  94. McMahon-Pratt, D., Rodriguez, D., Rodriguez, J.R., Zhang, Y., Manson, K., Bergman, C., Rivas, L., Rodriguez, J-F., Lohman, K.L., Ruddle, N.H. and Esteban, M. (1993). Recombinant GP46/M-2 vaccinia viruses protect against Leishmania infection.  Infect. and Immun.61, 3351-3359..  95. Rodriguez, D., Rodriguez, J-R. and Esteban, M. (1993).  The vaccinia 14KDa fusion protein forms a complex with the processed protein encoded by the vaccinia virus A17L gene.  J. Virol. 67 ,3435-3440.  96. Li, S., Rodrigues, M., Rodriguez, D., Rodriguez, J.R., Esteban, M., Palese, P., Nussenzweig, R.S. and Zavala, F. (1993). Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA 90, 5214-5218.   97. Diaz-Guerra, M. and Esteban, M. ( 1 9 9 3 ) .   Vaccinia virus nucleoside triphosphate phosphohydrolase I (NPH-I) controls early and late gene expression by regulating the rate of transcription. J. Virol. 67, 7561-7572.   98. Diaz-Guerra, M., Kahn, J . S .   and Esteban, M. ( 1 9 9 3 ) .   A  m u t a t i o n  o f  t h e  n u c l e o s i d e  triphosphate phosphohydrolase I (NPH-I) gene confers sensitivity of vaccinia virus to Interferon. Virology, 197, 485-491.  99. Bablanian, R., Scribani, S, and Esteban, M (1993). Amplification of polyadenylated small RNA sequences (POLADS) during superinfection correlates with the inhibition of viral and cellular protein synthesis. Cell. Mol. Biol. Res. 39, 243-255  100. Melkova, Z. and Esteban, M. (1994). Interferon-gamma severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology 198, 731-735.  101. Lee. S.B. and Esteban, M. (1994). The interferon-induced human protein kinase (p68 kinase) induces apoptosis. Virology  199, 491-496.  102. Lee, S.B., Green, S., Mathews, M.B and Esteban, M. (1994). Activation of the double-stranded (dsRNA)-activated human protein kinase in vivo in the absence of its dsRNA binding domain. Proc. Natl. Acad. Sci. USA 91, 10551-10555.  103. Rodrigues, M., Li, S., Rodriguez, D., Rodriguez, J.R., Bacik,I., Bennink, J.R., Yewdell, J.W., Garcia-Sastre, A., Esteban, M., Palese, P., Nussenzweig, R.S and Zavala, F. (1994). Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes: Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol.153, 4636-4648  104. Rodriguez, D., Rodriguez, J.R and Esteban, M. (1995). Enhanced proteolytic processing of the human immunodeficiency virus type I envelope protein in murine Ltk(-) cells. AIDS Res. and Human Retrovirus  11, 81-85  105. Miyahira, Y., Murata, K., Rodriguez, D., Rodriguez, J.R., Esteban, M., Rodrigues, M and Zavala, F.(1995). Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J. Immunol. Methods 181, 45-54.                   15  106. Sodeik, B., Ericson, M., Esteban, M., Niles, E.G and Griffiths, G. (1995). Assembly of vaccinia virus: Incorporation of two membrane proteins into the intracellular mature virus. J. Virol. 69, 3560-3574.  107. Rodriguez, D., Esteban, M and Rodriguez, J.R (1995). Vaccinia virus    A17L gene product is essential for an early step in virion morphogenesis. J. Virol. 69, 4640-4648.  108. Esteban, Mariano (1995). Vaccinia virus vectors as potential vaccines against malaria. In \" Combating Malaria\" UNESCO/WHO, 65-74  109. Melkova, Z and E s t e b a n ,  M . ( 1 9 9 5 ). Inhibition of vaccinia virus replication by inducible expression of nitric oxide synthase. J. Immunol  155, 5711-5718.  110. Rodriguez, J.R., Rodriguez, D and Esteban, M. (1996). Poxvirus: su utilizaci\u00f3n como vacunas. En Microbiologia y Gen\u00e9tica Molecular. Editado por J. Casades\u00fas y F. Ruiz-Berraquero. Secretariado de la Universidad de Sevilla. Vol II, pp 821-847.  111. Suarez, P., Diaz-Guerra, M., Prieto, C., Esteban, M., Castro, J.M., Nieto, A and Ort\u00edn, J. (1996). Open reading frame 5 of porcine reproductive and respiratory syndrome virus as a cause of virus-induced apoptosis. J. Virol. 70, 2876-2882.  112. Murata, K., Garcia-Sastre, A., Tsuji,M., Rodrigues, M., Rodriguez, D., Rodriguez, J-R., Nussenzweig, R., Palese, P., Esteban, M and Zavala, F (1996). Characterization of the in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell. Immunol.173, 96-107  113. Rodriguez, D., Risco, C., Rodriguez, J.R., Carrascosa,, J.L and Esteban, M (1996).  Inducible expression of vaccinia virus A17L gene provides a synchronized system to monitor sorting of viral proteins during morphogenesis. J. Virol.70, 7641-7653.       114. Esteban, M., Rodriguez, D., Jimenez, V and Rodriguez, J.R (1996). Use of persistent infections with vaccinia virus recombinants to introduce alterations in foreign proteins: an aplication to HIV-1 env protein. Virus Research. 46, 45-56  115. Martin-Gallardo, A., Moratilla, M., Funes, J.M., Agromayor, M., Nu\u00f1ez, A., Varas, A.J., Collado, M., Valencia, A., Lopez-Estebaranz and Esteban, M.  (1996). Sequence analysis of Mollucum Contagiosum virus DNA region which includes the gene encoding protein kinase 2 and other genes with unique organization. Virus Genes 13, 19-29  116. Brun, A., Rivas, C., Esteban, M., Escribano, J.M and Alonso, C. (1996). African Swine Fever Virus gene A179L, a viral homologue of bcl-2 protects cells from programme cell death. Virology 225, 227-230  117. Lee, S.B., Bablanian, R and Esteban, M (1996).  Regulated expression of the interferon-induced protein kinase p68(PKR) by vaccinia v i r u s  r e c o m b i n a n t s  i n h i b i t  t h e  r e p l i c a t i o n  o f  vesicular  stomatitis virus but not that of poliovirus. J. Interferon and Cytokine Res. 16, 1073-1078.  118. Nu\u00f1ez, A., Funes, J.M., Agromayor, M., Moratilla, M., Vara, J., Lopez-Estebaranz, J. L., Esteban, M and Mart\u00edn-Gallardo, A (1996). Detection and typing of Molluscum Contagiosum virus in skin lesions by using a simple lysis method and polymerase chain reaction. J. Medical Virology  50, 342-349.  119. Schwanig, M., Esteban, M., Ghislain C., Grandjean, Y., Jepsen, S and Roumiantzeff, M (1996). Models for scientific and economic interaction in vaccines R&D. Vaccine 14, 582-610.  16  120. Cudmore, S., Blasco, R., Vincentelli, R., Sodeik, B., Esteban, M., Griffiths, G and Krijnse-Locker, J (1996). A vaccinia virus core protein, p39, is membrane associated. J. Virol. 70, 6909-6921  121. Diaz-Guerra, M., Melkova, Z., and Esteban, M (1996). Inducible expression of the 2-5A synthetase/RNase L system results in  inhibition of vaccinia virus replication. Virology 226,220-228.  122. Taylor, D.R., Lee, S.B., Romano, P. R., Marshak, D. R., Hinnebusch, A. G., Esteban, M and Mathews, M. B (1996).  Authophosphorylation sites participate in the activation of the double-stranded RNA-activated protein kinase PKR. Mol. Cell. Biol. 16, 6295-6302   123. Moratilla, M . ,  A g r o m a y o r ,  M . ,  N u \u00f1 e z ,  A . ,  F u n e s ,  J . M . ,  V a r a s ,  A . ,  L o p e z-Estebaranz, J., Esteban, M and Martin-Gallardo, A (1997). A random DNA sequencing computer based approach for the generation of a gene map of Molluscum Contagiosum virus. Virus Genes 14, 75-82  124. Rodriguez, J.R., Risco, C., Carrascosa, J. L., Esteban, M a n d  R o d r i g u e z ,  D  ( 1 9 9 7 ) .  Characterization of early stages of vaccinia virus membrane biogenesis: implication of the 21 kDa and a newly identified 15 kDa envelope protein. J. Virol. 71, 1821-1833  125. Lee, S.B., Rodriguez,D., Rodriguez, J.R and Esteban, M ( 1 9 9 7 ) .  The apoptosis pathway triggered by the interferon-induced protein kinase PKR is independent of eIF-2a phosphorylation, is initiated upstream of bcl-2 and involves ICE/CED3-like proteases. Virology  231, 81-88  126. Melkova, Z., Lee, S.B and Esteban, M (1997). Bcl-2 prevents nitric oxide-mediated apoptosis  and poly(ADP-ribose)polymerase cleavage. FEBS Letters 403, 273-278.  127. Diaz-Guerra, M., Esteban, M and Martinez, J.L (1997). Growth of E. coli in acetate as a sole carbon source is inhibited by ankyrin-like repeats present in the  2',5'-linked oligoadenylate-dependent human RNase L enzyme. FEMS  Microbiology Letters 149, 107-113.   128. Diaz-Guerra, M., Rivas, C and Esteban, M (1997). Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells. Virology, 235, 354-363  129. Salmons, T., Kuhn, A., Schleich, S., Rodriguez, J.R., Rodriguez, D., Esteban, M., Griffiths, G., and Krijnse Locker, J (1997). Vaccinia virus membrane proteins p8 and p16 are cotranslationally inserted into the rough ER and retained in the intermediate compartment. J. Virol. 71, 7404-7420.  130. Rodriguez, J.R., Risco, C., Carrascosa, J.L., Esteban, M and Rodriguez, D (1998). Vaccinia virus 15 kDa (A14L) protein is essential for assembly and attachment of viral crescents to virosomes. J. Virol.72, 12871296.  131. Miyahira, Y., Garcia-Sastre, A., Rodriguez, D., Rodriguez, J.R., Tsuji, M., Palese, P., Esteban, M., Zavala and Nussenzweig, R.S (1998). Recombinant viruses expressing a human malaria antigen elicit a protective immune response in mice. Proc. Natl. Acad. Sci. USA. 95, 3954-3959  132. Rivas, C., Gil, J., Melkova, Z., Esteban, M a n d  D i a z-Guerra, M (1998). Vaccinia virus E3L protein is an inhibitor of the interferon(IFN)-induced 2-5A synthetase enzyme. Virology, 243, 406-414  133. Gonzalo, R.M., Rodriguez, D., Rodriguez, J.R., Garcia-Sastre, A., Palese, P., and Esteban, M (1999). Enhanced CD8 T cell response to HIV_1 env by combined immunization with influenza  17 and vaccinia virus recombinants. Vaccine 17, 887-892  134. Gherardi, M and Esteban, M (1999). Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants. Vaccine 17, 1074-1083  135. Rodriguez, D., J.R Rodriguez,J.R.,Llorente., M., Vazquez, I., Lucas, P., Esteban, M., Martinez, C-A and del Real, G (1999).  A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. J. Gen. Virol 80, 217-223.  136. Vazquez, M-I., Rivas, G., Cregut, D., Serrano, L.,and Esteban, M (1998). The vaccinia virus 14kDa (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21 kDa (A17L) virus membrane protein through a C-terminal a-helix. J. Virol 72, 10126-10137   137. Diaz-Guerra, M., Rivas, C and Esteban, M (1999). Full activation of RNaseL in animal cells requires binding of 2-5A within ankyrin repeats 6 to 9 of this IFN-inducible enzyme. J. Interferon and Cytokine Research 19, 113-119  138. Pav\u00f3n, M and Esteban, M (1999). Identification by two-dimensional gel electrophoresis (2D-PAGE) of vaccinia virus and cellular phosphoproteins modified after inducible expression of the dsRNA-activated protein kinase (PKR). J. Interferon and Cytokine Research 19, 591-601.  139. Gil, J., Alcami, J., and Esteban, M ( 1 9 9 9 ) .  Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kB. Mol. Cell. Biol. 19, 4653-4663   140. Vazquez, M-I and Esteban, M (1999). Identification of fuctional domains in the 14-Kilodalton envelope protein (A27L) of vaccinia virus. J. Virol 73, 9098-9109  141. Gherardi, M., Ramirez, J.C., Rodriguez, Rodriguez, J.R., Gen-Ischiro, S., Zavala, F and Esteban, M (1999). IL-12 delivered from vaccinia virus recombinants attenuates the vector and enhances the cellular immune response against HIV-1 env in a dose-dependent manner. J. Immunology 162, 6724-6733.  142. Rodriguez, D., Rodriguez, J.R., Llorente, M., Lucas, P., Esteban, M., Martinez-A, C and del Real, G (1999). Use of DNA priming and vaccinia virus boosting to trigger an efficient immune response to HIV-1 gp120. Gene Therapy and Molecular Biology 3, 179-187.  143. Risco, C., Rodriguez,J.R., Carrascosa, J.L Esteban, M and Rodriguez, D (1999). The Vaccinia virus 39 kDa protein ( A4L gene) forms a stable complex with the p4a/4a major core protein early in morphogenesis.  Virology 265, 375-386.  144. Rivas, C., Gil, J and Esteban, M (1999). Identification of functional domains of the interferon-induced enzyme PKR in cells lacking endogenous PKR. J. Interferon and Cytokine Research, 19, 1229-1236.  145. Gherardi, M.M., Ramirez, J.C., Rodriguez, D., Rodriguez, J.C., Sano, G-I., Zavala, F, and Esteban, M (1999). The cytokine IL-12 attenuates Vaccinia virus and enhances the cellular immune response against HIV-1 env in a dose-dependent manner. The Fourth European Conference on Experimental AIDS Research. Monduzzi Ed. p79-83.  146. Ramirez, J.C., Gherardi, M.M, and Esteban, M (2000). Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B and T cell immune responses in comparison with the western reserve strain and advantages as a vaccine. J. Virol 74 923-933.   18 147. Oliveira-Ferreira, J., Myahira, Y., Layton, G.T., Esteban, M., Rodriguez, D., Rodriguez, J.R., Nussenzweig, R.S and Zavala, F (2000). Immunogenicity of Ty-like particles bearing a CD8+ T cell epitope  of the CS protein of Plasmodium yoelii. Vaccine 18, 1863-1869  148. Gil, J., Esteban, M a n d  R o t h , D .  ( 2 0 0 0 ) .  I n  v i v o  r e g u l a t i o n  o f  p r o t e i n  s y n t h e s i s  b y  phosphorylation of the alpha subunit of wheat eukaryotic initiation factor 2. Biochemistry. 39, 7521-7530.  149. Ding, D., Moskowitz, S.I., Li, R., Lee, S.B., Esteban, M., Tomaseli, K., Chan, J, and Bergold, P. J (2000). Acidosis induces necrosis and apoptosis of cultured hippocampal neurons. Experimental Neurology 162, 1-12  150. Gil, J., Alcami, J and Esteban, M (2000) . Activation of NF-kB by the dsRNA dependent protein kinase PKR involves the IkB kinase complex. Oncogene, 19, 1369-1378.  151. Gil, J and Esteban, M ( 2 0 0 0 ) .  A p o p t o s i s  i n d u c t i o n  b y  t h e  d s R N A-dependent protein kinase PKR: mechanism of action. Apoptosis  5, 107-114.  152. Collado, M., Rodriguez, D., Rodriguez, J.R., Vazquez, I., Gonzalo, R.M and Esteban, M (2000). Chimeras between the human inmunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate broadly reactive antibodies and specific activation of CD8+ T cell responses to Env. Vaccine 18, 3123-3133.  153. Gil, J and Esteban, M (2000). The interferon induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-a receptors. Oncogene 19, 3665-3674.  154. Gherardi, M.M., Ramirez, J.C and Esteban, M (2000). IL-12 e n h a n c e m e n t  o f  t h e  c e l l u l a r  immune response against HIV-1 Env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose-dependent. J. Virol 74, 6278-6286.  155.  Esteban, M  a n d  P a t i \u00f1 o ,  C  ( 2 0 0 0 ) .  I d e n t i f i c a t i o n  b y  e l e c t r o n  m i c r o s c o p y  o f  t h e  maturation steps in vaccinia virus morphogenesis inhibited by the interferon-induced enzymes, protein kinase (PKR), 2-5A synthetase and nitric oxide synthase (iNOS). J. Interferon and Cytokine Res.20, 867-877.  156. Gil, J., Esteban, M, and Roth, D (2000. In vivo regulation of the dsRNA-dependent protein kinase PKR by the cellular glycoprotein p67. Biochemistry 39, 16016-16025.   157. Fernandez-Cruz, E., Navarro, J., Abad, M.L., Resino, R., Jimenez, J.L., Cant\u00f3, C., Diaz, L., Rodriguez, D., Esteban, M, and Mu\u00f1oz-Fernandez, M.A (2000). Effect of a Gp 120-depleted inactivated HIV-1 immunogen (Remune TM) on the control of nuclear factor Kappa-B activation, cytokine production and augmentation of HIV-1 specific cytotoxic T lymphocytes. Fifth. Eur. Conf. Exp. AIDS Res. Monduzzi Edit. 105-111.  158. Zavala, F., Rodrigues, M., Rodriguez, D., Rodriguez, J.R.,Nussenzweig, R.S and Esteban, M (2001). A striking property of vaccinia viruses: efficient inducers of in vivo expansion of primed CD8+ T cells. Virology  280, 155-159.  159. Gonzalo, R.M., Rodriguez, J.R., Rodriguez, D., Gonzalez-Aseguinolaza, G., Larraga, V and Esteban, M ( 2 0 0 1 ) .  Protective immune response against cutaneous leishmaniasis by  prime/booster immunisation regimes with vaccinia virus recombinant expressing Leishmania infantum  p36/LACK in combination with purified p36. Microbes and Infection 3, 701-711.  160. Gil, J., Rullas, J., Alcami, J, and Esteban, M (2001), The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kB activation. Oncogene 20, 385-394.  19  161.  Heljasvaara, R., Rodriguez, D., Risco, C., Carrascosa, J.L., Esteban, M, and Rodriguez, J.R (2001). The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles. J. Virol 75, 5778-5795.  162. Gil, J, and Esteban, M (2001). Mecanismo de acci\u00f3n de los interferones. Investigaci\u00f3n y Ciencia, 299, 44-51.  163. Gherardi, M-M., Ramirez, J.C, and Esteban, M (2001). Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histology and Histopathology 16, 655-667.  164. Gil, J, and Esteban, M ( 2 0 0 1 ) .  A n t i v i r a l  r o l e  o f  t h e  d s R N A-dependent protein kinase, PKR. Recent Res. Devel. Virol. 3, 13-27.  165.  Gomez, C.E, and Esteban, M ( 2 0 0 1 ) .  R e c o m b i n a n t  p r o t e i n s  p r o d u c e d  b y  v a c c i n i a  v i r u s  vectors can be incorporated within the virion (IMV form) into different compartments. Arch.Virol.146, 875-892.  166. Wallengreen, K., Risco, C., Krinse-Locker, J., Esteban, M, and Rodriguez, D (2001). The A17L gene product of vaccinia virus is exposed on the surface of IMV. Virology 290, 143-152.  167. Esteban, M ( 2 0 0 1 ) .  R e t o s  d e  l a  b i o t e c n o l o g \u00ed a  e n  l a  I + D + I  e n  e l  s i g l o  X X I .  E n  \u201c N o t a s  d e  Opini\u00f3n\u201d, Real Academia de Ciencias Morales y Pol\u00edticas, p155-161.  168. Esteban, M ( 2 0 0 1 ) .  T h e  h u m a n  g e n o m e  a n d  b i o m e d i c i n e :  f u t u r e  g o a l s .  Editorial. Rev. Oncolog\u00eda 3, 119-120.  169. Gil, J., Rullas, J., Alcami, J, and Esteban, M ( 2 0 0 1 ) .  M C 1 5 9 L  p r o t e i n  f r o m  t h e  p o x v i r u s  Molluscum contagiosum inhibits NF-kB activation and apoptosis induced by PKR. J. Gen. Virol 82, 3027-3034.   170.  Risco, C., Rodriguez, J.R., L\u00f3pez-Iglesias, C., Carrascosa, J.L., Esteban, M, and Rodriguez, D (2002). ERGIC membranes and vimentin filaments participate in vaccinia virus assembly. J. Virol. 76, 1839-1856.  171. Gomez, C.E., Rodriguez, D., Rodriguez, J.R., Abaitua, F., Duarte, C, and Esteban, M (2002). Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector. Vaccine 20, 961-971.  172. Gonzalo, R.M., Del Real, G., Rodriguez, J.R., Rodriguez, D., Heljasvaara, R., Lucas, P, and Esteban, M ( 2 0 0 2 ) .   A heterologous prime-boost regime using DNA and recombinant VV expressing Leishmania infantum-P36 antigen protects Balb/c mice from cutaneous leishmaniasis. Vaccine 20, 1226-1231.  173. Ramirez, J.C., Tapia, E, and Esteban, M ( 2 0 0 2 ) .  Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J. Gen. Virol. 83, 1059-1067.  174. Agromayor, M., Ortiz, P., Lopez-Estebaranz, J.L., Gonzalez-Nicolas, J., Esteban, M, and Martin-Gallardo, A (2002). Molecular epidemiology of molluscum contagiosum virus and analysis of the host-serum antibody response in Spanish HIV-negative patients. J. Med. Virol  20 66, 151-158.  175. Humlova, Z., Vokurka, M., Esteban, M, and Melkova, Z (2002) Vaccinia virus induces apoptosis of infected macrophages. J. Gen. Virol. 83, 2821-2832.  176.  Lopez-Fuertes, L., Perez-Jimenez, E., Vila-Coro, A.J., Sack, F., Moreno, S., Konig, S.A., Junghams, C., Wittig, B., Timon, M, and Esteban, M ( 2 0 0 2 ) .  DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21, 247-257.  177. Garc\u00eda, M.A., Guerra, S., Gil, J., Jimenez, J, and Esteban, M (2002). Antiapoptotic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene 21,8379-8387.  178. Gil, J., Garc\u00eda, M.A, and Esteban, M (2002). Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance. FEBS Letters 529, 249-255.  179. Sanchez, A.B., Rodriguez, D., Garzon, A., Amorena, B., Esteban, M, and Rodriguez, J.R     (2002). Visna Maedi virus Env protein expressed by a vacccinia virus recombinant induces cell-to-cell fusion in cells of different origins in the apparent absence of Env protelytic processing. Arch. Virol 147, 2377-2392.  180. Tapia, E., P\u00e9rez-Jimenez, E., Lopez-Fuertes, L., Gonzalo, R, and Esteban, M ( 2 0 0 3 ) .  The combination of vectors expressing IL-12+IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes and Infection 5, 73-84.  181. Ramirez, J.C., Finke, D., Esteban, M., Kraehenbuhl, J.P, and Acha-Orbea, H (2003). Tissue distribution of Modified Vaccinia Virus Ankara (MVA) after mucosal or systemic administration. Arch. Virol. 148, 827-839  182. Gherardi, M.M., N\u00e1jera, J.L., P\u00e9rez-Jim\u00e9nez, E., Guerra, S., Garc\u00eda-Sastre, A, and Esteban, M (2003). Prime/boost immunization schedules based on influenza and vaccinia virus (VV) vectors (MVA and WR) potentiate cellular immune responses against HIV-env protein systemically and in the genito-rectal draining lymph nodes. J. Virol 77, 7048-7057  183. Ramiro, M.J., Z\u00e1rate, J.J., Hanke, T., Rodriguez, D., Rodriguez, J.R., Esteban, M., Lucientes, J., Castillo, J.A, and Larraga, V (2003). Protection against Leishmania infantum visceral leihsmaniasis in dogs is achieved by immunization with heterologous prime-booster regime using LACK-expressing DNA and recombinant vaccinia virus. Vaccine 21, 2471-2484.  184. Guerra, S., L\u00f3pez-Fernandez, L., Pascual-Montano, A., Mu\u00f1oz, M., Harsman, K, and Esteban, M (2003). Cellular gene expression survey upon vaccinia virus infection of human HeLa cells. J. Virol 77, 6493-6506.  185. Esteban, M., Garcia, M.A., Domingo-Gil, E., Arroyo, J., Nombela, C, and Rivas, C (2003). The latency protein LANA 2 from Kaposi\u00b4s sarcoma associated herpesvirus (KSHV) inhibits apoptosis induced by PKR but not RNase L activation. J. Gen.Virol 84, 1463-1470  186. Gherardi, M.M., Ramirez, J.C, and Esteban, M ( 2 0 0 3 ) .  I n t e r l e u k i n-12 (IL-12) and IL-18 synergize to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J. Gen. Virol. 84, 1961-1972.  187. Gonzalez-Lopez, C., Martinez-Costas, J., Esteban, M, and Benavente, J (2003). Avian reovirus \u03c3A protein is an inhibitor of the double-stranded RNA-dependent protein kinase PKR.  21 J. Gen. Virol. 84,1629-1639 .  188. Gallego-G\u00f3mez, J.C., Risco, C., Rodr\u00edguez, D., Cabezas, P., Guerra, S., Carrascosa, J.L, and Esteban, M ( 2 0 0 3 ) .  Differences in virus-induced cell morphology and in virus maturation between the MVA and other strains (WR, Ankara, NYCBH) of vaccinia virus in infected human cells. J. Virol  77, 10606-10622.  189. Gonzalez-Aseguinolaza, G., Nakaya, Y., Molano, A., Dy, E., Esteban, M., Rodriguez, D., Rodriguez, J.R., Palese, P., Garcia-Sastre, A, and Nussenzweig, R.S (2003). Induction of protective immunity against malaria by prime/boost immunization with recombinant cold- adapted influenza and modified vaccinia virus Ankara viruses expressing a CD8+ T cell epitope derived from the cincumsporozoite protein of Plasmodium yoelii. J. Virol  77 , 11859-11866.  190. G\u00f3mez, C.E., Abaitua, F., Rodriguez, D., Duarte, C, and Esteban, M (2003). Efficient CD8+ T cell response to HIV-env V3 loop epitope from multiple isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunisation regime and enhancement by the cytokine IFN-\u03b3. Virus Research 105, 11-22   191. Diderlaurent, A., Ramirez, J.C., Graff, M., Gherardi, M., Orbea, H-A.,Wagner, H., Esteban, M., Kraehenbuhl, J-P, and Sirard, J-C (2004). Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2 restricted cytotoxic T cell responses. Vaccine 22, 3395-3403   192. Gil, J., Garc\u00eda, M-A., G\u00f3mez-Puertas, P., Guerra, S., Rull\u00e1s, J., Alcam\u00ed, J, and Esteban, M (2004). TRAF family proteins link PKR with NF-kB activation. Mol. Cell. Biol. 24, 4502-4512.  193. Guerra, S., Lopez-Fernandez, L.A., Conde, R., Pascual-Montano, A., Harshman, K, and Esteban, M. (2004). Microarray Analysis Reveals Characteristic Changes of Host Cell Gene Expression in Response to Attenuated Modified Vaccinia Virus Ankara Infection of Human HeLa Cells. J Virol 78(11): 5820-34.  194. Gherardi, M. M., Perez-Jimenez, E., N\u00e1jera, J.L and Esteban, M ( 2 0 0 4 ) .  Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.\" J Immunol 172(10): 6209-20.  195. Esteban, M ( 2 0 0 4 ) .  C o n c e p t o s  y  f u t u r a s  a p l i c a c i o n e s  d e  l a  g e n \u00f3 m i c a ,  p r o t e \u00f3 m i c a  y  bioinform\u00e1tica en el campo de la salud. En Genoma Espa\u00f1a, Salud Humana, pp 99-104  196. Esteban, M (2004). Desarrollo de nuevas vacunas basadas en poxvirus. En \u201cReal Expedici\u00f3n Filantr\u00f3pica de la Vacuna. Doscientos a\u00f1os de lucha contra viruela\u201d. Biblioteca de Historia de Am\u00e9rica, CSIC. p 333-345  197. Gil, J, and Esteban, M ( 2 0 0 4 ) .  V a c c i n i a  v i r u s  r e c o m b i n a n t s  a s  a  m o d e l s y s t e m  t o  a n a l y z e  interferon-induced pathways. J. Interferon and Cytokine Research 24, 637-646  198. Guerra, S., Aracil, M., Conde, R., Bernad, A, and Esteban, M ( 2 0 0 5 ) .  Wiskott-Aldrich S\u00edndrome protein is needed for vaccinia virus pathogenesis.J. Virol. 79, 2133-2140  199. Cyrklaff, M., Risco, C., Fern\u00e1ndez, J.J., Jim\u00e9nez, M.V., Esteban, M., Baumeister, W, and Carrascosa, J.L (2005). Cryo-Electron tomography of vaccinia virus. Proc. Natl. Acad. Sci. USA. 102, 2772-2777  200. C. Munoz-Fontela., Garcia, M.A., Garcia-Cao, I., Collado, M.,Arroyo,J., Esteban, M., Serrano, M and Rivas, C (2005). Resistance to viral infection of super p53 mice. Oncogene 24, 3059-3062  22  201. G\u00f3mez, C.E., Vandermeeren, A., Garc\u00eda, M.A, Domingo, E, and Esteban, M ( 2 0 0 5 ) .  Involvement of PKR and RNase L in translational control and induction of apoptosis after hepatitis C virus gene expression. Viroloy Journal (online publication, Sept 12; 2 (1):81.  202. Dondji, B., P\u00e9rez-Jim\u00e9nez, E., Goldsmith-Pestana., Esteban, M, and McMahon-Pratt, D (2005). Heterologous prime-boost vaccination using LACK antigen protects against murine visceral leishmaniasis. Infect. Immunity 73, 5286-5289 .  203. Gonzalez, B., Reina, R., Garcia, I., Andres, S., Glaria, I., Alzueta, M., Mora, M.I Mora, Jugo, B.M., Arrieta-Aguirre, I., Lastra, J.M., Rodriguez, D., Rodriiguez, J.R., Esteban, M., Grillo, M.J., Blacklaws, B.A., Harkiss, G.D., Chebloune, Y., Lujan, L., Andres, D, and Amorena, B (2005). Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection. Vaccine 23, 4342-4352.  204. Gherardi, M.M and Esteban, M (2005). Recombinant poxviruses as mucosal vaccine vectors. J. Gen. Virol. 86, 2925-2936  205. Alcami, J., Munne, J., Mu\u00f1oz-Fernandez, MA and Esteban, M (2005). Current situation in the development of a preventive HIV vaccine. Enferm. Infecc. Microbiol. Clin. 23 (suppl. 2), 15-24  206. Abaitua, F., Rodr\u00edguez, J.R., Garz\u00f3n, A., Rodr\u00edguez, D, and Esteban, M ( 2 0 0 6). Improving recombinant MVA immune responses: Potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing env and the cytokines IL-12 and IFN-gamma. Virus Research 116, 11-20 .  207. Ventoso, I., Sanz, M.A., Molina, S., Berlanga, J.J, Carrasco, L, and Esteban, M ( 2 0 0 6 ) .  Translational resistance of late alphavirus mRNA to eIF-2 alfa phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Development 20, 87-100.  208. Guerra, S., L\u00f3pez-Fern\u00e1ndez, L.A., Pascual-Montano, A., N\u00e1jera, J.L., Zaballos., A, and Esteban, M (2006). Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kB-responsive genes in infected HeLa cells. J. Virol 80, 985-998  209. P\u00e9rez-Jimenez, E., Kochan, G., Gherardi, M.M and Esteban, M (2006). MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes and Infection 8, 810-822.  210. Rodriguez D., B\u00e1rcena, M., M\u00f6bius,W., Schleich, S., Esteban, M., Geerts W.J.C., Koster, A.J., Griffiths, G., and Krijnse Locker J (2006). A vaccinia virus lacking A10L: viral core proteins accumulate on structures derived from the endoplasmic reticulum. Cell. Microbiol. 8, 427-437  211. E. Domingo and Esteban, M (2006). Role of mitochondria in apoptosis induced by the 2-5A system and mechanisms involved. Apoptosis 11, 725-738  212. N\u00e1jera, J.L., G\u00f3mez, C.E., Domingo, E., Gherardi, M.M, and Esteban, M (2006). Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of C7L gene. J. Virol 80, 6033-6047   213. Esteban, M ( 2 0 0 6 ) .  P o x v i r i d a e .  \" V I R U S  P a t \u00f3 g e nos\". Editores Carrasco, L y J.M Almendral. HELICE, Madrid. Cap\u00edtulo 12,  pp 245-261.  214. Esteban, M (2006). Interferones y Vacunas como control de enfermedades prevalentes. Discurso de ingreso como Acad\u00e9mico de N\u00famero en la Real Academia Nacional de Farmacia, 26 Enero. Ed. Realigraf, p1-86  215. Guerra, S., L\u00f3pez-Fern\u00e1ndez, L.A., Garc\u00eda, M.A., Zaballos, A., and Esteban, M (2006). Human  23 gene profiling in response to active protein kinase PKR in infected cells: involvement of the transcription factor ATF-3 in PKR-induced apoptosis. J. Biol. Chem 281, 18734-18745  216. Garc\u00eda, M.A., Gil, J.,. Ventoso, I., Guerra, S., Dom\u00ednguez, E., Rivas, C, and Esteban, M (2006). The impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microb. Mol. Biol. Reviews 70, 1032-1060.  217. Garcia, M.A., Collado, M., Mu\u00f1oz, C., Mathew, A., Arroyo, J., Esteban, M., Serrano, M, and Rivas, C (2006). Antiviral action of tumour suppressor ARF. The EMBO Journal 25, 4284-4292.  218. G\u00f3mez, C.E., N\u00e1jera, J.L., P\u00e9rez-Jim\u00e9nez, E., Jim\u00e9nez, V., Wagner, R., Graf, M., Franchette, M.J., Liljestr\u00f6m, P., Pantaleo, G., and Esteban, M ( 2 0 0 7 ) .  He a d-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the poxvirus strains MVA and NYVAC coexpressing in a single locus the HIV-1BX08 and HIV-1 Gag-Pol-Nef proteins of clade B. Vaccine 25, 2863-2885  219. G\u00f3mez, C.E., N\u00e1jera, J.L., Jim\u00e9nez, V., Goranson, E., Liljest\u00f6m, P., Bieler, K., Wild, J., Franchette, M.J., Pantaleo, G., Wolf, H., Wagner, R, and Esteban, M. Immunogenicity of HIV/AIDS vaccine candidates targetting HIV-1 Env/Gag-Pol-Nef antigens of clade C (2007). Vaccine 25, 1969-1992  220. Mu\u00f1oz-Fontela, C., Garc\u00eda, M.A., Collado, M., Marcos-Villar, L., Gallego, P., Esteban, M, and Rivas, C (2007). Control of virus infection by tumour suppressors. Carcinogenesis 28, 1140-1144  221. Garc\u00eda, M.A., Meurs, E, and Esteban, M (2007). The dsRNA protein kinase PKR: virus and cell control. Biochimie 89, 799-811  222. G\u00f3mez, C.E., N\u00e1jera, J.L., Domingo-Gil, E., Ochoa-Callejero, L., Gloria Gonz\u00e1lez-Aseguinolaza, and Esteban, M (2007). Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J. Gen. Virol  88, 2473-2478  223. Guerra, S., N\u00e1jera, J.L., Gonz\u00e1lez, J.M., L\u00f3pez, L., Climent, N., Gallart, T., Gatell, J.M, and Esteban, M (2007). Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J.Virol 81, 8707-8721  224. Esteban, M ( 2 0 0 7 ) .  R N A  i n t e r f e r e n t e :  d e l  d e s c u b r i m i e n t o  a  s u s  a p l i c a c i o n e s. An. R. Acad. Nac. Farm., 73 (1), 97-124.  225. Esteban, M (2007). Interferones y vacunas c\u00f3mo control de enfermedades prevalentes. En \u201c Bioqu\u00edmica y Fisiopatolog\u00eda del Sistema Immune\u201d, eds, Mar\u00eda Cascales Angosto & Pedro Garc\u00eda Barreno. Instituto de Espa\u00f1a. 245-301   226. Esteban, M ( 2 0 0 7 ) .  D e s a r r o l l o  d e  v a c u n a s  c o n t r a  e l  V I H / S I D A .  A c a d e m i a  d e  F a r m a c i a  d e  Galicia (discurso de toma de posesi\u00f3n como Acad\u00e9mico correspondiente, 28 Marzo). An. R. Acad. Nac. Farm. 73, 1047-1078.  227. Garc\u00eda, M.A., Mu\u00f1oz-Fontela, C., Collado, M . ,  M a r c o s-Villar, L., Esteban, M, and Rivas, C (2007). Novel and unexpected role for the tumor suppressor ARF in viral infection surveillance. Future Virology, 2, 625-629.  228. Fraile-Ramos, A., Pelchen-Matthews, A., Risco, C., Rejas, M.T., Emery, V., Walker, A., Carrascosa, J.L., Esteban, M, and Marsh, M (2007). The ESCRT machinery is not required for human cytomegalovirus envelopment. Cell Microbiol 9, 2955-2967.    24 229. Kochan, G., Escors, D., Gonz\u00e1lez, J.M., Casasnovas, J.M, and Esteban, M (2008). Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cell Microbiol 10, 149-164  230. Domingo-Gil, E., P\u00e9rez-Jim\u00e9nez, E., Ventoso, I., N\u00e1jera, J.L, and Esteban, M ( 2 0 0 8 ) .  Expression of the E3L gene of vaccinia virus in transgenic mice decreases the host resistance to vaccinia virus and Leishmania major infection. J. Virol 82, 254-267  231. Corbett, M., Bogers, W., Gerber, S., Genin, C., Didierlaurant, A., Oostermeijer, H., G\u00f3mez, C.E., Esteban, M., Koopman, G., Heeney, J.L., van der Burg, S., Kraehenbuhl, J.P, and Le Pape, A (2008). Aerosol immunisation with the recombinant poxvirus vaccine vectors NYVAC and MVA is safe and immunogenic. Proc. Natl. Acad. Sci. USA 105, 2046-2051.   232. Mooij, P.,  Balla-Jaghjoorsingh, S.S.,  Koopman, G., Beenhakker, N.,  van Haaften, P.,  Baak, I., Nieuwenhuis, I., Kondova, I., Wagner ,R., Wolf, H., G\u00f3mez, C.E., N\u00e1jera,J.L., Jim\u00e9nez,V.,  Esteban, M,  and Heeney, J.L (2008). Differential CD4+ versus CD8+ T cell responses elicited by different Poxvirus-based human immunodeficiency virus type I vaccine candidates provide comparable efficacies in primates. J. Virol 82, 2975-2988.  233. Harari A, Bart PA, St\u00f6hr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G.(2008). An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008 Jan 21;205(1):63-77.  234. Dondji, B., Deak, E., Goldsmith-Pestana, K., P\u00e9rez-Jim\u00e9nez, E., Esteban, M., Yammaura, T, and McMahon-Pratt, D (2008).  Intradermal activation of NFKTi cells during DNA priming in heterologous prime-boost vaccination enhances effector and memory T cell responses and protection against Leishmania major infection. Eur. J. Immunol 38, 706-719.  235. Bart, P-A., Goodall, R., Barber, T., Harari, A., Guimaraes-Walker, A., Khonkarly, M., Shepperd, N., Bangala, Y., Frachette, M-J., Wagner, R., Liljestr\u00f6m, P., Krahenbuhl, J-P., Girard, M., Goudsmit, J., Esteban, M., Heeney, J., Sattentau, Q., McCormack, S., Babiker, A., Pantaleo, G, and Weber, J (2008). EVO1: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc consortium. Vaccine 26, 3153-3161.  236. G\u00f3mez, C.E., N\u00e1jera, J.L., Krupa, M, and Esteban, M (2008). The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Current Gene Therapy 8, 97-120.  237. Guerra, S., C\u00e1ceres-Nu\u00f1ez, A., Horak, I, and Esteban, M ( 2 0 0 8 ) .  V a c c i n i a  v i r u s  E 3  p r o t e i n  prevents the antiviral action of ISG15. PLoS Pathogens 4 (7)..  238. G\u00f3mez, C.E., N\u00e1jera, J.L., Krupa, M, and Esteban, M (2008). Poxvirus vectors and their use as vaccines. European Infectious Disease 2, 80-83 .  239. Vandermeeren, A., G\u00f3mez, C.E, Domingo-Gil, E, and Esteban, M (2008). Subcel l ul ar forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector. Virology Journal 5: 102.  240. Chich\u00f3n, F.J., Rodr\u00edguez, M.J., Risco, C., Fraile-Ramos, A., Fern\u00e1ndez, J.J., Esteban, M and Carrascosa, J.L (2009). Membrane remodelling during vaccinia virus morphogenesis.  Biology of Cell 101, 401-414.  241. G\u00f3mez, C.E., N\u00e1jera, J.L., Sanchez, R., Jim\u00e9nez, V and Esteban, M (2009). Multimeric soluble CD40L ligand (sCD40L) efficiently enhances specific cellular immune responses during DNA  25 prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens . Vaccine 27, 3165-3174.  242. Delaloye, J., Roger, T., Steiner-Tardivel, Q-G., Leroy, D., Knaup, R.M ., Akira, S., Petrilli, V., Tschopp, J., Pantaleo, G., G\u00f3mez, C.E., Perdiguero, B., Esteban, M and Calandra, T (2009). Cross-activation of TLR-2-TLR6, MDA-5 and the NALP3 inflammasome for innate immune sensing of modified vaccinia virus Ankara (MVA). PLoS Pathogens 5 (6).  243. Garc\u00eda, M.A., Gallego, P., Campagna, M., Gonz\u00e1lez-Santamaria, J., Mart\u00ednez, G., Marcos-Villar, L., Vidal A., Esteban, M a n d  R i v a s ,  C  ( 2 0 0 9 ) .  A c t i v a t i o n  o f  N F-kB pathway by virus infection requires Rb expression. PLoS ONE 4 (7)..  244. Carrascosa, J.L., Chich\u00f3n, F.J., Pereiro, E., Rodr\u00edguez, M.J., Fernandez, J.J., Esteban, M., Heim, S., Guttman, P, and Schneider, G (2009). Cryo-X-ray tomography for detection of vaccinia virus membranes and inner compartments. J. Structural Biol 168,234-239. .  245. Esteban, M (2009). Un Nobel esperado: descubrimiento de los agentes causales del SIDA y del c\u00e1ncer cervical. Ann. Real. Acad. Nac. Farmacia 75, 77-98.  246. Perdiguero, B and Esteban, M ( 2 0 0 9 ) . T h e  i n t e r f e r o n  s y s t e m  a n d  v a c c i n i a  v i r u s  e v a s i o n  mechanisms. J. Interferon Cytokine Res 29, 581-598.  247. Wild, J., Fanchette, M.J., Jeffs, S., Vieira, S., Esteban, M., Lijestr\u00f6m, P., Pantaleo, G., Wolf, H, and Wagner, R (2009). Preclinical evaluation of the immunogenicity of C-type HIV-1 based DNA and NYVAC vaccines in the Balb/c mouse model. Viral Immunology 22, 309-319  248. Rodr\u00edguez, A.M., Gabriela T., Ferrer, F., Pascutti, F., N\u00e1jera, J.L., M\u00f3naco, D.C., Esteban, M., Salom\u00f3n, H., Calamante, G, and Gherardi, M (2009). Characterization of DNA and MVA vectors expressing NEF from HIV-1 CRF12-BF revealed high immune specificity with low cross-reactivity against subtype B. Virus Research 146, 1-12  249. Esteban, M (2009). Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Human Vaccines 5 (12), 867-871   250. Cordeiro, J. V., Guerra, S., Arakawa, Y., Dodding, M.P., Esteban, M and Way, M (2009). F11-mediated inhibition of RhoA signalling enhances the spread of vaccinia virus in vitro and in vivo in an intranasal mouse model of infection. PLoS ONE 4 (12):e8506  251. Cepeda, V., Esteban, M, and Fraile-Ramos, A (2009). Human cytomegalovirus final envelopment on membranes containing both trans-Golgi network and endosomal markers. Cell. Microbiol. 12, 386-404  252. Esteban. M (2009). Hepatitis C and evasi\u00f3n of the Interferon system: a PKR paradigm. Cell Host & Microbes 6 (6), 495-497  253. Domingo-Gil,., Gonzalez, J.M, and Esteban, M (2010). Identification of cellular genes induced in human cells after activation of the OAS/RNaseL pathway by vaccinia virus recombinants expressing these antiviral enzymes. J. Interferon Cytokine Res 30, 171-188  254. Gonzalez, J.M, and Esteban, M (2010). A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virology Journal 7: 59  255. Guerra, S., Gonzalez, J.M., Climent, N., Reyburn, H., Lopez-Fernandez, L.A., Najera, J.L., Gomez, C.E., Garcia, F., Gatell, J.M., Gallart, T, and Esteban, M (2010). Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J. Virol 84,  8141-8152.   26 256.  Najera, J.L., Gomez, C.E., Garcia-Arriaza, J, and Esteban, M ( 2 0 1 0 ) .  I n s e r t i o n  o f  v a c c i n i a  virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PloS ONE 5 (6): e11406.  257. Garc\u00eda, MA., Krupa, M and Esteban, M (2010). Antitumoral activity of oncolytic vaccinia virus expressing the interferon-induced ds-RNA dependent protein kinase PKR. An. Real Acad. Nac. Farm. 76, 327-342  258. Pantaleo, G., Esteban, M., Jacobs, B and Tartaglia, J (2010). Poxvirus vector-based vaccines. Curr. Opin. HIV AIDS 5 (5) 391-396  259. Garcia-Arriaza, J., Najera, J.L., Gomez, C.E, and Esteban, M (2010). Immunogenic profiling in mice of an candidate HIV/AIDS vaccine candidate (MVA-B) expressing four HIV antigens and potentiation by specific gene deletions. PLoS ONE 5 (8): e12395.   260. Wilks AB, Christian EC, Seaman MS, Sircar P, Carville A, Gomez CE, Esteban M, Pantaleo G, Barouch DH, Letvin NL, Permar SR (2010). Robust Vaccine-Elicited Cellular Immune Responses in Breast Milk following Systemic Simian Immunodeficiency Virus DNA Prime and Live Virus Vector Boost Vaccination of Lactating Rhesus Monkeys. J. Immunol 185, 7097-7106  261. Perdiguero, B and Esteban, M (2011). Poxviruses and interferons. In Viruses and Interferon: Current Research.  Ed. K. Mossman. Caiser Academic Press. Norfolk, UK. pp 113-150  262. Garc\u00eda MA, Carrasco E, Aguilera M, Alvarez P, Rivas C, Campos JM, Prados JC, Calleja MA, Esteban M, Marchal JA, Ar\u00e1nega A ( 2 0 1 1 ). The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PLoS One. 2011;6(8):e23887.  263. Campagna, M., Herranz, D., Garc\u00eda, M.A., Marcos-Villar, L., Gonz\u00e1lez-Santamar\u00eda, J., Gallego, P., Gutierrez, S., Collado, M., Serrano, M., Esteban, M, and Rivas, C (2011). SIRT1 stablizes PML promoting its sumoylation. Cell Death and Differentiation 18, 72\u201379.   264. Krupa, M., Canamero, M., G\u00f3mez, C.E., N\u00e1jera, J.L and Esteban, M (2011). Immunization with DNA and vaccinia virus MVA vectors expressing PSCA and STEAP antigens reduces prostate cancer development. Vaccine 29, 1504-1513.  265. Flynn B.J., Kastenmueller K., Willie-Reece U., Tamara, G.D., Munir Alam S., Lindsay R.W.B., Salazar, A., Perdiguero B., Gomez C.E., Esteban M., Park C.G., Trumpfheller C., Keler T., Pantaleo G., Steinman R.M, and Seder R.A (2011). Prime-boost immunization with prote\u00edn targeted to the dendritic cell receptor DEC205 followed by recombinant NYVAC induces robust Gag CD4 and CD8+ T cell responses in non human primates. Proc. Natl. Acad. Science USA. 108, 7131-7136  266. Domingo-Gil, E. Toribio, R., Najera, JL, Esteban, M, and Ventoso, I (2011). Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergence. PLoS ONE 6, e16711  267. Quakkelaar, E.D., Redeker, A., Haddad, E. K., Harari, A., McCaughey, S. M., Duhen, T., Filali-Mouhim, A., Goulet, J-P., Loof, N. M., Ossendorp, F., Perdiguero, B., Heinen, P., Gomez, C.E., Kibler, K. V., Koelle, D. M., S\u00e9kaly, R. P., Sallusto, F., Lanzavecchia, A., Pantaleo, G., Esteban, M., Tartaglia, J., Jacobs, B. L, and Melief, C. J. M (2011). Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS ONE, 6, e16819.  268. Daniela C. M\u00f3naco, Ana M. Rodr\u00edguez, Mar\u00eda F. Pascutti, Mauricio Carobene, Juliana Falivene, Alejandro G\u00f3mez, Cynthia Maeto, Gabriela Turk, Jos\u00e9 L. N\u00e1jera, Mariano Esteban,  27 M. Magdalena Gherardi (2011). T-Cell Immune Responses Against Env from CRF12_BF and Subtype B HIV-1 Show High Clade-Specificity that Can Be Overridden by Multiclade Immunizations. PLoS ONE 6 (2): e17185.   269. Climent, N., Guerra, S., Garc\u00eda, F., Rovira, C., Miralles, L., G\u00f3mez, C.E., Piqu\u00e9, N., Gil, C., Gatell, J.M., Esteban, M, and Gallart, T (2011). Dendritic cells exposed with MVA-based HIV-1 vaccine induce highly polyfunctional HIV-1-specific CD8+ T cell response in HIV-1-infected individuals. PLoS ONE 6 (5): e19644  270. Garc\u00eda F, Bernaldo de Quir\u00f3s JC, G\u00f3mez CE, Perdiguero B, N\u00e1jera JL, Jim\u00e9nez V, Garc\u00eda-Arriaza J, Guardo AC, P\u00e9rez I, D\u00edaz-Brito V, Conde MS, Gonz\u00e1lez N, Alvarez A, Alcam\u00ed J, Jim\u00e9nez JL, Pich J, Arnaiz JA, Maleno MJ, Le\u00f3n A, Mu\u00f1oz-Fern\u00e1ndez MA, Liljestr\u00f6m P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M. ( 2 0 1 1 )  S a f e t y  a n d  i m m u n o g e n i c i t y  o f  a  modified pox vector-based HIV/AIDS vaccine candidate expressing env, gag, pol, nef proteins of HIV-1 subtype B (MVA-B) in HIV-1-uninfected volunteers. Vaccine 29, 8309-8316  271. G\u00f3mez CE, N\u00e1jera JL, Perdiguero B, Garc\u00eda-Arriaza J, Sorzano CO, Jim\u00e9nez V, Gonz\u00e1lez-Sanz R, Jim\u00e9nez JL, Mu\u00f1oz-Fern\u00e1ndez MA, L\u00f3pez Bernaldo de Quir\u00f3s JC, Guardo AC, Garc\u00eda F, Gatell JM, Plana M, Esteban M. ( 2 0 1 1 ) .  T h e  H I V / A I D S v a c c i n e  c a n d i d a t e  M V A-B administered as a single immunogen in humans triggers robust, polyfunctional and selective effector memory T cell responses to HIV-1 antigens. Journal Virology 85, 11468-11478.  272. Garc\u00eda-Arriaza J, N\u00e1jera JL, G\u00f3mez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M.(2011). A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.PLoS One. 2011;6(8):e24244.  273. Perreau M., Welles H.C., Harari A., Hall O., Martin R., Maillard M., Dorta G., Bart P-A., Kremer E-J., Tartaglia J., Wagner R., Esteban M., Levy I, and Pantaleo G (2011). DNA-C/NYVAC-C vaccine regimen induces HIV-specific CD4 and CD8 T cell-responses in intestinal mucosa. J. Virol 85, 9854-9862  274. Alan G. Goodman., Bertrand C Tanner., Stewart T Chang., Mariano Esteban and Michael G Katze (2011). Virus infection rapidly activates the p58IPK pathway, delaying peak kinase activation to enhance viral replication. Virology 417, 27-36  275. Gonz\u00e1lez-Santamar\u00eda J, Campagna M, Garc\u00eda MA, Marcos-Villar L, Gonz\u00e1lez D, Gallego P, Lopitz-Otsoa F, Guerra S, Rodr\u00edguez M, Esteban M, Rivas C. (2011). Regulation of vaccinia  virus E3 protein by SUMO. J Virol. 85:12890-900.  276. Goodman A. G., Heinen P.P., Guerra S., Vijayan A., Sorzano CO., Gomez C.E and Esteban M (2011). A human multi-epitope recombinant vaccinia virus a s  a  u n i v e r s a l  T  c e l l  v a c c i n e  candidate against influenza virus. PLoS ONE 6, 10. e25938  277. Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, Arndt W, Jimenez V, Gonzalez-Sanz R, Denzler K, Haddad EK, Wagner R, S\u00e9kaly RP, Tartaglia J, Pantaleo G, Jacobs BL, Esteban M. (2011). Improved NYVAC-Based Vaccine Vectors. PLoS ONE. 2011;6(11):e25674.  278. G\u00f3mez CE, N\u00e1jera JL, Krupa M, Perdiguero B, Esteban M. ( 2 0 1 1 ) .  MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther. 11(3):189-217. Review.  279. Guerra S, Abaitua F, Mart\u00ednez-Sobrido L, Esteban M, Garc\u00eda-Sastre A, Rodr\u00edguez D (2011) Host-Range Restriction of Vaccinia Virus E3L Deletion Mutant Can Be Overcome In Vitro, but Not In Vivo, by Expression of the Influenza Virus NS1 Protein. PLoS ONE. 2011;6(12):e28677.  28  280. Chichon J.F., Rodriguez M.J., Pereiro E., Chiapi M., Perdiguero B., Guttman S., Rehbein S., Scheneider G., Esteban M, and Carrascosa J.L (2012). Cryo X-ray nano-tomography of vaccinia virus infected cells. J Struct Biol 177, 202-211.  281. Falivene J, Del M\u00e9dico Zajac MP, Pascutti MF, Rodr\u00edguez AM, Maeto C, Perdiguero B, G\u00f3mez CE, Esteban M, Calamante G, Gherardi MM (2012). Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein. PLoS ONE. 2012;7(2):e32220.  282. G\u00f3mez CE, Perdiguero B, Jim\u00e9nez V, Filali-Mouhim A, Ghneim K, Haddad EK, Quakkelaar ED, Delaloye J, Harari A, Roger T, Duhen T, S\u00e9kaly RP, Melief CJ, Calandra T, Sallusto F, Lanzavecchia A, Wagner R, Pantaleo G, Esteban M. (2012). Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. PLoS ONE 7(4): e35485.  283. Rodr\u00edguez D, Gonz\u00e1lez-Aseguinolaza G, Rodr\u00edguez JR, Vijayan A, Gherardi M, Rueda P, Casal JI, Esteban M.(2012). Vaccine Efficacy against Malaria by the Combination of Porcine Parvovirus-Like Particles and Vaccinia Virus V e c t o r s  E x p r e s s i n g  C S  o f  P l a s m o d i u m . PLoS ONE 7(4): e34445  284. G\u00f3mez CE, Perdiguero B, N\u00e1jera JL, Sorzano CO, Jim\u00e9nez V, Gonz\u00e1lez-Sanz R, Esteban M   (2012). Removal of Vaccinia Virus G e n e s  T h a t  B l o c k  I n t e r f e r o n  T y p e  I  a n d  I I  P a t h w a y s  Improves Adaptive and Memory Responses of the HIV/AIDS Vaccine Candidate NYVAC-C in Mice. J. Virol 86, 5026-5038.  285. Vijayan A, G\u00f3mez CE, Espinosa DA, Goodman AG, Sanchez-Sampedro L, Sorzano CO, Zavala F, Esteban M (2012). Adjuvant-like Effect of Vaccinia Virus 14K Protein: A Case Study with Malaria Vaccine Based on the Circumsporozoite Protein. J Immunol. 15;188(12):6407-17.  286.  G\u00f3mez CE, Perdiguero B, Garcia-Arriaza J, Esteban M (2012). Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother. Sep 1;8(9): 1192-207  287. S\u00e1nchez-Sampedro L, G\u00f3mez CE, Mej\u00edas-P\u00e9rez E, Sorzano CO, Esteban M. (2012). High Quality Long-Term CD4(+) and CD8(+) Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection.PLoS ONE;7(6):e3885.  288. Lucero, M.C., Diaz-Brito, V., Murillo, B. YT., Carretero S. C., Sala M., Casades\u00fas, C., Conde M. S., Jimenez J. L., Pich J., Arnaiz J. A., Leon A., Perez I., Mu\u00f1oz-Fernandez M. A., Gatell J. M., Plana M., Esteban M., Bernaldo de Quiros J. C and Gar ci a F.  ( 2012) .  Reasons for Not Participating in a Phase 1 Preventive HIV Vacci ne St udy i n a Resource-Rich Country. AIDS Patient Care STDS (7):379-382.  289. Garc\u00eda-Arriaza J, Arn\u00e1ez P, Jim\u00e9nez JL, G\u00f3mez CE, Mu\u00f1oz-Fern\u00e1ndez M\u00c1, Esteban M. (2012). Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors. Virus Res. 167(2):391-6.  290. Pattacini L, Mize GJ, Graham JB, Fluharty TR, Graham TM, Lingnau K, Wizel B, Perdiguero B, Esteban M, Pantaleo G, Shen M, Spies GA, McElrath MJ, Lund JM (2012). A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PLoS One ;7(7):e42163.  291. Gonz\u00e1lez-Santamar\u00eda J, Campagna M, Ortega-Molina A, Marcos-Villar L, de la Cruz-Herrera CF, Gonz\u00e1lez D, Gallego P, Lopitz-Otsoa F, Esteban M, Rodr\u00edguez MS, Serrano M, Rivas C (2012). Regulation of the tumor suppressor PTEN by SUMO. Cell Death Dis. 27;3:e393.  29  292. Perdiguero B, G\u00f3mez CE, N\u00e1jera JL, Sorzano CO, Delaloye J, Gonz\u00e1lez-Sanz R, Jim\u00e9nez V, Roger T, Calandra T, Pantaleo G, Esteban M (2012). Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens. PLoS One ;7(10):e48524.  293. Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, Cheng C, Kong WP, Gall JG, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, Price DA, Gomez CE, Esteban M, Wyatt LS, Moss B, Morgan C, Roederer M, Bailer RT, Nabel GJ, Koup RA, Seder RA. (2013). Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization.J Immunol. 190, 2720-2735.  294. S\u00e1nchez-Sampedro L, G\u00f3mez CE, Mej\u00edas-P\u00e9rez E, P\u00e9rez-Jim\u00e9nez E, Oliveros JC, Esteban M (2013). Attenuated and replication competent Vaccinia Virus s t r a i n s  M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens. J Virol. 12, 6955-6974  295. G\u00f3mez CE, Perdiguero B, Cepeda MV, Mingorance L, Garc\u00eda-Arriaza J, Vandermeeren A, Sorzano CO, Esteban M (2013). High, broad, polyfunctional and durable T cell immune responses induced in mice by a novel hepatitis C v i r u s  ( HCV)  v a c c i n e  c a n d i d a t e  b a s e d  o n  MVA expressing the near full-length HCV genome (MVA-HCV).  J Virol. 13, 7282-7300   296. Garc\u00eda-Arriaza J, Arn\u00e1ez P, G\u00f3mez CE, Sorzano CO, Esteban M (2013). Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus G e n e s  ( C 6 L  a n d  K 7 R )  B l o c k i n g  I n t e r f e r o n  S i g n a l i n g  P a t h w a y s . PLoS One. 2013 Jun 27;8(6):e66894.  297. Caceres A., Perdiguero B., Gomez C.E., Cepeda M., Caelles, C., Sorzano CO, and Esteban M (2013). Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection. PLoS Pathog. 2013 Nov;9(11):e1003719  298. E. Y\u00e1ng\u00fcez, A. Garc\u00eda-Culebras, A. Frau, C. Llompart, K.-P. Knobeloch, S. Gutierrez-Erlandsson, A. Garc\u00eda-Sastre, M. Esteban, A. Nieto & S. Guerra (2013). ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS Path., 9:e1003632. PMC3796851.  299. Di Pilato M, Mej\u00edas-P\u00e9rez E, G\u00f3mez CE, Perdiguero B, S\u00e1nchez-Sorzano CO, Esteban M (2013). New vaccinia virus promoter as potential candidate for future vaccines. J Gen Virol. 2013 Dec;94 Pt 12:2771-6.  300. Perdiguero B, G\u00f3mez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, Calandra T, Pantaleo G, Esteban M. (2013). Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C. PLoS One. 2013 Sep 17;8(9):e74831   301. G\u00f3mez CE., Perdiguero B., Garc\u00eda-Arriaza J, and Esteban M (2013). Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines. 2013 Dec;12(12):1395-416.  302. Cepeda V and Esteban M (2014). Novel insights on the progression of intermediate viral forms in the morphogenesis of vaccinia virus. Virus Res. 183:23-9.  303. Garc\u00eda-Arriaza J., Cepeda V., Halleng\u00e4rd D., Sorzano C.O., K\u00fcmmerer B.M., Liljestr\u00f6m P., & Esteban M (2014). A Novel Poxvirus-based Vaccine (MVA-CHIKV) is Highly Immunogenic and Protects Mice against Chikungunya Infection. J Virol. 2014 Mar;88(6):3527-47.  30  304. McKay PF, Cope AV, Mann JF, Joseph S, Esteban M, Tatoud R, Carter D, Reed SG, Weber J, Shattock RJ (2014). Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV S p e c i f i c  T  and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine R e g i m e n . PLoS One. 23;9(1):e84707. doi: 10.1371/journal.pone.0084707.   305. Garc\u00eda-Arriaza J, G\u00f3mez CE, Sorzano CO, Esteban M. (2014). Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of MVA expressing HIV-1 antigens. J Virol. 2014 Mar; 88(6):3392-410.  306. Marchal JA, Lopez GJ, Peran M, Comino A, Delgado JR, Garc\u00eda-Garc\u00eda JA, Conde V, Aranda FM,  Rivas C, Esteban M ,  G a r c i a  M A  ( 2 0 1 4 ) . The impact of PKR a c t i v a t i o n :  f r o m  neurodegeneration to cancer. FASEB J. May; 28(5):1965-74   307. Garc\u00eda-Arriaza J, Esteban M (2014). Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother. May 5; 10(8):2235-44  308. de la Cruz-Herrera CF, Campagna M, Garc\u00eda MA, Marcos-Villar L, Lang V, Baz-Mart\u00ednez M, Guti\u00e9rrez S, Vidal A, Rodr\u00edguez MS, Esteban M, Rivas C (2014). Activation of the Double-stranded RNA-dependent Protein Kinase PKR by Small Ubiquitin-like Modifier (SUMO). J Biol Chem. Sep 19;289(38):26357-67.  309. Halleng\u00e4rd D, Lum FM, K\u00fcmmerer BM, Lulla A, Lulla V, Garc\u00eda-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LF, Esteban M, Liljestr\u00f6m P (2014). Prime-boost immunization strategies against Chikungunya virus. J Virol. 2014 Nov;88(22):13333-43.   310. Knudsen ML, Ljungberg K, Kakoulidou M, Kostic L, Halleng\u00e4rd D, Garc\u00eda-Arriaza J, Merits A, Esteban M, Liljestr\u00f6m P (2015). Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons a n d  h o m o l o g o u s  o r  h e t e r o l o g o u s  b o o s t e r  immunizations. J Virol. Nov; 88(21):12438-51  311. Knudsen ML, Ljungberg K, Tatoud R, Weber J, Esteban M, Liljestr\u00f6m P (2015). Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV g p 1 4 0  P r o t e i n  A n t i g e n . PLoS One. Feb 2;10(2):e0117042.  312. Delaloye J, Filali-Mouhim A, Cameron MJ, Haddad EK, Harari A, Goulet JP, Gomez CE, Perdiguero B, Esteban M, Pantaleo G, Roger T, S\u00e9kaly RP, Calandra T (2015). Interleukin 1- and type I interferon-dependent enhancement of the innate immune profile of a NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletion of type I and type II interferon-binding proteins. J Virol. Apr;89(7):3819-32  313. Daszkiewicz L, V\u00e1zquez-Mateo C, Rackov G, Ballesteros-Tato A, Weber K, Madrigal-Avil\u00e9s A, Di Pilato M, Fotedar A, Fotedar R, Flores JM, Esteban M, Mart\u00ednez-A C, Balomenos D (2015). Distinct p21 r e q u i r e m e n t s  f o r  r e g u l a t i n g  n o r m a l a n d  s e l f-reactive T cells through IFN-\u03b3 production. Sci Rep. Jan 9;5:7691. doi: 10.1038/srep07691.  314. Perdiguero B, G\u00f3mez CE, Cepeda V, S\u00e1nchez-Sampedro L, Garc\u00eda-Arriaza J, Mej\u00edas-P\u00e9rez E, Jim\u00e9nez V, S\u00e1nchez C, Sorzano C\u00d3, Oliveros JC, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler KV, Jacobs BL, Pantaleo G, Esteban M (2015). Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. J Virol. Jan 15;89(2):970-88..  315. Mothe B, Climent N, Plana M, Ros\u00e0s M, Jim\u00e9nez JL, Mu\u00f1oz-Fern\u00e1ndez M\u00c1, Puertas MC, Carrillo J, Gonzalez N, Le\u00f3n A, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcam\u00ed J,  31 Martinez-Picado J, Alvarez-Fern\u00e1ndez C, S\u00e1nchez-Palomino S, Guardo AC, Pe\u00f1a J, Benito JM, Rall\u00f3n N, G\u00f3mez CE, Perdiguero B, Garc\u00eda-Arriaza J, Esteban M, L\u00f3pez Bernaldo de Quir\u00f3s JC, Brander C, Garc\u00eda F; on behalf of the RISVAC-03 Study Group (2015) Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. J Antimicrob Chemother. Jun;70(6):1833-42   316. Mooij P, Koopman G, Drijfhout JW, Nieuwenhuis IG, Beenhakker N, Koestler J, Bogers WM, Wagner R, Esteban M, Pantaleo G, Heeney JL, Jacobs BL, Melief CJ. (2015). Synthetic long peptide booster immunization in rhesus macaques primed with replication competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1 (2015).J Gen Virol. Feb 9. pii: vir.0.000074. doi: 10.1099/vir.0.000074. [Epub ahead of print].  317. Di Pilato M, Mej\u00edas-P\u00e9rez E, Zonca M, Perdiguero B, G\u00f3mez CE, Trakala M, Nieto J, N\u00e1jera JL, S Sorzano CO, Combadi\u00e8re C, Pantaleo G, Planelles L, Esteban M ( 2 0 1 5 ) . NF\u03baB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. Proc Natl Acad Sci U S A. 2015 Mar 4 17;112(11):E1333-42. doi: 10.1073/pnas.  318. S\u00e1nchez-Sampedro L, Perdiguero B, Mej\u00edas-P\u00e9rez E, Garc\u00eda-Arriaza J, Di Pilato M, Esteban M (2015).  The Evolution of Poxvirus Vaccines. Viruses. Apr 7;7(4):1726-1803.  319. Hulot SL, Korber B, Giorgi EE, Vandergrift N, Saunders KO, Balachandran H, Mach LV, Lifton MA, Pantaleo G, Tartaglia J, Phogat S, Jacobs B, Kibler K, Perdiguero B, Gomez CE, Esteban M, Rosati M, Felber BK, Pavlakis GN, Parks R, Lloyd K, Sutherland L, Scearce R, Letvin NL, Seaman MS, Alam SM, Montefiori D, Liao HX, Haynes BF, Santra S (2015). Comparison of immunogenicity in rhesus macaques of transmitted-founder, HIV-1 group M consensus and trivalent mosaic Envelope vaccines formulated as a DNA prime, NYVAC and Envelope protein boost. J Virol. June 15;89(12):6462-80.   320. Ahola T, Courderc T, Ng LF, Halleng\u00e4rd D, Powers A, Lecuit M, Esteban M, Merits A, Roques P, Liljestr\u00f6m P (2015). Therapeutics and vaccines against chikungunya virus. Vector Borne Zoonotic Dis. 2015 Apr;15(4): 250-7. doi: 10.1089/vbz.2014.1681.  321. Di Pilato M, Esteban M (2015). Neutrophil and vaccine. Cell Cycle. Jun 3;14(11):1615-6.  322. Di Pilato M, S\u00e1nchez-Sampedro L, Mej\u00edas-P\u00e9rez E, Sorzano CO, Esteban M ( 2 0 1 5 ) . Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression. J Gen Virol. Aug;96(8):2360-71doi: 10.1099/vir.0.000183.   323. Shen X, Duffy R, Howington R, Cope A, Sadagopal S, Park H, Pal R, Kwa S, Ding S, Yang OO, Fouda GG, Le Grand R, Bolton D, Esteban M, Phogat S, Roederer M, Amara R, Picker LJ, Seder RA, McElrath MJ, Barnett S, Permar SR, Shattock R, DeVico AL, Felber BK, Pavlakis GN, Pantaleo G, Korber BT, Montefiori DC, Tomaras GD (2015). Vaccine Induced Epitope Specific Antibodies to SIVmac239 Envelope Are Distinct from Those Induced to the HIV-1 Envelope in Non-Human Primates. J Virol. 2015 Aug;89(16):8643-50.   324. Garc\u00eda-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori DC, Labranche C, Yates NL, Shen X, Tomaras GD, Ferrari G, Foulds KE, McDermott A, Kao SF, Roederer M, Hawkins N, Self S, Yao J, Farrell P, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo A, Weiss D, Lee C, Kibler K, Jacobs B, Asbach B, Wagner R, Ding S, Pantaleo G, Esteban M (2015). Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime/boost combination with Env protein in non-human primates. J Virol. 2015 Aug;89(16):8525-39. doi: 10.1128/JVI.01265-15.   32   325. Vijayan A, Garc\u00eda-Arriaza J, Raman SC, Conesa JJ, Chich\u00f3n FJ, Santiago C, Sorzano C\u00d3, Carrascosa JL, Esteban M (2015). A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen. PLoS One. 2015 Jul 24;10(7):e0133595  326. G\u00f3mez CE, Perdiguero B, Garc\u00eda-Arriaza J, Cepeda V, S\u00e1nchez-Sorzano C\u00d3, Mothe B, Jim\u00e9nez JL, Mu\u00f1oz-Fern\u00e1ndez M\u00c1, Gatell JM, L\u00f3pez Bernaldo de Quir\u00f3s JC, Brander C, Garc\u00eda F, Esteban M (2015). A Phase I Randomized Therapeutic MVA-B V a c c i n a t i o n  Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.PLoS One. 2015 Nov 6;10(11):e0141456.  327. Rallon NI, Mothe B, Lopez Bernaldo DE Quiros JC, Plana M, Ligos JM, Montoya M, Mu\u00f1oz MA, Esteban M, Garcia F, Brander C, Benito JM; RISVAC03 Study Group (2015). Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. AIDS. 20;30(4):553-62  328. Fern\u00e1ndez-Escobar M, N\u00e1jera JL, Baldanta S, Rodriguez D, Way M, Esteban M, Guerra S (2015). Suppression of NYVAC infection in HeLa cells requires RNase L but is independent of PKR activity. J Virol. 2015 Dec 9. 90(4):2135-41. doi: 10.1128/JVI.02576-15.   329. Asbach B, Kliche A ,  K \u00f6 s t l e r  J ,  P e r d i g u e r o  B ,  Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R.(2016). Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol. 2016 Mar 28;90(8):4133-49. doi: 10.1128/JVI.03135-15. Print 2016 Apr 15.  330. S\u00e1nchez-Sampedro L, Mej\u00edas-P\u00e9rez E, S Sorzano C\u00d3, N\u00e1jera JL, Esteban M.(2016). NYVAC vector modified by C7L viral gene insertion improves T cell immune responses and effectiveness against leishmaniasis. Virus Res. 2016 Mar 29; 220:1-11. doi: 10.1016/j.virusres.2016.03.007. [Epub ahead of print].  331. de la Cruz-Herrera CF, Baz-Mart\u00ednez M, Lang V, El Motiam A, Barbaz\u00e1n J, Couceiro R, Abal                                     M, Vidal A, Esteban M, Mu\u00f1oz-Fontela C, Nieto A, Rodr\u00edguez MS, Collado M, Rivas C (2016). Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation. Oncogene. Jun 2;35(22):2873-80. doi: 10.1038/onc.2015.356. Epub 2015 Sep 28.  332.  Wicklein B, Darder M, Aranda P, Martin del Burgo M.A, del Real G, Esteban M, and Ruiz-Hitzky E (2016).  Clay-lipid nanohybrids: towards influenza vaccines and beyond. Clay Minerals 51, 529-538.   333. Ljungberg K, K\u00fcmmerer B.M, Roques P, Esteban M, M e r i t s  A ,  a n d  L i l j e s t r \u00f6 m  P  ( 2 0 1 6 ) .  Vaccines Against Chikungunya Virus Infection. Springer International Publishing Switzerland. C.M Okeoma (ed.), Chikungunya Virus, DOI 10.1007/978-3-319-42958-8_4   334. Joseph S, Quinn K, Greenwood A, Cope AV, McKay PF, Hayes PJ, Kopycinski JT, Gilmour J, Miller AN, Geldmacher C, Nadai Y, Ahmed MI, Montefiori DC, Dally L, Bouliotis G, Lewis DJ, Tatoud R, Wagner R, Esteban M, Shattock RJ, McCormack S, Weber J (2017). A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV V a c c i n e s  i n  T w o  I m m u n ization Regimes. F r o n t  I m m u n o l .  2 0 1 7  F e b  22;8:149. doi: 10.3389/fimmu.2017.00149..  335. Vijayan A, Mej\u00edas-P\u00e9rez E, Espinosa DA, Raman SC, Sorzano CO, Zavala F, Esteban M (2017). A prime/boost PfCS14KM/MVA-sPfCSM vaccination protocol generates robust CD8+ T cell and antibody responses to Plasmodium falciparum circumsporozoite protein and protects  33 mice against malaria. Clin Vaccine Immunol. 2017 Mar 15. pii: CVI.00494-16. doi: 10.1128/CVI.00494-16.  336. Garc\u00eda-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M (2017). HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. J Virol. Apr 13;91(9). doi: 10.1128/JVI.02182-16. Print 2017 May 1.  337. Roques P, Ljungberg K, K\u00fcmmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, Halleng\u00e4rd D, Garc\u00eda-Arriaza J, Meinke A, Esteban M, Merits A, Le Grand R, Liljestr\u00f6m P (2017). Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. Journal Clinical Investigation Insight. 2017 Mar 23;2(6):e83527. doi: 10.1172/jci.insight.83527  338. Guardo AC, G\u00f3mez CE, D\u00edaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, Garc\u00eda-Arriaza J, Gonz\u00e1lez N, Sorzano COS, Jim\u00e9nez L, Jim\u00e9nez JL, Mu\u00f1oz-Fern\u00e1ndez M\u00c1, Gatell JM, Alcam\u00ed J, Esteban M, L\u00f3pez Bernaldo de Quir\u00f3s JC, Garc\u00eda F, Plana M; RISVAC02boost study (2017). Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. P L o S  O n e .  2 0 1 7  O c t  24;12(10):e0186602.   339. Di Pilato M, Mej\u00edas-P\u00e9rez E, Sorzano COS, Esteban M (2017). Distinct Roles of Vaccinia Virus NF-\u03baB Inhibitor Proteins A52, B15, and K7 in the Immune Response. J  V i r o l .  2 0 1 7  J u n  9;91(13). pii: e00575-17.  340. de la Cruz-Herrera CF, Baz-Mart\u00ednez M, Motiam AE, Vidal S, Collado M, Vidal A, Rodr\u00edguez MS, Esteban M, Rivas C (2017). Phosphorylable tyrosine residue 162 in the double-stranded RNA-dependent kinase PKR modulates its interaction with SUMO. Sci Rep. 2017 Oct 25;7(1):14055.  341. Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA, Mart\u00ednez-Cano S, Mej\u00edas-P\u00e9rez E, Esteban M, Melero I, Hidalgo A, Sancho D (2017). Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells. Nat Commun. 2017 Jul 17;8:16073.  342. Ros\u00e1s-Umbert M, Mothe B, Noguera-Julian M, Bellido R, Puertas MC, Carrillo J, Rodriguez C, Perez-Alvarez N, Cobars\u00ed P, Gomez CE, Esteban M, J\u00edmenez JL, Garc\u00eda F, Blanco J, Martinez-Picado J, Paredes R, Brander C (2017) Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. PLoS One. 2017 Sep 27;12(9):e0184929  343. Lorente E, Barriga A, Garc\u00eda-Arriaza J, Lemonnier FA, Esteban M, L\u00f3pez D (2017). Complex antigen presentation pathway for an HLA-A*0201-restricted epitope from Chikungunya 6K protein. PLoS Negl Trop Dis. Oct 30;11(10):e0006036.  344. Gomez, CE, Perdiguero B, Sanchez-Corzo C, Sorzano COS and Esteban M (2017). Immune modulation of NYVAC-based HIV vaccines by combined deletion of viral genes thart act on several signalling pathways. Viruses. 10, 7; doi:10.339  345. Mej\u00edas-P\u00e9rez E, Carre\u00f1o-Fuentes L, Esteban M (2017). Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-\u03944 with a Set of Gene Deletions on Several Viral  34 Pathways. Mol Ther Oncolytics. 2017 Dec 5;8:27-40. doi: 10.1016/j.omto.2017.12.002  346. Saunders KO, Santra S, Parks R, Yates NL, Sutherland LL, Scearce RM, Balachandran H, Bradley T, Goodman D, Eaton A, Stanfield-Oakley SA, Tartaglia J, Phogat S, Pantaleo G, Esteban M, Gomez CE, Perdiguero B, Jacobs B, Kibler K, Korber B, Montefiori DC, Ferrrari G, Vandergrift N, Liao HX, Tomaras GD, Haynes BF (2018). Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates. J Virol. 2018 Feb 7. pii: JVI.02035-17.  347. L\u00e1zaro-Fr\u00edas A, G\u00f3mez-Medina S, S\u00e1nchez-Sampedro L, Ljungberg K, Ustav M, Liljestr\u00f6m P, Mu\u00f1oz-Fontela C, Esteban M, Garc\u00eda-Arriaza J (2018). Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins. J Virol. 2018 Mar 7. pii: JVI.00363-18. doi: 10.1128/JVI.00363-18.  348. Fernandez L, Carrillo E, Sanchez-Sampedro L, Sanchez C, Ibarra-Meneses AV, Jimenez MA, Almeida VA, Esteban M and Moreno J (2018). Antigenicity of Leishmania-Aativated C-Kinases antigen (LACK) in human peropheral blood mononuclear cells and protective effect of prime/boost vaccination with pCI-neo-LACK plus attenuated L A C K-expressing viruses in hamsters. Frontiers Immunology 9, 843, doi:10.3389/fimmu.2018.00843  PATENTES  -VECTORES RECOMBINANTES BASADOS EN EL VIRUS MODIFICADO DE ANKARA (MVA) COMO VACUNAS CONTRA LEISHMANIASIS. Solicitud de invenci\u00f3n N\u00ba 200501886, 30 Julio 2005; PCT/ES2006/070122. US Application Serial No. 11/989.614, filing date January 29, 2008. Concedido T\u00edtulo de Patente de Invenci\u00f3n,  Oficina Espa\u00f1ola de Patentes y Marcas,  16 Febrero, 2009. N\u00ba publicaci\u00f3n 2281252. Eva P\u00e9rez-Jim\u00e9nez, Vicente Larraga y Mariano Esteban (licenciada).  - RECOMBINANT VECTORS BASED ON ANKARA MODIFIED VIRUS (MVA) AS PREVENTIVE AND THERAPEUTIC VACCINES AGAINST HIV. Carmen E. G\u00f3mez, Jos\u00e9 L. N\u00e1jera, Victoria Jim\u00e9nez y Mariano Esteban- Application Number and priority date: P200501841, 27/07/2005 and P200600762 (24.03.2006)- International PCT Application: PCT/ES06/070114- Countries selected in National Phase: EU, US- Present situation: Exclusive license agreement to Laboratorios del Dr. Esteve S.A. y la Fundaci\u00f3n Privada Institut de Recerca de la SIDA-CAIXA (Fundaci\u00f3n Irsi-CAIXA). (30/06/2012). EU Patent has been granted (EP1921146 B1) and has been validated in the following countries: Espa\u00f1a, Francia, Austria, B\u00e9lgica, Dinamarca, Finlandia, Alemania, Grecia, Islandia, Irlanda, Italia, Letonia, Luxemburgo, M\u00f3naco, Pa\u00edses Bajos, Portugal, Suecia, Suiza, Gran Breta\u00f1a, Polonia, Rumania y Chipre. US Patent has been granted (US 8,871,219 B2, 28/10/2014).   -MEJORAS INTRODUCIDAS EN EL OBJETO DE LA PATENTE PRINCIPAL N\u00ba ES200501841 PARA VECTORES RECOMBINANTES BASADOS EN EL VIRUS MODIFICADO DE ANKARA (MVA) COMO VACUNAS PREVENTIVAS Y TERAP\u00c9UTICAS CONTRA EL SIDA. Solicitud P200600762. 24 Marzo, 2006; PCT/ES2006/070114. Carmen E. G\u00f3mez, Jos\u00e9 L. N\u00e1jera, Victoria Jim\u00e9nez y Mariano Esteban (licenciada)  -VECTORES EN LOS QUE SE INSERTA EL GEN C7L Y USO DE LOS MISMOS EN LA FABRICACION DE VACUNAS Y DE COMPOSICIONES PARA TERAPIA G\u00c9NICA. Solicitud de Invenci\u00f3n N\u00ba200601240, 18 Mayo, 2006; PCT/ES2007/070091. Jos\u00e9 Luis N\u00e1jera, Carmen E. G\u00f3mez y Mariano Esteban.    35 -MODIFIED POXVIRUSES. US Provisional Patent Application No. 61/102,401. November 11, 2008. Michael Way, Antonio Postigo, Yoshiki Arakawa, Mariano Esteban, Susana Guerra.  -MODIFIED IMMUNIZATION VECTORS. US Provisional Patent Application, number 61174024, April 2009. PCT/US2010/032966. Mariano Esteban, Bertram Jacobs, Giuseppe Pantaleo, Thierry Calandra, Cornelius Melief, Rafick Sekaly, James Tartaglia . Application Number and priority date: 61/174024, 30/04/2009. Co-titularity with Arizona State University (AZ, USA), Centre Hospitalier Universitaire Vaudois (Switzerland), Leiden University Medical Center (The Netherlands), Universit\u00e9 de Montr\u00e9al (Canada), Sanofi Pasteur Ltd.- International PCT Application: PCT/US10/032966- Countries selected in National Phase: EU, US, CA  -M\u00c9TODO DE OBTENCI\u00d3N DE DATOS \u00daTILES PARA EVALUAR LA RESPUESTA AL TRATAMIENTO CON 5-FLUOROURACILO (5-FU). Solicitud de invenci\u00f3n N\u00ba P201130247, 24 Febrero 2011. G\u00e1rc\u00eda Ch\u00e1ves M.A., Aguilera G\u00f3mez M., Calleja Hern\u00e1ndez M.A., Marchal Corrales J.A., Esteban Rodr\u00edguez M., Carrasco Pardo E., Jim\u00e9nez Gonzalez G., Ar\u00e1nega Jim\u00e9nez A.  -VECTORES RECOMBINANTES  BASADOS EN EL VIRUS MODIFICADO DE ANKARA (MVA) CON DELECI\u00d3N  E N  E L  GEN C6L COMO VACUNA CONTRA EL VHI/SIDA Y OTRAS ENFERMEDADES. Presentada ante la Oficina Espa\u00f1ola de Patentes y Marcas el 19  de Julio de 2011. N\u00famero de solicitud 201131230. PCT/ES2012/070521 Juan F. Garc\u00eda-Arriaza, Carmen E. G\u00f3mez y Mariano Esteban.  -EFECTO ADYUVANTE DE LA PROTE\u00cdNA A27 DEL VIRUS VACCINIA (14K) Y SUS APLICACIONES EN VACUNAS. Presentada en la Oficina Espa\u00f1ola de Patentes y Marcas, 17 Noviembre de 2011. N\u00ba solicitud P201131854. Aneesh Vijayan, Carmen E. G\u00f3mez and Mariano Esteban.   -MVA-HCV como vacuna contra hepatitis C. Mariano Esteban., Beatriz Perdiguero y Carmen E. G\u00f3mez. Application Number and priority date: P201330467, 02/04/2013.- International PCT Application: PCT/ES2014/070246, 31/03/2014. On 09/10/2014 the mentioned International Patent Application has been published as WO 2014/162031. - Present situation: Exclusive license agreement to Plant Bioscience Limited (PBL) (6/05/2014) but sublicensing rights are available from PBL.  -MVA-CHIKV as a vaccine against Chikungunya virus. Mariano Esteban, Juan Garc\u00eda-Arriaza and Peter Liljestr\u00f6m. PCT/EP2014/076310, 2 Dic 2014- Present situation: Exclusive license agreement to Plant Bioscience Limited (PBL) (14/07/2014) but sublicensing rights are available from PBL (licenciada). WO2016/086980-A1, June 9, 2016.    ESTANCIAS EN CENTROS EXTRANJEROS    Centro: National Institute for Medical Research, Mill Hill      \n Localidad: Londres Pa\u00eds    Reino Unido Fecha: 1970-74 Duraci\u00f3n: 4 a\u00f1os Tema: Virus vaccinia, acci\u00f3n del interfer\u00f3n, control traduccional   Centro: Departamento de Microbiolog\u00eda. Rutgers Medical School  36 Localidad: New Jersey Pa\u00eds    USA Fecha: 1974-77 Duraci\u00f3n : 4 a\u00f1os Tema: Transcripci\u00f3n y replicaci\u00f3n del DNA del virus vaccinia   Centro: Laboratorio de Biolog\u00eda Molecular. Universidad de Gante Localidad: Gante Pa\u00eds B\u00e9lgica  Fecha: 1978 Duraci\u00f3n: 6 meses Tema: Clonaje y secuenciaci\u00f3n de DNA   Centro: Departamento de Microbiolog\u00eda e Inmunolog\u00eda. State University of New York ( S U N Y ), Downstate Medical Center Localidad: New York Pa\u00eds    USA Fecha: 1979-92 Duraci\u00f3n: 13.7 a\u00f1os Tema: Patog\u00e9nesis viral y expresi\u00f3n g\u00e9nica, accion del interferon.     CONTRIBUCIONES A CONGRESOS   1  1. Esteban, M. and Regueiro, B.  Mecanismo de accion del algunos antibioticos en el metabolismo de ribosomas del Streptococcus faecalis (enterococo). II Congreso Nacional de Microbiologia, Madrid, Noviembre 1969.  2. Esteban, M. and Regueiro, B.   Accion de la Nitrofurantoina sobre el metabolismo de ribosomas del Streptococcus faecalis (enterococo).  I. Symposium international on the mechanism of action of antibiotics, Zaragoza, Spain October, 1970.  3. Metz, D.H., Esteban, M. and Danielescu, G.  The processing of messenger - RNA in cells infected with vaccinia virus.  The virus group Meeting, SGM, University of Warwick, Coventry, England, September 1, 1974.  4. Kerr, I.M., Dobos, P., Martin, E.M., Metz, D.H. and Esteban, M.  Proteins synthesis in interferon-treated and virus-infected cells.  FEBS, Varna, Bulgaria, September 1971.  5. Esteban, M. and Metz, D.H.  Very early proteins synthesized in vaccinia infected cells. The virus group Meeting, SGM, Imperial College, London, April 1972.  6. Friedman, R.M., Esteban, M., Metz, D.H., Tovell, D.R., Kerr, I.M. and Williamson, R. Translation of RNA by cell-extracts:  effect of interferon.  FEBS, Amsterdam, Holland, August 1972, Abstract 476.  7. Esteban, M., Tovell, D.R., Friedman, R.M., Ball, L.A., Sonnabend, J.A. and Kerr, I.M. Inhibition of encephalomyocarditis (EMC) viral protein synthesis by interferon. International Congress of Biochemistry, Stockholm, Sweden, July 1973, Abstracts p. l75.  8. Friedman, R.M., Ball, L.A., Sonnabend, J.A., Esteban, M. and Kerr, I.M. Inhibition of v i r a l  m R N A  translation:  The mechanism of interferon action. International Congress of Biochemistry, Stockholm, Sweden, July 1973, p.l75.  9. Kerr, I.M., Friedman, R.M., Esteban, M., Brown, R.E., Ball, L.A., Metz, D.H., Risby, D., Tovell, D.R. and Sonnabend, J.A.  The control of protein synthesis in interferon-treated cells.  Workshop on virus-cell interactions, Berlin, January, 1973.                                                                37  10. Esteban, M.  Interferon inhibits the translation of viral mRNA in animal cell-free systems.  Gulbenkian Institute of Science, Oeiras, Portugal, September l973.  11. Esteban, M.  Characteristics of the interferon-mediated inhibitor(s) of viral mRNA translation in cell-free systems.  The virus group meeting, SGM, University of Leicester, England, January l974.  12. Esteban, M. and Holowczak, J.A.  The replication of vaccinia virus DNA. In vitro DNA synthesis in cytoplasmic cell-extracts from vaccinia virus infected L-cells.  III. International Congress for Virology, Madrid, Spain, September 1975, Abstracts p. l74.  13. Bablanian, R. and Esteban, M.  Vaccinia virus inducted inhibition of host protein synthesis is related to viral RNA synthesis.  III.  International Congress for Virology, Madrid, Spain, September 1975, Abstracts p. l0l.  14. Esteban, M., Cabrera, C.V. and Holowczak, J.A. l977.  In vitro transcription of Vaccinia virus DNA:  Analysis of viral mRNA by Electronmicroscopy.  Abstracts of the Annual Meeting, ASM, New Orleans; page 309.  15. Soloski, M.J., Esteban, M. and Holowczak, J.A. 1977.  DNA binding proteins in vaccinia virus infected mouse L-cells.  Abstracts of the Annual Meeting, ASM, New Orleans, p. 309.  16. Cabrera, C.V. and Esteban, M. 1977.  Transcription del virus vaccinia: Cuantificacion y Localizacion del ARN con fragmentos de restriccion.  VI Congreso Nacional de Microbiologia, Santiago de Compostela, Spain, Julio 6/9.  17. Soloski, M., Esteban, M. and Holowczak, J.A. 1977.  Evidence for proteins linked to the termini of Vaccinia DNA molecules, Poxvirus Workshop.  Cold Spring Harbor Laboratories, October, l2/l5.  18. Cabrera, C.V. and Esteban, M. 1977.  A procedure for purification of intact DNA from Vaccinia virus.  Poxvirus workshop.  Cold Spring Harbor Laboratories, October, l2/l5.  19. McCarron, R.J., Cabrera, C.V., Esteban, M., McAllister, W.T. and Holowczak, J.A. l977.  Structure of Vaccinia DNA:  Analysis of the viral genome by restriction endonucleases.  Poxvirus workshop.  Cold Spring Harbor Laboratories, October, l2/l5.  20. Esteban, M., Cabrera C.V. and Holowczak, J.A. 1977.  Proposed model for vaccinia DNA replication.  Poxvirus workshop.  Cold Spring Harbor Laboratories, October, l2/l2.  21. Esteban, M., Cabrera, C.V. and Holowczak, J.A. 1977.  Transcription of vaccinia DNA by E. coli RNA polymerase:  visualization and physical location of RNA transcripts. Poxvirus workshop.  Cold Spring Harbor Laboratories, October l2/l2.  22. Cabrera, C.V., Esteban, M., McCarron, R.J., McAllister, W.T. and H o l o w c z a k ,  J . A .  l 9 7 7 .   V a c c i n i a  virus transcription:  Hybridization of mRNA to restriction fragments of vaccinia DNA.  Poxvirus workshop.  Cold Spring Harbor Laboratories, October l2/l5.  23. Esteban, M., Cabrera, C., Soloski, J. and Holowczak, J.A. 1978. Replication of vaccinia DNA.  Synposium on DNA structure and replication. Cold Spring Harbor Laboratories.  May/June.  24. Soloski, M., Cabrera, C.V., Esteban, M. and Holowczak, J.A. l978.  Replication of vaccinia DNA.  IV  International Congress for Virology, The Hague, Holland, August 30/September.  6th Abstracts, p. 549.  25. Bablanian, R., Esteban, M. and Coppola, G.R. 1980.  The role of vaccinia virus transcription in the inhibition of host protein synthesis. ASM Miami Beach, pp. 230.  38  26. Soloski, M., Esteban, M. and Holowczak, J.A. (1980).  Vaccinia virus DNA replication. ICN-UCLA Symposia on Extrachromosomal DNA.  27. Esteban, M. and Pellicer, A. (l980).  Gene transfer of vaccinia DNA into animal cells. Third Poxviruses and Iridoviruses Workshop Set p. l5-l8. Cold Spring Harbor Laboratory.  28. Esteban, M. and Benavente, J. (1981).  Mechanism of action of interferon, VIII National Microbiology Congress.  Sept. 28 - Oct. l.  Madrid, Spain.  29. Esteban, M. and Benavente, J. (l981).  The effect of interferon on protein synthesis in vaccinia virus infected cells.  II International Congress for Interferon Research.  Oct. l.  San Francisco.  30. Esteban, M. (1982).  An effect of interferon on initiation and elongation of vaccinia DNA synthesis.  First annual meeting.  ASV Cornell University, Ithaca, New York, August l-5.  31. Santoro, M.G. Jaffe, B.M., Garaci, E. and Esteban, M. (1982).  Antiviral action of Prostaglandins of the A series:  inhibition of the replication of vaccinia virus.  V International Conference on Prostaglandins; Florence, May l8-2l, Italy.  32. Benavente, J. and Esteban, M. (1982).  Mechanism of inhibition of vaccinia virus protein synthesis by interferon.  Fourth Poxvirus-Iridovirus workshop, Cold Spring Harbor Laboratory, September 20-23.  33. Paez, E. and Esteban, M. (1982).  Vaccinia virus can overcome the antiviral action of interferon in some cells.  Fourth Poxvirus-Iridovirus workshop.  Cold Spring Harbor Laboratory, September 20-23.  34. Esteban, M., Boni, C. and Pellicer, A. (l982).  Phenotypic changes of cells transformed with vaccinia DNA.  Fourth Poxvirus-Iridovirus workshop. Cold Spring Harbor Laboratory.  September 20-23.  35. Santoro, G., Benavente, J., Paez, E., Jaffe, B. and Esteban, M. (1982). Inhibition of vaccinia virus protein synthesis by Prostaglandings of the A series.  Fourth Poxvirus-Iridovirus workshop.  Cold Spring Harbor Laboratory.  September 20-23.  36. Lewis, J.A., Mengheri, E. and Esteban, M. (1982).  Induction of an antiviral response by interferon requires thymidine kinase.   III International Congress for Interferon Research.  Miami, Florida; Nov. l-3.  37. Mengheri, E., Esteban, M. and J.A. Lewis (1982).  Thymidine Kinase genes and interferon sensitivity.  American Society for Cell Biology, 22nd Annual Meeting, Baltimore, Nov. 30-Dec.4.  38. Mengheri, E., Esteban, M. and Lewis, J.A. (1983).  Thymidine Kinase genes and interferon sensitivity.  83rd Annual Meetings, American Society for Microbiology, New Orlenans, 6-ll March; T-86.  39. Esteban, M. (l984).  Antiviral and antitumor properties of interferon: M e c h a n i s m  o f  a c t i o n .  3 r d  International Duran-Reynals Symposium on Viruses, Oncogenes and Cancer Barcelona, Spain, May 14-l7  40. Esteban, M., Benavente, J. and Paez, E. (l984).  Indiscriminate degradationof RNAs in interferon-treated, virus infected mouse L cells.  Third Annual Meeting of the American Society for Virology, Madison WI. July 22-26.  41. Paez, E. and Esteban, M. (1984).  Interferon inhibits marker rescue of vaccinia virus. Third Annual Meeting of the American Society for Virology.  Madison WI, July 22-26.  42. Esteban, M . ,  B o n i ,  C  a n d  P e l l i c e r ,  A .  ( 1984).  Expression of cloned v a c c i n i a  D N A  s e q u e n c e s  introduced into animal cells.  Fifth International Poxvirus/Irido virus Workshop.  Madison WI, July 22- 39 26.  43. Paez, E and Esteban, M. (1984).  Resistance of vaccinia virus to interferons: Activation of the 2-5A synthetase/endoribonucleare system and interference by viral proteins. Fifth International Poxvirus/Irido-virus Workshop, Madison.  WI. July 22-26.  44. Esteban, M. and Paez, M. (1985).  The 2-5A system in interferon-treated vaccinia virus infected cells.  Conference on \"The 2-5A system\" Toronto, Canada, June 2-5, 1985.  45. Paez, E. and Esteban, M. (1985).  Interferon prevents the generation of spontaneous deletions at the left terminus of vaccinia virus DNA. Conference on \"The 2-5A system.\"  Toronto, Canada, June 2-5, 1985.  46. Esteban, M. (1986).  Mechanism of antiproliferative action of interferons. In \"Interferons as cell growth inhibitors and antitumor factors.\" UCLA Symposia, April 6-12, Steamboat Springs, Colorado (Invited participant).  47. Rodriguez, J.F., Paez, E. and Esteban, M. (1986).  A 14K envelope protein of vaccinia virus is involved i n  v i r u s-induced cell fusion.  Six International Poxvirus/Iridovirus Workshop.  Cold Spring Harbor Laboratory, New York, Sept. 24-28.  48. Kahn, J., Rodriguez, J.F. and Esteban, M. (1986).  Molecular cloning, e n c o d i n g  s e q u e n c e  a n d  expression of vaccinia virus nucleic acid dependent nucleoside triphosphatase gene.  Six International Poxvirus/Iridovirus Workshop.  Cold Spring Harbor Laboratory, New York, Sept. 24-28.  49. Paez, E. and Esteban, M. (1986).  Isolation and characterization of spontaneous deletion mutants of vaccinia virus.  Six International Poxvirus/Iridovirus Workshop. Cold Spring Harbor Laboratory, New York, Sept. 24-28.  50. Paez, E. and Esteban, M. (1986).  Isolation and characterization of spontaneous mutants of vaccinia virus sensitive to inhibition by interferon. Six International Poxvirus/Iridovirus Workshop.  Cold Spring Harbor Laboratory, New York, Sept. 24-28.  51. Dallo, S., Maa, J-S. and Esteban, M. (1986).  Isolation and characterization of attenuated mutants of vaccinia virus.  Six International Poxvirus/Iridovirus Workshop. Cold Spring Harbor Laboratory, New York, Sept. 24-28.  52. Bablanian, R., Goswami, S.K., Esteban, M. and Banerjee A.K. (1986). Mechanism of selective inhibition of protein synthesis by vaccinia virus: role of poly A. Six International Poxvirus/Iridovirus Workshop.  Cold Spring Harbor Laboratory, New York, Sept. 24-28.  53. Portela, A., Rodriquez, J.R., Rodriguez, D., Rodriguez, J.F., Esteban, M. and Melero, J.A. (1988) I Congreso Nacional de Virologia, Madrid, Spain.  \"Expression de l a  p r o t e i n a  d e  f u s i o n  d e l  v i r u s  sincitial respiratorio en recombinantes del virus de la vacuna.  p.19.  54. Esteban, M., Rodriquez, D., Rodriguez, J.R., Rodriguez, J.F., and Trauber, D. (1988) I Congreso Nacional de Virologia, Madrid, Spain 1988.  \"Attenuated vaccinia virus to generate safe recombinant vaccines\".  Simposio.   55. Esteban, M., Rodriquez, D., Rodriguez, J.R., and Rodriguez, J.F. (1988) II Congreso Nacional de Biotecnologia, Barcelona, Spain.  \"Vaccinia virus as an expression vector and a polyvalent vaccine\".  p.25.   56. Esteban, M., Rodriquez, D., Rodriguez, J.R., Rodriguez, J.F. (1988)  III Congreso Luso-Espanol de Bioquimica.  Santiago de Compostela, Spain.  \"Virus  recombinantes atenuados de HIV-vaccinia como vacunas contra el SIDA\".  p.100.  40  57. Rodriguez, D., Rodriquez, J-R., Rodriguez, J.F., Trauber, D., and Esteban, M. (1988) VII International Meeting on Poxvirus-Iridovirus.  Heidelberg, Germany.  \"Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses\". p.93.  58. Maa, J.S., Rodgriguez, J.F. and Esteban, M. (1988).  Mode of entry of poxviruses into cells:  structural and functional studies of vaccinia virus cell attachment and fusion proteins.  VII International Meeting on Poxvirus-Iridovirus.  Heidelberg, Germany, August 22-26.  pg.66.  59. Portela, A., Rodriguez, D., Rodriguez, J-R., Rodriguez, J.F., Esteban, M. and Melero, J.A. (1988).  \"Expression of the fusion (F) protein of human respiratory syncytial virus using an attenuated strain of vacccinia virus\". International Meeting on negative strand RNA virus.  France  60. Esteban, M .  ( 1 9 8 9 ) .   P r e v e n t i o n  o f  v i r a l  D N A  s e q u e n c e  a l t e r a t i o n s  b y  i n t e r f e r o n .  N A T O ,  T h e  Molecular basis of cell growth regulation, Mallorca, Spain, April 30-May 10.  61. Esteban, M., Irvine, M. and Kahn, J.S. (1989).  Mechanism of resistance of vaccinia virus to interferons.  Annual Meeting of the International Society for Interferon Research, Florence, Italy, Oct. 22-27.  62. Lai, C., Gong, S, and Esteban, M (1989). Structural and functional an\u00e1lisis of the 14 kDa membrane protein of vaccinia virus. Symposium on Life Sciences for the Chinese Students in the USA. Cambridge, Massachussets, USA, July 21-23, p98.  63. Esteban, M., Lai, C., Rodriguez, D. and Rodriguez, J.R. (1990) Functional characterization of the 32 KDa cell surface binding protein of vaccinia virus.  8th International Poxvirus/Iridovirus Meeting, Wintergreen, Virginia, USA, May 15-20, p 98.  64. Rodriguez, D., Zhou, Y., Rodriguez, J.R., Russell, U.D., Jiminez, V., McAllister, W.T. and Esteban, M. (1990) Regulated e x p r e s s i o n  o f  n u c l e a r  g e n e s  b y  T 3  R N A  p o l y m e r a s e  a n d  l a c  r e p r e s s o r  u s i n g  recombinant vaccinia virus vectors.  8th International Poxvirus/Iridovirus Meeting, Wintergreen, Virginia, USA, May 15-20, p 143.  65. Lai, C., Gong, S. and Esteban, M. (1990) Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14KDa virus envelope protein. 8th International Poxvirus/Iridovirus Meeting, Wintergreen, Virginia, USA, May 15-20, p 109.  66. Gong, S., Lai, C. and  Esteban, M. (1990).  Mechanism of cell fusion induced by vaccinia virus.  VIII International Congress of Virology, Berlin, August 26-31, p 77.  67. Rodriguez, J.R., Rodriguez, D. and Esteban, M. (1990).  Chimeras of HIV-1 env a n d  t h e  1 4 K D a  envelope protein of vaccinia virus.  VIII International Congress of Virology, Berlin, August 26-31, p 357.  68. Esteban, M., Maa, J-S and Demkowicz, W.E. (1991).  Indentification of vaccinia virus genes encoding immunodominant proteins in vaccinated humans.  10th Annual Meeting.  American Society for Virology.  Colorado State University, Fort Collins, July 7-11.  69. Diaz-Guerra, M. and Esteban, M. (1992).  Role of vaccinia virus ATPase-I on viral gene expression.  9th International Congress on Poxviruses and Iridoviruses.  Les Diablerets, Switzerland, Sept. 1-6, p.96.  70. Rodriguez, D., Rodriguez, J-R and Esteban, M. (1992).  The 14KDa fusion protein of vaccinia virus forms a heterodimer.  9th International Congress on Poxviruses and Iridoviruses.  Les Diablerets, Switzerland, Sept. 1-6,; p121.   41 71. Lee, S.B., Melkova, Z., Yan, W., Williams, B.R.G., Hovanessian, A. and Esteban, M. (1992).  The interferon-induced double-sttranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells.  9th International Congress on Poxvirus and Iridoviruses.  Les Diablerets, Switzerland, Sept. 1-6, p153.    72. Bablanian, R. and Esteban, M. (1992).  Translational control of vaccinia virus-infected cells.  Workshop on Translational Control.  Cold Spring Harbor Laboratory, New York, Sept. 9-13.  73. Lee, S.B and Esteban, M ( 1 9 9 3 ) .  T h e  i n t e r f e r o n-induced ds-RNA dependent human p68 protein kinase inhibits the replication of vaccinia virus. Annual Meeting of the International Society of Interferon Research. Toronto, Canada.  74. Lee, S.B and Esteban, M ( 1 9 9 3 ). The interferon-induced ds-RNA dependent human p68 protein kinase induces apoptosis. IX International Congress of Virology, 8-13 August, Glasgow. U.K  75. Esteban, M. ( 1 9 9 3 ) .  V a c c i n i a  v i r u s  v e c t o r s  a s  p o t e n t i a l  v a c c i n e s .  F i r s t  W o r k s h o p  o n  \" M o l e c u l a r  Genetics in Modern Biotecnology\", Mallorca. Spain.   76. Esteban, M. (1993). The interferon-induced ds-RNA dependent human p68 protein kinase as an inducer of apoptosis. Workshop on 'Viral Evasion of Host Defence Mechanisms\". Fundacion Juan March, 20-22 September. Madrid. Spain.   77. Esteban, M. (1994). Vaccinia Virus Vectors as Potential Vaccines Against Malaria. UNESCO meeting on \"Combating Malaria\", 19-21 January. Paris. France.  78. Lee, S.B and Esteban, M. (1994). Vaccinia virus induces apoptosis and this process could involve a ds-RNA dependent protein kinase. 10th International Poxvirus/Iridovirus Meeting. April 30-May 5, Banff. Alberta. Canada.  79. Melkova, Z and Esteban, M. (1994). Role of nitric oxide in the inhibition of vaccinia virus replication in macrophages by interferon-gamma. 10th International Poxvirus/Iridovirus Meeting. April 30-May 5. Banff. Alberta. Canada.   80. Lee, S.B., Greene, S., Mathews, M.B and Esteban, M. (1994). Activation of the double-stranded RNA (dsRNA)-activated human protein kinase in the absence of its dsRNA binding domain. Meeting on Translational Control. Cold Spring Harbor Laboratory, New York, August 24-28, USA.  81. Esteban, M a n d  L e e ,  S . B  ( 1 9 9 4 ) .  R o l e  o f  t h e  i n t e r f e r o n-induced human protein kinase(p68) in the induction of apoptosis. International Workshop on The Biochemistry and Regulation of Programme Cell Death. Fundaci\u00f3n Juan March. May 33-25, Madrid, Spain.  82. Esteban, M (1994). Combined live virus immunization against pathogens. International Workshop on  Resistance to Viral Infection. Fundaci\u00f3n Juan March. June 20-22, Madrid, Spain.  83. Lee, S.B., Green,R., Mathews, M.B, and Esteban, M. (1994). Identification of  a novel domain important for the activation of the double-stranded RNA-activated human protein kinase. BIOTEC 94. II Congreso Ib\u00e9rico de Biotecnologia. 1-4 Octubre, Universidade do Algarve. Portugal.  84. Rodriguez, D., Rodriguez, J.R and Esteban, M. (1994). Vaccinia virus A17L gene product is essential for virus replication. BIOTEC 94. II Congreso Ib\u00e9rico de Biotecnologia. 1-4 Octubre. Universidade do Algarve. Portugal.  85. Esteban, M ( 1 9 9 4 ) .  Novel vaccine strategies against HIV. II International Symposium on HIV Therapeutic and Vaccine Strategies. Fundaci\u00f3n Ram\u00f3n Areces. October 27-28, Madrid, Spain.  86. Melkov\u00e1, Z., Lee, S.B and Esteban, M (1995). Bcl-2 prevents development of nitric oxide-mediated  42 apoptosis. In \" Molecular Biology and Pathophysiology of nitric oxide. Juan March Foundation. Madrid, June 5-7.  87. Melkov\u00e1, Z and Esteban, M (1995). Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. In \" Molecular Biology and Pathophysiology of nitric oxide \"Juan March Foundation. Madrid, June 5-7.  88. Rodriguez, D., Rodriguez, J.R and Esteban, M (1995). The product of the vaccinia virus A17L gene is essential for an early stage of viral morphogenesis. In IV National Congress of Virology. Madrid, September, 21-23, p129  89. Pav\u00f3n, M., Jimenez, V and Esteban, M ( 1 9 9 5 ) .  T h e  h u m a n  p r o t o o n c o g e n  B c l-2 inhibits apoptosis induced by vaccinia virus. In IV National Congress of Virology. Madrid, September, 21-23, p200.  90. Suarez, P., Diaz-Guerra, M., Prieto, C., E s t e b a n ,  M., Castro, J.M and Ortin, J (1995). The protein encoded by ORF-5 of PRRS virus induces apoptosis. In IV National Congress of Virology. Madrid, September 21-23, p201.  91. Diaz-Guerra, M and Esteban, M (1995). Activation of the 2-5 A Synthetase/RNase L  system during infection with vaccinia virus. In IV National Congress of Virology. Madrid, September 212-23, p227.  92. Esteban, M., Mathews, M.B and Lee, S.B (1995). Structure-function of the protein kinase p68 induced by interferons. In IV National Congress of Virology. Madrid, September 21-23, p161.  93. Collado, M., Rodriguez, J.R., Rodriguez, D and Esteban,M (1995). Chimeric proteins of HIV-vaccinia as immunogens. In IV National Congress of Virology. Madrid, September 21-23, p190.  94. Pav\u00f3n, M and Esteban,M (1995). The protein kinase induced by interferons changes the pattern of phosphorylation of proteins in HeLa cells. In IV National Congress of Virology. Madrid, September 21-23, p220.  95. Melkova, Z and Esteban, M (1995). Inhibition of vaccinia virus replication by nitric oxide. In IV National Congress of Virology. Madrid, September 21-23, p221.  96. Diaz-Guerra, M., Melkov\u00e1, Z and Esteban, M (1995). Ability of the 2-5-Synthetase/RNase l system to inhibit the replication of vaccinia virus. Annual Meeting of the International Society for Interferon and Cytokine Research. Baltimore. November 6-11, p119.  97. Melkov\u00e1, Z and Esteban, M (1995). Inhibition of vaccinia virus replication by inducible expression of nitric oxide synthase. Annual Meeting of the International Society for Interferon and Cytokine  Research. Baltimore. November 6-11, p131.  98. Mart\u00edn-Gallardo, A., Moratilla, M., Agromayor, M., Funes, J.M Nu\u00f1ez, A.J., Varas, A., Lopez-Estebaranz, J.L., Valencia, A., Collado, M and Esteban, M. (1996). Random DNA sequencing computer-based approach for the construction of a gene map of Molluscum Contagiosum virus. XI Poxvirus and Iridovirus Meeting. Toledo, Spain. May 4-9. p41  99. Moratilla, M., Agromayor, M., Nu\u00f1ez, A., Funes, J.M., Esteban, M a n d  M a r t i n-Gallardo, A (1996). Sequencing and analysis of a DNA region from Molluscum Contagiosum virus that include the homolog of the vaccinia fusion protein. XI Poxvirus and Iridovirus Meeting. Toledo, Spain. May 4-9. p 62  100. Rodriguez, J.R., Rodriguez, D., Risco, C., Carrascosa, J.L and Esteban, M. (1996).  Vaccinia virus A14L gene product is a component of the virion membrane. XI Poxvirus and Iridovirus Meeting. Toledo, Spain. May 4-9. p 63   43 101. Vazquez, M.I., Valencia, A., Serrano, L and Esteban, M (1996). Structural analysis of the membrane fusion protein (ORF A27L) of vaccinia virus. XI Poxvirus and Iridovirus Meeting. Toledo, Spain. May 4-9. p 79.  102. Rodriguez, D., Rodriguez, J.R., Risco, C., Carrascosa, J.L and Esteban, M ( 1 9 9 6 ) .  Reversibility of vaccinia virus morphogenesis blockage caused by inhibition of VV A17L gene expression. XI Poxvirus and Iridovirus Meeting. Toledo, Spain. May 4-9. p 136.   103. Krijnse-Locker, J., Schleich, S., Rodriguez, D., Esteban, M and Griffiths, G (1996). The role of p21 (A17L) in the assembly of vaccinia virus from the intermediate compartment. XI Poxvirus and Iridovirus Meeting. Toledo, Spain. May 4-9. p 137.  104. Murata, K., Garcia-Sastre, A., Tsuji, M., Rodrigues, M., Rodriguez, D., Rodriguez, J.R., Nussenzweig, R., Palese, P., Esteban, M a n d  Z a v a l a ,  F  ( 1 9 9 6 ) .   Enhanced primary and secondary CD8+T cell responses by immunizing with live recombinants of influenza and vaccinia viruses expressing malaria antigens. XI Poxvirus and Iridovirus Meeting. Toledo, Spain. May 4-9. p 224.  105. Garcia-Sastre, A., Miyahira, Y., Zavala, F., Nussenzweig, R., Rodriguez, D., Rodriguez, J.R., Esteban, M and Palese, P (1996).  Influenza vectors expressing B-cell and T-cell epitopes from the circumsporozoite protein of Plasmodium falciparum.  In \"Genetic Engineering of Viruses and Viral Vectors\". Irvine, CA. June 8-11.  106. Pav\u00f3n, M and Esteban, M (1996). Identification of modulators and new substrates of the interferon-induced ds-RNA activated protein kinase (PKR) by affinity binding assays. FEBS Meeting. Barcelona. July 8-12.  107. Esteban, M (1996). Role of interferon-induced enzymes in control of viral infections. In \"Cytokines and Infectious Diseases\". Juan March Foundation. Madrid. June 3-5.  108. Gonzalo, R., Rodriguez, D., Rodriguez, J.R., Garcia-Sastre, A., Palese, P, and Esteban, M (1997). Enhanced cellular immune response to HIV-1 env b y  c o m b i n e d  i m u n i z a t i o n  w i t h  i n f l u e n z a  a n d  vaccinia virus recombinants. 2nd European Conference on Experimental AIDS Research. Stockholm, Sweden. May 31-June 3, 1997. Abstract, 107-P3.  109. Collado, M., Rodriguez, D., Rodriguez, J.R., Gonzalo, R.M., Vazquez, I, and Esteban, M ( 1 9 9 7 ) .  Modulation of the immune response elicited against HIV-env ant i gen t hr ough i t s f usi on t o vacci ni a virus antigens. 2nd European Conference on Experimental AIDS Research. Stockholm, Sweden. May 31-June 3, 1997. Abstract, 108-P3.  110. Rodriguez, J.R., Rodriguez, D., Risco, C., Carrascosa, J.L and Esteban, M (1997). El producto del gen A14L del virus vacunal es esencial en e s t a d i o s  t e m p r a n o s  e n  l a  m o r f o g \u00e9 n e s i s .  V  C o n g r e s o  Nacional de Virologia. Santiago de Compostela. Septiembre 7-10. p289  111. Vazquez, M.I., Rivas, G., Blanco, F ., Serrano, L and Esteban, M (1997). Modelo estructural de la proteina de fusi\u00f3n de 14 KD (ORF A27L) del virus vacunal. V Congreso Nacional de Virologia. Santiago de Compostela. Septiembre 7-10. p294  112. Collado, M., Rodriguez, D., Rodriguez, J.R., Vazquez, M.I and Esteban, M (1997). Modulaci\u00f3n de la respuesta inmune frente al ant\u00edgeno env del VIH-1 mediante su fusi\u00f3n a ant\u00edgenos del virus vaccinia. V Congreso Nacional de Virologia. Santiago de Compostela. Septiembre 7-10. p 313.  113. Vazquez, M.I., Serrano, L and Esteban, M (1997). Estudios in vitro e in vivo acerca de la interacci\u00f3n de las pproteinas codificadas por los genes A17L y A27L del virus vacunal. V Congreso Nacional de Virologia. Santiago de Compostela. Septiembre 7-10. p 31.  114. Rodriguez, J.R., Gonzalo, R.M., Rodriguez, D., Garcia-Sastre, A., Palese., and Esteban, M (1997). La  44 inmunizaci\u00f3n combinada con virus recombiantes vaccinia aumenta la respuesta inmune celular contra ant\u00edgenos de VIH-1. V Congreso Nacional de Virologia. Santiago de Compostela. Septiembre 7-10. p329  115. Rivas, C., Diaz-Guerra, M and Esteban, M ( 1 9 9 7 ) .  L a  a c t i v a c i \u00f3 n  d e  l a  e n z i m a  i n d u cible por el interfer\u00f3n RNasa L, expresada en c\u00e9lulas infectadas por un virus vaccinia recombinante induce apoptosis. V Congreso Nacional de Virologia. Santiago de Compostela. Septiembre 7-10. p 341  116. Esteban, M., Rodriguez, D., Rodriguez, J.R., Vazquez, I., Llorente, M., Lucas, P., Martinez, C and del Real, G (1998). Fusion of GM-CSF to HIV-1 env enhances the cellular immune response against env. Third European Conference on Experimental AIDS Research, Munich, Germany, February 28-March 3.  117. Vazquez, I., Rivas, G., Cregut, D., Serrano, L and Esteban, M (1998). Triple coiled-coil model for 14 kDa fusion protein (ORF A27L) of vaccinia virus: structural and functional analyses. XII International Poxvirus Symposium. St. Thomas, Virgin Islands, June 6-10  118. Rivas, C., Gil, J., Melkova, Z., Esteban, M a n d  D i a z-Guerra, M (1998). Inhibition of the interferon (IFN)-induced 2-5 A synthetase by the E3L protein of vaccinia virus. XII International Poxvirus Symposium. St. Thomas, Virgin Islands, June 6-10  119. Gonzalo, R., Rodriguez, D., Gonzalez, G., Larraga, V., Rodriguez, J.R and Esteban, M ( 1 9 9 8 ) .  Protection of mice against Leishmania infection by vaccinia virus recombiants. XII International Poxvirus Symposium. St. Thomas, Virgin Islands, June 6-10  120. Miyahira, Y., Garcia-Sastre., Rodriguez, D., Rodriguez, J.R., Tsuji, M., Palese, P., Zavala, F., Nussenzweig, R and Esteban, M (1998). Recombiant viruses expressing a human malaria antigen elicit a protective immune response in mice. XII International Poxvirus Symposium. St. Thomas, Virgin Islands, June 6-10  121. Risco, C., Rodriguez, J.R., Demkowicz, W., Heljasvaara, R., Carrascosa, J.L ., E s t e b a n ,  M a n d  Rodriguez, D (1998). The vaccinia virus 39 kDa protein forms a stable complex with the p4a/4a major core protein. XII International Poxvirus Symposium. St. Thomas, Virgin Islands, June 6-10  122. Gherardi, M and Esteban, M (1998). Oral immunization with recombinants of vaccinia virus induces mucosal and systemic immune responses to the vector and to the recombinant product HIV env. XII International Poxvirus Symposium. St. Thomas, Virgin Islands, June 6-10  123. Heljasvaara, R., Rodriguez, J.R., Risco, C., Carrascosa., Esteban, M a n d  R o d r i g u e z ,  D  ( 1 9 9 8 ) .  Phenotypic characterization of a conditional lethal vaccinia virus mutant that inducibly express the A10L gene. . XII International Poxvirus Symposium. St. Thomas, Virgin Islands, June 6-10.  124. Gil, J and Esteban, M (1998). Involvement of eIF-2a and IkBa in aspoptosis mediated by the dsRNA dependent protein kinase PKR. Second Joint Meeting of the International Society for Interferon and Cytokine Research. Jerusalem, Israel, 25-30 October.  125. Esteban, M ( 1999) .  Enhancement  of  t he i mmune r esponse t o pat hogens by pr i me/ boost  wi t h DNA and vaccinia-MVA recombinants.  ELMAU Workshop \u201cThe modified Vaccinia Ankara\u201d in Vaccination and Immunotherapy. 28-31 January. Munich, Germany.  126. Esteban, M., Rodriguez, D., Rodriguez, J.R Garcia-Sastre, A., Palese, P., Zavala, F, and Nussenzweig, R (1999). Malaria vaccine: activation of potent and protective immune responses to malaria by combined immunization with recombinant viruses. In \u201cPerspectives on Infectious Disease Research. EU Conference. Dresden, February 1-3.  127. Rodriguez, D., Rodriguez, J., Llorente, M., Lucas, P., Esteban, M., Martinez, C, and del Real, G. Use  45 of DNA priming and vaccinia virus boosting to trigger an efficient immune response to HIV-1 gp120. In \u201cPerspectives on Infectious Disease Research. EU Conference. Dresden, February 1-3.  128. Gil, J and Esteban, M (1999). Induction of apoptosis by the dsRNA dependent protein kinase PKR involves eIF-2a and NF-kB. In Regulation of Protein Synthesis in Eukaryotes. Juan March Workshop, March 8-12, Madrid, Spain.  129. Gherardi, M., Ramirez, J.C., Rodriguez, D., Rodriguez, J.R., Gen-Ichiro, S., Zavala, F., and Esteban, M (1999). IL-12 delivered from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-env in a dose-dependent manner. The fourth European Conference on Experimental AIDS Research. June 18-21.Tampere, Finland   130. Rodriguez, D., Rodriguez, J., Llorente, M., Lucas, P., Esteban, M., Martinez, C, and del Real, G. Use of DNA priming and vaccinia virus boosting to trigger an efficient immune response to HIV-1 gp120. The fourth European Conference on Experimental AIDS Research. June 18-21.Tampere, Finland   131. Gil, J., Alcami, J, and Esteban, M (1999). Mechanism of NF-kB activation of the interferon-induced enzyme PKR: role in apoptosis. III Joint meeting of the International Cytokine Society and International Society for Interferon and Cytokine Research. Paris, September 5-9.  132. Ramirez, J.C., Gherardi, M.M, and Esteban, M (1999). Caracterizaci\u00f3n in vivo de la multiplicaci\u00f3n y respuesta inmune inducida por el virus vaccinia atenuado MVA en ratones. VI Congreso Nacional de Virologia. Majadahonda, Madrid, Octubre 24-27  133. Gil, J., Alcami, J, and Esteban, M (1999). Mecanismo de apoptosis inducida por la proteina antiviral PKR. . VI Congreso Nacional de Virologia. Majadahonda, Madrid, Octubre 24-27  134. Gherardi, M.M., Ramirez, J.C., Rodriguez, D., Rodriguez, J.R and Esteban, M (1999). Desarrollo de estrategias de vacunaci\u00f3n frente al HIV basadas en recombinantes del virus vaccinia y la citoquina IL-12. . VI Congreso Nacional de Virologia. Majadahonda, Madrid, Octubre 24-27  135. Rodriguez, J.R., Heljasvaara, R., Risco, C., Carrascosa, J.L., Esteban, M, and Rodriguez, D (1999). La proteina p4a (gen A10L) del virus vaccinia es esencial para la maduraci\u00f3n del virus.  VI Congreso Nacional de Virologia. Majadahonda, Madrid, Octubre 24-27  136. Risco, C., Rodriguez, D., Rodriguez, J.R., Esteban, M. and Carrascosa,J.L.(1999). Immunogold studies on vaccinia virus assembly: localization of p15, p21,p14, and p39 viral proteins after reversal of morphogenesis blockage. XI European Congress on Microscopy (Dublin, Ireland, August, 26-30).  137. Risco, C., Rodriguez, D., Rodriguez, J.R., Esteban M. y Carrascosa J.L. (1999). Morfogenesis de poxvirus: aspectos estructurales. XIX Reunion Bienal de la Sociedad Espanola de Microscopia Electronica (Murcia, 28-30 de abril).  138. Risco C., Rodriguez D., Lechaire J.P., Rodriguez J.R., Gaill F., Esteban M. and Carrascosa J.L. (2000). New insights on the structure and morphogenesis of vaccinia virus. XII European Congress on Electron Microscopy (Brno, Czech Republic, July 9-14).  139. Navarro, J., Abad, M.L., Resino, S., Jimenez, J.L., Canto, C., Rodriguez, D., Lopez, F., Esteban, M., Mu\u00f1oz-Fernandez, M.A, and Fernandez-Cruz, E (2000). Effect of a gp120-depleted inactivatyed HIV-1 immunogen (Remunetm) on the control of nuclear factor kappa-B activation, cytokine production and augmentation of HIV-specific cytotoxic T lymphocytes. V European Conference on Experimental Aids Research (ECEAR). Madrid, June 16-19.  140.  Ramirez, J.C., Gherardi, M. M, and Esteban, M ( 2 0 0 0 ) .  IL-2 actions on the specific anti-env cell mediated immune response when delivered from vaccinia virus and bimodal DNA prime/boost vaccination regimen. . V European Conference on Experimental Aids Research (ECEAR). Madrid,  46 June 16-19.  141. Gomez, C. E., Rodriguez, D., Rodriguez, J.R., Abaitua, F., Duarte, C, and Esteban, M (2000). A V3 loop multiepitope polypeptide of HIV-1 Env (TAB13) expressed from DNA, vaccinia virus WR and modified virus Ankara vectors induces peptide specific CD8+ T cell response in mice. V European Conference on Experimental Aids Research (ECEAR). Madrid, June 16-19.  142. Yang, W.Y.,Chang, L-Y., Gil, J., Esteban, M, and Roth, D (2000). The effect of specific phosphorylation of plant eIF-2a on plant translational control. Translational Control. Cold Spring Harbor . New York. August   143. Risco, C., Rodriguez, D., Rodriguez, J.R., Esteban, M and Carrascosa, J.L (2000). New insights on the structure and morphogenesis of vaccinia virus. XIII International poxvirus and Iridovirus symposium. Montpellier, France, September 2-6, p79.  144. Abaitua, F., Rodriguez, J.R., Rodriguez, D, and Esteban, M (2000). Coadministration of two vaccinia virus recombinants expressing HIV-env and interferon gamma results in a decreased in viral replication but favours a strong anti-env immune response. XIII International poxvirus and Iridovirus symposium. Montpellier, France, September 2-6, p138.  145. Gil, J, and Esteban, M (2000). Inhibition of vaccinia virus replication by the interferon-induced protein kinase PKR: mechanism of action. XIII International poxvirus and Iridovirus symposium. Montpellier, France, September 2-6, p154.  146. Ramirez, J.C., Gherardi, M, and Esteban, M (2000). IL-18 and IL-12 synergize in protection against vaccinia virus infection in mice and enhance the cellular immune response against the virus. XIII International poxvirus and Iridovirus symposium. Montpellier, France, September 2-6, p158.   147. Rodriguez, J.R., Gherardi, M., Rueda, G.G., Nussenzweig, R., Casal, I., Esteban, M, and Rodriguez, D (2000). Immunogenicity of parvovirus VLPs bearing a CD8+ T cell epitope of the CS protein of P. yoelii: enhanced CD8+ T cell response by boosting with vaccinia virus recombinant. XIII International poxvirus and Iridovirus symposium. Montpellier, France, September 2-6, p188.  148. Navarro, J., Abad, M.L., Resino, R., Jimenez, J.L., Cant\u00f3, C., Diaz, L., Rodriguez, D., Esteban, M, Mu\u00f1oz-Fernandez, M.A and Fernandez-Cruz, E (2000). Effect of a Gp 120-depleted inactivated HIV-1 immunogen (Remune TM) on the control of nuclear factor Kappa-B activation, cytokine production and augmentation of HIV-1 specific cytotoxic T lymphocytes. Fifth. Eur. Conf. Exp. AIDS Res (ECEAR) 16-19 June, Madrid, Spain.   149.  Ramirez, J.C., Gherardi, M.M., Rodriguez, D., Rodriguez, J.R and Esteban, M (2000). IL-12 actions on the specific anti-env cell mediated immune response when delivered from vaccinia virus in bimodal DNAprime /VV boost vaccination regimen.  Fifth. Eur. Conf. Exp. AIDS Res (ECEAR) 16-19 June, Madrid, Spain.  150. Garc\u00eda, M.A., Gil, J., Jimenez, V y Esteban, M ( 2 0 0 1 ) .  L a  e x p r e s i \u00f3 n  d e  la proteina E3L del virus vaccinia en c\u00e9lulas 3T3 inhibe la apoptosis mediada por PKR. . VII Congreso Nacional de Virolog\u00eda. Valencia, 16-19 Sept. p94  151. Gil, J., Garc\u00eda, M.A., Rull\u00e1s, J., Alcam\u00ed, J y Esteban, M (2001). Inducci\u00f3n de la apoptosis y activaci\u00f3n del factor de transcripci\u00f3n NF-kB por la enzima PKR. . VII Congreso Nacional de Virolog\u00eda. Valencia, 16-19 Sept. p79  152. Abaitua, F., Rodriguez, J.R., Rodriguez, D y Esteban, M ( 2 0 0 1 ) .  L a  r e s p u e s t a  i n m u n e  f r e n t e  a  l a  proteina env del VIH se incrementa por la coexpresi\u00f3n de la proteina de choque t\u00e9rmico Hsp70. . VII Congreso Nacional de Virolog\u00eda. Valencia, 16-19 Sept. p74.   47 153. Gallego, J.C., Rodriguez, D., Risco, C., Cabezas, P., Carrascosa, J.L., Rodriguez, J.R y Esteban, M (2001). Morfog\u00e9nesis de un mutante (M65) del virus vaccinia: caracterizaci\u00f3n estructural y funcional. VII Congreso Nacional de Virolog\u00eda. Valencia, 16-19 Sept. p162  154.  Blanco, S., Rodriguez, J.R., Abaitua, F., Zavala, F., Esteban, M y Rodriguez, D (2001). Modulaci\u00f3n por citoquinas de la respuesta inmune frente al ant\u00edgeno CS de Plasmodium. . VII Congreso Nacional de Virolog\u00eda. Valencia, 16-19 Sept. p165  155.  C.G\u00f3mez, C.E., Rodriguez, D., Rodriguez, J.R., Abaitua, F., Duarte, C y Esteban, M ( 2 0 0 1 ) .  V I I  Congreso Nacional de Virolog\u00eda. Valencia, 16-19 Sept. p166.  156. L\u00f3pez-Fuertes, L., P\u00e9rez-Jimenez, E., Moreno, S., Vila-Coro, A., Wittig, B., Junghans, C., Konig, S.A., Simon, M and Esteban, M ( 2 0 0 1 ) .  DNA immunization of susceptible mice with minimalistic expression constructs expressing the LACK protein of Leishmania major.  VII Congreso Nacional de Virolog\u00eda. Valencia, 16-19 Sept. p166  157. Tapia, E., P\u00e9rez-Jimenez, E., L\u00f3pez-Fuertes, L., Gonzalo, R y Esteban, M (2001). Inducci\u00f3n de una respuesta inmune protectiva frente a la Leishmaniasis cut\u00e1nea mediante la utilizaci\u00f3n de vectores de DNA y virus vaccinia recombinantes que expresan la proteina LACK de Leishmania infantum. . VII Congreso Nacional de Virolog\u00eda. Valencia, 16-19 Sept. p167.  158. S\u00e1nchez, A.B., Rodriguez, D., Garz\u00f3n, A., Amorena, B., Esteban, M y  R o d riguez, J.R (2001). La proteina env del virus Maedi-Visna expresada por un recombinante del virus vaccinia induce fusi\u00f3n en c\u00e9lulas de distintos or\u00edgenes. . VII Congreso Nacional de Virolog\u00eda. Valencia, 16-19 Sept. p169.  159. Gallego, J.C., Rodriguez, D., Cabezas, P., Risco, C., Rodriguez, J.C., Carrascosa, J.L and Esteban, M (2001). Vaccinia Virus Morphogenesis: Characterization of the Attenuated Mutant M65. EMBO Workshop \"Cell Biology of Virus infection\". Heidelberg. Sept. 22-25..   160. Gherardi, M.M.,  Ram\u00edrez, J.C, and Esteban, M. (2001). IL-18 and IL-12 induce a synergistic effect in the protection against Vaccinia virus infection in mice.10thEuropean Congress on Biotechnology, Madrid (Spain), July.   161. L\u00f3pez-Fuertes, L, P\u00e9rez-Jim\u00e9nez,E., Moreno, S., Vila-Coro, A., Wittig, B., Junghans, C., Konig, S.-A.,  Timon, M, and Esteban, M ( 2 0 0 1 ) .  D N A  i m m u n i z a t i o n  o f  s u s c e p t i b l e  m i c e  w i t h  m i n i m a l i s t i c  expression constructs expressing the LACK protein of Leishmania major.  11TH International. Congress of Immunology, Stockholm, July 22-27.    162. Didierlaurent A., Ramirez J. C., Finke D., M. Esteban, JC. Sirard and J. P. Kraehenbuhl. (2001). Portal of entry of HIV at mucosal sites and strategies to prevent infection. Proceedings of the 6th European Conference on Experimental AIDS Research - ECEAR 2001 (Edinburgh, UK, June 23-26, 2001).   163. Gherardi, M.M., P\u00e9rez-Jimenez, E., N\u00e1jera, J.L., D. Rodr\u00edguez., Garc\u00eda-Sastre, A., Palese, P and Esteban, M (2002). Prime/Boost immunization schedules based on influenza and vaccinia virus (VV) vectors (MVA and WR) potentiate cellular immune responses agasinst HIV-env protein systemically and in the genito-rectal draininig lymph nodesXIV International AIDS conference, Barcelona (Spain), July 7-12.  164. Gallego-G\u00f3mez, J.C., Risco, C., Rodriguez, D., Cabezas, P., Carrascosa, J.L, and Esteban, M .  (2002). Vaccinia virus and attenuated mutants induces epithelial to mesenchimal transitions.  XIV International Poxvirus Symposium. Lake Placid, New York, July, p138.  165. Esteban, M. (2002). Recombinant poxviruses as efficient inducers of primed CD8+T cells: role of cytokines. Juan March Workshop on \u201cMolecular Mechanisms of immune modulation: Lessons from viruses. Madrid, February 25-27.  48  166. Esteban, M. ( 2 0 0 3 ) .  C e l l  s i g n a l l i n g  i n  a p o p t o s i s  a n d  r o l e  o f  P K R .  I n t e r n a t i o n a l  S ymposium on \u201cTriggering and modulation of natural and acquired immunity to pathogens\u201d. W\u00fcrzburg, Germany, April 3-5.  167. Gherardi, M., Perez-Jimenez, E., N\u00e1jera, J.L, and Esteban, M (2003). Modified vaccinia Ankara virus can be used as a mucosal vector for HIV a n t i g e n s :  i t s  i m m u n o g e n i c i t y  c a n  b e  i m p r o v e d  w i t h  a  mucosal adjuvant or after applying a DNA/MVA scheme. Modern Vaccines Adjuvants and Delivery Systems. Dublin, 4-6 June.  168. P\u00e9rez-Jimenez, E., Gherardi, M., Kochan, G, and Esteban, M. (2003). Recombinant modified vaccinia virus Ankara expressing the leishmania infantum p36/Lack (MVAp36) antigen triggered a pronounced Th1 immune response against the antigen. Modern Vaccines Adjuvants and Delivery Systems. Dublin, 4-6 June.  169. A. M\u00f6rner, A. Aubertin, V. Erfle, M. Esteban, H. Fredlund, M-JFrachette, K. Karl\u00e9n, P. Liljestr\u00f6m, C. Nilsson, E. Olausson-Hansson, G.Sutter, R. Wagner, B. Wahren, M. Widfeldt, R. Thorstensson, G. Biberfeld. (2003). Comparison of different heterologous prime-boost HIV-1/SIV vaccine regimens including recombinant DNA, SFV, MVA and proteins; immune responsesand viral load in cynomolgus macaques after intrarectal challenge with SHIV-BX08\". The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France,13-16 July.  170. Guerra, S., L\u00f3pez, L., C o n d e ,  R . ,  P a s c u a l-Montano, A., Esteban, M, (2003). Alteraci\u00f3n de la expresi\u00f3n g\u00e9nica de c\u00e9lulas humanas tras la infecci\u00f3n con el virus Vaccinia empleando microchips de cDNA. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept.: p. 178.  171. Mu\u00f1oz-Fontela, C., Arroyo, J., Nombela, C., Esteban, M., Rivas, C. (2003). Actividad transformante de la prote\u00edna latente LANA2 del virus del sarcoma de Kaposi (KSHV) en c\u00e9lulas B. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept.: p. 29.  172. Guerra, S., Aracil, M., Conde, R., Bernard, A., Esteban, M. (2003). La prote\u00edna celular Wasp regula la salida del virus Vaccinia de la c\u00e9lula mediante la formaci\u00f3n de colas de actina. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept.: p. 33.  173. Garc\u00eda, M. A., Gil, J., G\u00f3mez-Puertas, P., Guerra, S., Rullas, J., Alcam\u00ed, J., Moscat, M., Esteban, M. (2003). Los factores de asociaci\u00f3n a receptores de la familia TNF (TRAF) median la activaci\u00f3n del factor de transcripci\u00f3n NFKB mediante la prote\u00edna quinasa PKR, dependiente de RNA bicatenario. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept.: p. 34.  174. Blanco, S., Abaitua, Esteban, M., F., Rodr\u00edguez, J. R., Zavala, F., Rodr\u00edguez, D. (2003). Mantenimiento de la respuesta inmune celular frente al ant\u00edgeno CS de P. yoelii m e d i a n t e  l a  administraci\u00f3n de IL-15. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept.: p. 147.  175. P\u00e9rez-Jim\u00e9nez, E., Gherardi, M. M., Kochan, G., Esteban, M. (2003). La inmunizaci\u00f3n con un virus MVA recombinante que expresa la prote\u00edna LACK de Leishmania infantum i n d u c e  u n a  p o t e n t e  respuesta TH1. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept.: p. 148.  176. Ventoso, I., Berlanga, J. J., De Haro, C., Esteban, M. (2003). Papel de las eIF2a prote\u00edna quinasas en la respuesta antiviral de la c\u00e9lula. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept.: p. 103.  177. Garz\u00f3n, A., Schleich, S., Rodr\u00edguez, J. R., Esteban, M., Griffiths, G., Krinjse-Locker, J., Rodr\u00edguez, D. (2003). Caracterizaci\u00f3n fenot\u00edpica de formas mutantes de la prote\u00edna A14L del virus Vaccinia. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept.: p. 132.  178. Esteban, M. (2003). An\u00e1lisis gen\u00f3mico de la respuesta celular a la infecci\u00f3n con el virus Vaccinia.  49 VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept.: p. 10.  179. Domingo-Gil, E., Garc\u00eda, M. A., Rivas, C., Esteban, M. (2003). La apoptosis mediada por el sistema 2-5A/RNasaL inducida por los interferones no implica la actividad de las caspasas 3, 8 y 9. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept. p. 173.  180. Vandermeeren, A. M., G\u00f3mez, C. E., Pati\u00f1o, C., Esteban, M. ( 2 0 0 3 ) .  E x p r e s i \u00f3 n  r e g u l a d a  d e  l a  poliprote\u00edna de HCV por recombinante del virus Vaccinia: an\u00e1lisis de las alteraciones celulares mediante microscop\u00eda electr\u00f3nica. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept. p. 153.  181. N\u00e1jera, J. L., Gherardi, M. M., Esteban, M. (2003). Estudio comparativo de vectores atenuados del virus Vaccinia (MVA y NYVAC) que expresan ant\u00edgenos del virus de la inmunodeficiencia humana (VIH-1). VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept. p. 204.  182. Gherardi, M. M., P\u00e9rez-Jim\u00e9nez, E., N\u00e1jera, J. L., Esteban, M. (2003). El virus atenuado de Vaccinia (MVA) puede ser utilizado como vector de ant\u00edgenos de HIV para impactar mucosas: aumento de su inmunogenicidad mediante un adyuvante de mucosas y la aplicaci\u00f3n de esquemas de inmunizaci\u00f3n ADN/MVA. VIII Congreso Nacional de Virolog\u00eda, Barcelona 2003, 12-15 Sept. p. 206.  183. Esteban, M ( 2 0 0 4 ) .  V a ccinia virus: its usefulnees as a vector for a wide range of vaccination purposes. Spanish-Belgian Symposium on Perspectives and Applications of Biotechnology within the European Uni\u00f3n framework. Madrid. Feb 2-3.  184. Guerra, S., L\u00f3pez-Fern\u00e1ndez, L., Pascual-Montano, A and Esteban, M ( 2 0 0 4 ) .  I d e n t i f i c a t i o n  o f  human genes during MVA infection. XVth International Poxvirus and Iridovirus meeting. Oxford, UK. September 3-8  185. Guerra, S., Aracil, M., Conde, R., Bernard, A and Esteban, M (2004). Involvement of Wiskott-Aldrich syndrome protein (WASP) in vaccinia virus pathogenesis. XVth International Poxvirus and Iridovirus meeting. Oxford, UK. September 3-8  186. Gherardi, M.M, P\u00e9rez-Jim\u00e9nez, E., N\u00e1jera, J.L and Esteban, M ( 2 0 0 4 ) .  E n h a n c e m e n t  o f  H I V  immunity in the genital tract after a DNA prime-MVA boost by the mucosal adjuvant cholera toxin. XVth International Poxvirus and Iridovirus meeting. Oxford, UK. September 3-8.  187. Risco, C., Fern\u00e1ndez, J.J., Esteban, M., Carrascosa, J.L., Cyrklaff, M, and Baumeister, W (2004). Tomographic reconstruction of vaccinia virus. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  188. P\u00e9rez-Jimenez, E., Kochan, G., Gherarrdi, M, and Esteban, M (2004). Patterns of immune response elicited by prime/boost vaccination with DNA and the attenuated modified vaccinia virus Ankara recombinants expressing LACK of Leishmania infantum. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  189. Kochan, G., P\u00e9rez-Jimenez, E., G\u00f3mez, C.E., MacMahon-Pratt, D, and Esteban, M ( 2 0 0 4 ) .  Comparison of protective efficacy of recombinant vaccinia virus expressing Leishmania p36/LACK, nuclease P-4 or methalloprotease gp63 in mice challenged with leishmania major. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  190. Mu\u00f1oz, C., Garc\u00eda, M-A., Garc\u00eda-Cao, I., Matheu, A., Arroyo, J., Collado, M., Esteban, M., Serrano, M, and Rivas, C (2004). Antiviral activity of tumor suppressors. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  191. Ventoso, I., Sanz, M. A., Molina, S., Berlanga, J., Carrasco, L, and Esteban, M (2004). Translation control and antiviral response of the cell. II European Virology Meeting (EuroVirology) (2004). Madrid,  50 September 5-9.  192. Garc\u00eda, M-A., Mu\u00f1oz, C., Matheu, A., Collado, M., Serrano, M., Esteban, M, and Rivas, C (2004). Antiviral activity of the tumor suppressor INK4a/ARF locus. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  193. Mu\u00f1oz, C., Garc\u00eda, M-A., Garc\u00eda-Cao, I., Arroyo, J., Collado, M., Esteban, M., Serrano, M, and Rivas, C (2004). Antiviral activity of the tumor suppressor p53. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  194. Gherardi, M., P\u00e9rez-Jimenez, E., N\u00e1jera, J.L, and Esteban, M ( 2 0 0 4 ) .  Induction of HIV specific immune responses in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-MVA boost immunization schedule together with a mucosal adjuvant. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  195. Guerra, S., L\u00f3pez-Fernandez, L., Pascual-Montano, A, and Esteban, M ( 2 0 0 4 ) .  Gene expression profiling of human cells infected with vaccinia virus wild type VV and MVA. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  196. Guerra, S., Aracil, M., Conde, R., Bernad, A, and Esteban, M (2004). WASP protein is needed for vaccinia virus pathogenesis. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  197. Vandermeeren, A., G\u00f3mez, C.E., Pati\u00f1o, C, and Esteban, M ( 2 0 0 4 ) .  M o r p h o l o g i c a l  a n d  ultraestructural analysis of human cells infected with a vaccinia virus recombinant expressing HCV-core antigen. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  198. G\u00f3mez, C.E., Vandermeeren, A., Garc\u00eda, M-A, and Esteban, M ( 2 0 0 4 ) .  E x p r e s s i o n  o f  h e p a t i t i s  C  polyprotein from a vaccinia virus recombinant triggers inhibition of translation and induction of apoptosis. II European Virology Meeting (EuroVirology) (2004). Madrid, September 5-9.  199. Esteban, M ( 2 0 0 5 ). Cryo-electron tomography of vaccinia virus. 5th A n n u a l  N I A I D  O r t h o p o x v i r u s  Research Group Meeting, Bethesda. April 19-21, 2005  200. Biescas, H., Gajardo, R., Vandermeeren, A., Esteban, M, and Jorquera, J. I (2005), FLEBOGAMMA intravenous immunoglobulin: evaluation of neutralizing antibodies to vaccinia virus. FOCIS 2005: Federation of Clinical Immunological Societies, May 12-16, Boston, USA.  201. Cristian I. Ca\u00f1ones, Ana M. Rodr\u00edguez, Eva P\u00e9rez-Jim\u00e9nez, Jos\u00e9 Luis N\u00e1jera, Mariano Esteban , Horacio Salom\u00f3n, and M. Magdalena Gherardi (2005). Mucosal immunization schemes based on attenuated Modified Vaccinia virus Ankara (MVA) vectors expressing HIV antigens.  VII Congreso Latinoamericano de Inmunolog\u00eda., octubre 2-6, C\u00f3rdoba, Argentina.  202. A. M. Rodr\u00edguez, C. I. Ca\u00f1ones, E. P\u00e9rez-Jim\u00e9nez, J. L. N\u00e1jera, M. Esteban, H. Salom\u00f3n, y M. M.Gherardi (2005). Reg\u00edmenes de inmunizaci\u00f3n de mucosas basados en vectores del virus vaccinia Ankara modificado (MVA) que expresan ant\u00edgenos del HIV. VII Congreso Argentino de SIDA, 24-26 de Noviembre. Teatro Argentino de La Plata, Buenos Aires, Argentina.  203. Esteban, M ( 2 0 0 5 ) .  T h e  p r i m e / b o o s t  s t r a t e g y  w i t h  p o x v i r u s  v e c t o r s  t o  c o n t r o l  p r e v a l e n t  h u m a n  diseases. Annual meeting of the Italian Society of Virology. Orvieto, September 26-29.  204. Guerra, S., L\u00f3pez-Fernandez, L.A., Garc\u00eda, M.A, and Esteban, M (2005). Microarray analysis reveals characteristic changes of host gene expression in response to the over expression of PKR infection of human HeLa cells. Annual meeting of International Society for Interferon and Cytokine Research (ISICR), Shangai, October 20-24, p231   51 205. Garc\u00eda, M.A., Collado, M., Mu\u00f1oz, C., Matheu, A., Arroyo, J., Esteban, M., Serrano, M, and Rivas, M (2005). PKR mediates the antiviral action of tumor suppressor Arf. Annual meeting of International Society for Interferon and Cytokine Research (ISICR), Shangai, October 20-24, p260  206. Esteban, M ( 2 0 0 6 ) .  M V A  a n d  N Y V A C  a s  v a c c i n e s  a g a i n s t  p r e v a l e n t  h u m a n  d i s e a s e s .  X V I  International Poxvirus meeting. FASEB Summer Research Conferences. Indian Wells, California, USA. June 3-8.  207. N\u00e1jera, J.L., G\u00f3mez, C.E., Domingo-Gil, E., Gherardi, M.M and Esteban, M ( 2 0 0 6 ) .  C e l l u l a r  a n d  Biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC). XVI International Poxvirus meeting. FASEB Summer Research Conferences. Indian Wells, California, USA. June 3-8.  208. Esteban, M (2006). Engineering attenuated poxvirus vectors (MVA and NYVAC) as vaccines against prevalent human diseases. In \u201cViral engineering: vaccines and gene therapy\u201d. 2nd FEMS Congress of European Microbiologists. Madrid, July 4-8.  209. CE G\u00f3mez , JL N\u00e1jera , E P\u00e9rez-Jim\u00e9nez , V Jim\u00e9nez , R Wagner , M Graf , MJ Franchette , P Liljestr\u00f6m ; G Pantaleo, and M Esteban (2006). Head-to-head comparison on the immunogenicity in mice of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B. AIDS Vaccine-2006 Conference. \u00c1msterdam. August 29-September 2.  210. A M. Rodr\u00edguez, D. M\u00f3naco, H.Salom\u00f3n, M.Esteban and M.Gherardi (2006). Intranasal delivery of DNA IL-12 during mucosal DNA-prime/MVA-boost immunization schemes enhanced the cellular immune response against HIV-1 Env antigen AIDS Vaccine-2006 Conference. \u00c1msterdam. August 29-September 2.  211. P Mooij,  S Balla-Jaghjoorsingh,  N Beenhakker,  P van Haaften, I Baak, I Nieuwenhuis, R Wagner,  , C.E G\u00f3mez,  J . L  N \u00e1 j e r a , , M.V Jim\u00e9nez, , M Esteban, a n d  J L .  H e e n e y . ( 2 0 0 6 )  H e a d-to-head comparison of immunogenicity and efficacy in macaques of MVA and NYVAC vectors expressing HIV-1 Env and SIV Gag/Pol/Nef. AIDS Vaccine-2006 Conference. \u00c1msterdam. August 29-September 2.  212. Domingo-Gil, E and  Esteban M (2006). Apoptosis induced by 2-5 A system: mechanisms involved and role of mitochondria. CYTOKINES 2006. Viena. August 27-31.   213. Esteban, M (2006). Activaci\u00f3n de una respuesta celular espec\u00edfica frente a pat\u00f3genos con vectores atenuados de poxvirus. Sociedad Espa\u00f1ola de Bioqu\u00edmica y Biolog\u00eda Molecular (SEBBM). Elche. Septiembre 7-10  214. Esteban, M ( 2 0 0 6 ) .  V a c u n a s  c o n t r a  e n f e r m e d a d e s  p r e v a l e n t e s .  B i o S p a i n  B i o t e c-2006. Madrid IFEMA. 18-20 Septiembre.  215. N\u00e1jera J.L, G\u00f3mez C.E, Domingo-Gil E, Guerra, S and Esteban, M (2007). Papel del gen C7L en el comportamiento diferencial entre dos cepas atenuadas del Virus Vaccinia, MVA y NYVAC. IX Congreso Nacional de Virolog\u00eda. Zaragoza . Abril 11- 14    216. G\u00f3mez, C.E., N\u00e1jera, J.L., P\u00e9rez-Jim\u00e9nez, E., Jim\u00e9nez, V., Wagner, R., Graf, M., Franchette, M.J., Liljestr\u00f6m, P., Pantaleo, G., and Esteban, M ( 2 0 0 7 ) . G e n e r aci\u00f3n y caracterizaci\u00f3n de un nuevo candidato vacunal frente al VIH/SIDA basado en la cepa atenuada de Poxvirus MVA.  IX Congreso Nacional de Virolog\u00eda. Zaragoza . Abril 11- 14  217. Domingo-Gil, E., P\u00e9rez-Jim\u00e9nez, E., Ventoso, I, and Esteban, M. La incorporaci\u00f3n del gen E3L del Virus Vaccinia en c\u00e9lulas de cultivo y ratones confiere mayor sensibilidad a infecciones virales y parasitarias.  IX Congreso Nacional de Virolog\u00eda. Zaragoza . Abril 11- 14   52  218. Guerra, S., C\u00e1ceres, A, and Esteban, M (2007).  Papel del gen estimulado por interfer\u00f3n ISG15 en la infecci\u00f3n del Virus Vaccinia. IX Congreso Nacional de Virolog\u00eda. Zaragoza . Abril 11- 14    219. Guerra, S., Najera., J.L., Gonz\u00e1lez, J.M., L\u00f3pez, L., Climent, N., Gallart, T, and Esteban, M (2007). Diferencias en la expresi\u00f3n gen\u00e9tica de c\u00e9lulas dendr\u00edticas humanas tras infecci\u00f3n con los virus MVA y NYVAC.  IX Congreso Nacional de Virolog\u00eda. Zaragoza . Abril 11- 14    220. Esteban, M (2007). Desarrollo de vacunas contra el VIH/SIDA. IX Congreso Nacional de Virolog\u00eda. Zaragoza . Abril 11- 14    221. N Climent, S Guerra, JL N\u00e1jera,  CE G\u00f3mez, N Nomdedeu, F Garc\u00eda, C Rovira, L Miralles, H Oliva, C Gil, JM Gatell, M Esteban, T Gallart (2007). In vitro r e s p o n s e  o f  T-cells from HIV+ patients to autologous dendritic cells infected with MVA and NYVAC expressing HIV-B genes. AIDS Vaccine07. Seattle, USA, August 20-23  222. CE G\u00f3mez, JL N\u00e1jera and M Esteban ( 2007). Multimeric soluble CD40L as immunomodulator for HIV vaccines. AIDS Vaccine07. Seattle, USA, August 20-23  223. Jose Luis N\u00e1jera, Carmen Elena G\u00f3mez, Elena Domingo-Gil, Laura Ochoa-Callejo, Gloria Gonz\u00e1lez-Aseguinolaza and Mariano Esteban ( 2 0 0 7 ) .  Virus dissemination and pro-inflammatory responses triggered by the attenuated MVA and NYVAC poxvirus strains in mice. A I D S  V a c c i n e 0 7 ,  S e a t t l e ,  USA, August 20-23  224. P Mooij,  S Balla-Jaghjoorsingh,  N Beenhakker,  P van Haaften, I Baak, I Nieuwenhuis, R Wagner,, C.E G\u00f3mez,  J.L N\u00e1jera, M.V Jim\u00e9nez, M Esteban, G. Koopman and JL. Heeney (2007). MVA and NYVAC vectors expressing HIV-1 Env and SIV Gag/Pol/Nef induce preferential boosting of CD8+ versus CD4+ T-cell responses but give similar efficacy against SHIV89.6p c h a l l e n g e  i n  r h e s u s  macaques. AIDS Vaccine07. Seattle, USA, August 20-23.  225. Esteban, M (2007). The impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. \u201c50th Anniversary of Interferon: from interferon discovery to clinical application\u201d. International meeting Paris, April 30.  226. AM.Rodr\u00edguez, G.Turk, F.Zanetti, F.Ferrer2, JL N\u00e1jera, M\u00f3naco, G.Schulman, MF.Pacutti,  G.Calamante,  M. Esteban, H.Salom\u00f3n1 y  M M . G h e r a r d i (2007). Desarrollo y caracterizaci\u00f3n de vectores vacunales que expresan la prote\u00edna Nef del intersubtipo de HIV-1. Congreso Nacional de Sida, Paran\u00e1 Entre R\u00edos, Argentina, 5-8 de septiembre.  227. Esteban, M (2007). La prote\u00edna quinasa PKR como inhibidor de la replicaci\u00f3n viral y regulador del crecimiento cellular. XXI Congreso Nacional de Microbiolog\u00eda. Sevilla 17-20 Septiembre.  228. Mooij, P; Balla-Jaghjoorsingh, S; Beenhakker, N; van Haaften, P; Baak, I; Nieuwenhuis, I; Gomez, CE; Najera, JL; Jimenez, MV; Wagner, R; Esteban, M; Heeney, JL. (2007). J. Med. Primatology   229. Esteban, M. ( 2 0 0 7 ) .  \u201c T h e  p r o b l e m  o f  m a l a r i a  i n  t h e  w o r l d \u201d .  D e v e l o p m e n t  o f  m a l a r i a  v a c c i n e s .  International Symposium. Foundation Areces. Madrid, December 13-14.  230. Domingo-Gil, E., P\u00e9rez-Jim\u00e9nez, E., Ventoso, I., N\u00e1jera, J.L and Esteban, M (2008). Expresi\u00f3n of the E3L gene of vaccinia virus in transgenic mice decreases the host resistance to VACV and Leishmania infection. 17th International Poxvirus and Iridovirus conference. Grainau (Bavaria), Germany. June 7-12, p40  231. Esteban, M., G\u00f3mez, C.E., N\u00e1jera, J.L., Jim\u00e9nez, V and the Eurovacc consortia (2008). Preclinical and clinical evaluation of the poxvirus vectors MVA and NYVAC as candidate vaccines against HIV/AIDS. 17th International Poxvirus and Iridovirus conference. Grainau (Bavaria), Germany. June  53 7-12, p71  232. N\u00e1jera, J.L., Domingo-Gil, E., G\u00f3mez, C.E and Esteban, M (2008). Involvement of the 2-5A/RNase L system in the apoptosis induced by NYVAC. 17th International Poxvirus and Iridovirus conference. Grainau (Bavaria), Germany. June 7-12, p139  233. Guerra, S., C\u00e1ceres A., Horak, I and Esteban, M (2008). Vaccinia virus prevents the antiviral action of ISG15. 17th International Poxvirus and Iridovirus conference. Grainau (Bavaria), Germany. June 7-12, p149  234. Garc\u00eda, M.A., Krupa, M and Esteban, M ( 2 0 0 8 ) .  A n t i t u m o r a l  a c t i v i t y  o f  o n c o l y t i c  v a c c i n i a  v i r u s  expressing the IFN-induced protein kinase PKR. 17th Internacional Poxvirus and Iridovirus conference. Grainau (Bavaria), Germany. June 7-12, p187  235. G\u00f3mez, C.E., N\u00e1jera, J.L., Domingo-Gil, E., Ochoa-Callejo, L., Goznz\u00e1lez-Aseguinolaza, and Esteban, M ( 2 0 0 8 ) .  D i s t i n c t  b e h a v i o u r  o f  M V A  a n d  N Y V A C  i n f e c t i o n s  i n  m i c e .  1 7 t h  I n t e r n a c i o n a l  Poxvirus and Iridovirus conference. Grainau (Bavaria), Germany. June 7-12, p193  236. Delaloye, J., Steiner-Tardivel, Q.G., Esteban, M., Roger, T, and Calandra, T (2008). Role of Toll-like receptor (TLR), RIG-I-like receptor (RLR) and Nod-like receptor (NLR) pathways in innate immune responses elicited by poxvirus. Annual meeting Swiss Society for Infectious Diseases. Lausanne, August 28/29.  237. Delaloye, J., Roger, T., Le Roy, D., Knaup Reymond, M., Esteban, M ,  a n d  C a l a n d r a ,  T  ( 2 0 0 8 ) .  Effects of viral vaccine vectors on macrophage migration inhibitory factor (MIF) expresi\u00f3n by myeloid cells. Toll2008 meeting, Lisbon, August.   238.  M\u00f3naco,D; Carobene,M; Rodr\u00edguez,AM; Najera, JL; Schulman,G; Pascutti,MF; Salom\u00f3n,H; Esteban, M y Gherardi,MM (2008). Generaci\u00f3n y caracterizaci\u00f3n de un vector viral que expresa la prote\u00edna gp160 de la forma recombinante circulante del HIV, CRF12_BF. Congreso Nacional de Sida, 5-8 de septiembre Paran\u00e1 Entre R\u00edos, Argentina.  239.  M\u00f3naco,D; Pascutti,MF; Carobene,M; Najera,JL; Rodr\u00edguez,AM; Schulman,G; Esteban,M; Salom\u00f3n,H and Gherardi,MM (2008). \u201cEvaluation of the Immune Response Induced in Balb/c Mice by a Viral Vector expressing env Gene of the Circulating Recombinant Form of HIV-1 in Argentina, CRF12_BF\u201d. XVII International AIDS Conference, M\u00e9xico 3-8 August.  240.  AM.Rodr\u00edguez, G.Schulman, MF.Pacutti, F.Ferrer, G.Turk, JL.N\u00e1jera, D.M\u00f3naco, G.Calamante, M. Esteban, H.Salom\u00f3n and MM.Gherardi (2008). \u201cCharacterization of vaccine-vectors expressing Nef of the BF recombinant HIV-1 circulating form and evaluation of the immune response induced in mice\u201d. XVII International AIDS Conference que se realizar\u00e1 en la ciudad de  M\u00e9xico 3-8 August 2008.   241. Esteban, M., G\u00f3mez, C.E., N\u00e1jera, J.L, Victoria Jim\u00e9nez, V and the EuroVacc consortia (2008). The poxvirus vectors MVA and NYVAC as candidate vaccines against HIV/AIDS: preclinical and clinical evaluation. XIV International Congress of Virology. Istanbul, 10-15 August.  242. Garc\u00eda, M., Gallego, P., Herranz, D., Marcos-Villar, L., Collado, M., Esteban, M., Serrano, M and Rivas, C. (2008). Antiviral activity of S i r t 1 .  X I V  I n t e r n a t i o n a l  C o n g r e s s  o f  V i r o l o g y .  I s t a n b u l  1 0-15 August.  243. Esteban, M (2008). Vacuna contra VIH/SIDA: un gran reto profil\u00e1ctico y terap\u00e9utico. BIOTEC2008. Granada 17-19, Sept.  244. Esteban, M ( 2 0 0 8 ) .  I m p r o v i n g  N Y V A C  i m m u n o g e n i c i t y .   G l o b a l  H I V  V a ccine Enterprise. Seattle, December 2-5.   54 245. Gonzalez-Santamaria, J., Campagna, M., Marcos-Villar, L., Garc\u00eda, M.A., Lopitz-Otsoa, F., Rodriguez, M., Esteban, M and Rivas, C (2009). Covalent attachment of SUMO proteins to vaccinia virus E3L protein. Ubiquitin-proteasome system, dynamics and targeting. 4TH Intracellular Proteolysis Meeting. Barcelona, Spain, May 27-29.  246. Campagna, M., Herranz, D.-, Garc\u00eda, M.A., Marcos-Villar, L., Gonzalez-Santamaria, J., Gallego, P., Gutieerez, S., Collado, M., Serrano, M., Esteban, M a n d  R i v a s ,  C  ( 2 0 0 9 ) .  S I R T 1  s t a b i l i z e s  P M L  through sumoylation and protects against viral infection. Ubiquitin-proteasome system, dynamics and targeting. 4TH Intracellular Proteolysis Meeting. Barcelona, Spain, May 27-29.  247. Esteban, M (2009). The attenuated poxvirus vectors MVA and NYVAC as candidate vaccines agains HIV/AIDS: preclinical and clinical evaluation (inaugural conference). X Congreso Nacional de Virolog\u00eda. Salamanca, 21-24 Junio.  248. Iniesta, M., N\u00e1jera, J.L., Esteban, M and Blasco, R (2009). Anclaje de ant\u00edgenos en la envuelta del virus vaccinia como dise\u00f1o de vacunas para VIH. X Congreso Nacional de Virolog\u00eda. Salamanca, 21-24 Junio.  249. Garc\u00eda-Arriaza, J., N\u00e1jera, J.L, and Esteban, M (2009). Mejora de la inmunogenicidad de la vacuna de VIH-1, cepa MVA-B. X Congreso Nacional de Virolog\u00eda. Salamanca, 21-24 Junio.  250. N\u00e1jera, J.L., G\u00f3mez, C.E., Garc\u00eda-Arriaza, J, and Esteban, M (2009). Caracterizaci\u00f3n de un nuevo candidato vacunal frente al VIH/SIDA basado en la cepa atenuada de vaccinia NYVAC. X Congreso Nacional de Virolog\u00eda. Salamanca, 21-24 Junio.  251. Perdiguero, B., G\u00f3mez, C.E., N\u00e1jera, J.L, and Esteban, M (2009). Efecto de la deleci\u00f3n del gen F1L sobre la inmunogenicidad frente a las prote\u00ednas Env/Gag-Pol-Nef del clade C de HIV-1 expresadas desde la cepa atenuada del virus vaccinia MVA. X Congreso Nacional de Virolog\u00eda. Salamanca, 21-24 Junio.  252. Gonzalez-Santamar\u00eda, J., Campagna, M., Marcos-Villar, L., Gallego, P., Garc\u00eda, M.A., Lopitz, F., Rodr\u00edguez, M.S., Esteban, M and Rivas, C (2009). Interacci\u00f3n de la prote\u00edna E3L del virus vaccinia con SUMO. X Congreso Nacional de Virolog\u00eda. Salamanca, 21-24 Junio.  253. Najera, J.L., Gomez, C.E and Esteban, M ( 2 0 0 9 ) .  M u l t i m e r i c  s o l u b l e  C D 4 0  l i g a n d  e f f i c i e n t l y  enhances HIV specific cellular immune responses during DNA p r i m e  a n d  b o o s t  w i t h  a t t e n u a t e d  poxvirus strains. AIDS VACCINE-2009. Paris, October 19-22.  254. Najera, J.L., Gomez, C.E., Garcia-Arriaza and Esteban, M (2009). Insertion of a vaccinia virus host range (hr) gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. AIDS VACCINE-2009. Paris, October 19-22.  255. Quakkelaar, E., Redeker, A., Loof, N., Perdiguero, B., Heinen, P., Gomez, C.E., Esteban, M., Jacobs, B., Pantaleo, G., and Melief, C (2009). Enhanced expresi\u00f3n of HIV antigens and improved antigen presentation alter infection with replication competent attenuated vaccinia virus in vitro. AIDS VACCINE-2009. Paris, October 19-22.  256. Garc\u00eda-Arriaza, J., N\u00e1jera, J. L., G\u00f3mez, C. E., and Esteban, M (2010). High-magnitude, polyfunctional and memory H I V-1-specific immune responses elicited by a poxvirus vector MVA expressing HIV-1 subtype B genes and containing deletions in A41L and B16R viral genes. 4th European Congress of Virology, Cernobbio, Como Lake, Italy. April 7-11  257. Kibler, K.V., Wong, S., Huynh, T., Holechek, S.A., Denzler, K., Arndt, W., Koelle, D., Parrington, M., Tartaglia, J., Esteban, M., Pantaleo, G., Jacobs, B.L (2010). Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines. XVIII International Poxvirus, Asfivirus, and Iridovirus Symposium. Sedona, Arizona, USA. June 5-10  55  258. Garcia-Arriaza, J., Najera, J.L., Gomez, C.E, and Esteban, M ( 2 0 1 0 ) .  I m m u n o g e n i c  p r o f i l i n g  o f  a  candidate HIV/AIDS vaccine (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. XVIII International Poxvirus, Asfivirus, and Iridovirus Symposium. Sedona, Arizona, USA. June 5-10  259. Esteban, M (2010). Viral vectors and vaccines. XVIII International Poxvirus, Asfivirus, and Iridovirus Symposium. Sedona, Arizona, USA. June 5-10  260. Gonzalez-Santamaria, J., Campagna, M., Marcos-Villar, L., Garcia, M.A., Gonzalez, D., Esteban, M, and Rivas, C.  (2010). SUMO regulation of vaccinia virus E3L protein. XVIII International Poxvirus, Asfivirus, and Iridovirus Symposium. Sedona, Arizona, USA. June 5-10  261. Guerra, S., Abaitua, F., Martinez-Sobrido, L., Esteban, M., Garcia-Sastre, A, and Rodriguez, D. Host-range restriction of vaccinia virus E3L deletion mutant can be overcome by expression of the influenza virus NS1 protein. XVIII International Poxvirus, Asfivirus, and Iridovirus Symposium. Sedona, Arizona, USA. June 5-10  262. Guerra, S., Gonzalez, J.M., Clment, N., Reyburn, H., Gallart, T, and Esteban, M (2010). Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. XVIII International Poxvirus, Asfivirus, and Iridovirus Symposium. Sedona, Arizona, USA. June 5-10  263. Najera, J.L., Gomez, C.E., Garcia-Arriaza, J, and Esteban, M (2010). Insertion of vaccinia C7L gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. XVIII International Poxvirus, Asfivirus, and Iridovirus Symposium. Sedona, Arizona, USA. June 5-10.  264. P. Mooij, I. Nieuwenhuis, N. Beenhakker, S. Hofman, M. Esteban, B. Jacobs, K. Kibler, G. Koopman, W.M.J.M. Bogers, G. Pantaleo, and J.L. Heeney (2010). Improved immunogenicity against HIV-1 clade C antigens by using NYVAC-C with restored replication competence. AIDS Vaccine Conference 2010. Atlanta, USA, 28 Sept-1 Oct.  265. E.D. Quakkelaar, A. Redeker, N.M. Loof, B. Perdiguero, P. Heinen, M. Esteban, K. Kibler, B. Jacobs, S. Mayo McCaughey, E.K. Haddad, G. Pantaleo and C.J.M. Melief. (2010). Improved vaccinia virus vectors for vaccination against HIV.  AIDS Vaccine Conference 2010. Atlanta, USA, 28 Sept-1 Oct  266. Kibler, K., Perdiguero, B., Gomez, C.E., Najera, J.L., Sanz, R., Jimenez, V., Quakkelaar, E.D., Melief, C.J.M., Haddad, E., Sekaly., Sallusto, F., Lanzavecchia, A., Harari, A., Tartaglia, J., Pantaleo, G., Jacobs, B, and Esteban, M. (2010). Improvement of the HIV/AIDS vaccine candidate NYVAC-C by deletion of the viral type I IFN inhibitor and/or acquisition of replication competence.  AIDS Vaccine Conference 2010. Atlanta, USA, 28 Sept-1 Oct  267. Gomez, C.E., Perdiguero, B., N\u00e1jera, J.L., Jim\u00e9nez, V., Gonzalez-Sanz, R, and Esteban, M. (2010) Removal of vaccinia virus genes that block type I and type II pathways improves the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. AIDS Vaccine Conference 2010. Atlanta, USA, 28 Sept-1 Oct.  268. Lopez JC1, Garcia F2, Esteban M3, Jimenez JL1, Perez I2,  Mu\u00f1oz MA1, Gatell JM2, Liljestr\u00f6m P4, Weber J5, Plana M2*. (2011) Safety and Immunogenicity of a Modified Pox Vector-Based Vaccine Candidate Expressing Env, Gag, Pol, and Nef Proteins of HIV-1 Subtype B (MVA-B) in HIV-1-Negative Healthy Volunteers: Results of the RISVAC02 Trial. 18th Conference on Retroviruses and Opportunistic Infections (CROI) Boston February 27-March 2.  269. Goodman, A.G., Guerra, S., Vijayan, A., Heinen, P.P., Sorzano, C.O.S., Esteban, M.  ( 2 0 1 1 ) . A recombinant vaccinia virus-based T cell vaccine against influenza virus reduces viral load upon challenge. Poster at the American Society of Gene and Cell Therapy Annual Meeting.  Seattle, WA.  May 18-21, 2011.   56  270. Yanguez E.,Garcia-Culebras A., Llompart C., Eduardo-Correia B., Knobeloch K.P., Nieto A., Esteban M a n d  G u e r r a  S .  ( 2 0 1 1 ) .  P a p e l  d e  l a  p r o t e \u00ed n a  d e  d e f e n s a  I S G 1 5  i n d u c i d a  p o r  i n t e r f e r o n  e n  l a s  infecciones virales. XI Congreso Nacional de Virolog\u00eda, Granada, Mayo 29-Junio 1.  271. Sanchez-sampedro L., Gomez C.E and Esteban M. (2011). Caracterizaci\u00f3n de nuevos mutantes replicativos del virus vaccinia como candidatos vacunales frente a leishmaniasis. XI Congreso Nacional de Virolog\u00eda, Granada, Mayo 29-Junio 1.  272. C\u00e1ceres A., Caelles C and Esteban M. ( 2 0 1 1 ) .  Interacci\u00f3n del virus vaccinia con el hospedador: papel de la fosfatasa dual DUSP1. XI Congreso Nacional de Virolog\u00eda, Granada, Mayo 29-Junio 1.  273. Perdiguero B., Gomez C.E., N\u00e1jera J.L and Esteban M. (2011). Mejora de la inmunogenicidad frente a las proteinas ENV/GAG-POL-NEF del subtipo C de VIH-1 expresadas desde la cepa atenuada del virus vaccinia MVA mediante la deleci\u00f3n del gen viral anti-apopt\u00f3tico F1L. XI Congreso Nacional de Virolog\u00eda, Granada, Mayo 29-Junio 1.  274. Guerra S., Abaitua F., Mart\u00ednez-Sobrino L., Esteban M., Garcia-Sastre A and Rodriguez D. (2011). La proteina NS1 del virus de la gripe es capaz de sustituir a la proteina E3 del virus vaccinia in vitro pero no in vivo. XI Congreso Nacional de Virolog\u00eda, Granada, Mayo 29-Junio 1..  275. Chichon F.J., Rodr \u00ed guez ,  M. J . ,  Per ei r o,  E. ,  Chiappi, M., Perdiguero, B., Guttmann, P., Werner, S., Rehbein, S., Schneider, G., Esteban, M. And Carrascosa, J.L. Cartography of vaccinica virus infection by cryo-x-ray nanotomography. 34\u00ba congreso de la SEBBM (Sociedad espa\u00f1ola de Bioqu\u00edmica y Biolog\u00eda Molecular). Barcelona, 5 \u2013 8 September 2011  276. Perreau M., Welles H.C., Harari A., Hall O., Martin R., Maillart M., Dorta G., Bart P., Kremer E.J., Tartaglia J., Wagner R., Esteban M., Levy Y, and Pantaleo G (2011). DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.  AIDS Vaccine 2011. Bangkok, Thailand, Sept. 12-15  277. Carmen E. G\u00f3mez, Jos\u00e9 L. N\u00e1jera, Beatriz Perdiguero, Juan Garc\u00eda-Arriaza, Carlos Oscar S. Sorzano, Victoria Jim\u00e9nez, Rub\u00e9n Gonz\u00e1lez-Sanz, Jos\u00e9 Luis Jim\u00e9nez, Mar\u00eda Angeles Mu\u00f1oz-Fern\u00e1ndez, Juan Carlos L\u00f3pez Bernaldo de Quir\u00f3s, Alberto C. Guardo, Felipe Garc\u00eda, Jos\u00e9 M. Gatell, Montserrat Plana and Mariano Esteban ( 2 0 1 1 ) .  T h e  H I V / A I D S  v a c c i n e  c a n d i d a t e  M V A-B triggers robust, polyfunctional and memory T cell responses to HIV-1 antigens i n  a  p h a s e  I  c l i n i c a l  t r i a l  i n  Spain. .  AIDS Vaccine 2011. Bangkok, Thailand, Sept. 12-15  278. Mooij P., Nieuwenhuis I., Beenhakker N., Quakkelaar E.D., Heeney J. L., Esteban M., Jacobs B., Pantaleo G., Bogers W., Melief C, and Koopman G (2011). Boosting of replication competent NYVAC primed HIV-1-specific T-cell responses by HIV synthetic long peptides (SLP). AIDS Vaccine 2011. Bangkok, Thailand, Sept. 12-15  279. Falivene J., Del Medico Zajac M.P., Rodriguez A.M., Pascutti M.F., Maeto, C.A., Perdiguero, B., Gomez C.E., Esteban M., Calamante G, and Guerardi M.M (2011). Optimization of the MVA vaccine potencial alter deletion of a viral gene coding for the IL-18 binding prote\u00edna. AIDS Vaccine 2011. Bangkok, Thailand, Sept. 12-15  280. Garc\u00eda-Arriaza, J., Najera J.L., Gomez C.E., Tewabe N., Sorzano C.S., Calandra T., Roger T, and Esteban M ( 2 0 1 1 ) .  A  c a n d i d a t e  H I V / A I D S  v a c c i n e  ( M V A-B) that enhances the magnitude and polyfunctionality of memory HIV-1-specific-T-cell responses. AIDS Vaccine 2011. Bangkok, Thailand, Sept. 12-15  281. McKay P.,Cope A., Swales J., Joseph S., Esteban M., Tatoud R., Carter D., Weber J, and Shattock R.J (2011). HIV CN54gp140 + GLA significantly enhances vaccine antigen-specific T and  B cell immune responses alter priming with DNA and MVA. AIDS Vaccine 2011. Bangkok, Thailand, Sept.  57 12-15  282. Perdiguero B., Gomez C.E., Najera J.L, and Esteban M ( 2 0 1 1 ) .  I m p r o v i n g  t h e  i m m u n o g e n i c i t y  against HIV-1 subtype C Env/Gag-Pol-Nef proteins expressed from MVA by the deletion of the viral anti-apoptotic gene F1L.  AIDS Vaccine 2011. Bangkok, Thailand, Sept. 12-15.  283. Chichon, F.J., Rodr\u00edguez, M.J., Pereiro, E., Chiappi, M., Perdiguero, B., Guttmann, P., Werner, S., Rehbein, S., Schneider, G., Esteban, M. And Carrascosa, J.L. Study of vaccinia virus assembly by x-ray cryo-tomographic reconstruction of whole cells. 2nd Joint Congress of the Portuguese and Spanish Microscopy Societies. Aveiro (Portugal), 18 - 21 October 2011.  284. Caceres A., Caelles C, and Esteban M (2012). Dual-specificity phosphatase 1 (DUSP-1) is involved in vaccinia virus replication and host anti-viral immune response. XIX International Poxvirus, Asfarvirus and Iridovirus Conference. Salamanca, Spain. June 24-28, 2012.  285. Chichon F.J., Rodriguez M.J., Pereiro E., Chiappi M., Perdiguero B., Guttmann P., Werner S., Rehbein S., Schneider G., Esteban M, and Car r ascosa J. L ( 2012) .   Car t ogr aphy of  vacci ni a vi r us infection by cryo-X-ray nanotomography. XIX International Poxvirus, Asfarvirus and Iridovirus Conference. Salamanca, Spain. June 24-28, 2012.  286. Garcia-Arriaza J., Najera J.L., Gomez C.E., Tewabe N., Sorzano C.O.S., Calandra T., Roger T, and Esteban M ( 2 0 1 2 ) .  A  c a n d i d a t e  H I V / A I D S  v a c c i n e  ( M V A-B) lacking vaccinia virus gene C6L enhances memory HIV-1 specific T-cell responses. XIX International Poxvirus, Asfarvirus and Iridovirus Conference. Salamanca, Spain. June 24-28, 2012.  287. Kibler K., Gomez C.E., Perdiguero B., Wong S., Huynh T., Holechek S., Arndt W., Jimenez V., Gonzalez-Sanz R., Denzler K., Haddad E.K., Wagner R., Sekaly R.P., Tartaglia J., Pantaleo G., Jacobs B.L, and Esteban M (2012). Replication-competent NYVAC demonstrates improved immune responses in animal studies. XIX International Poxvirus, Asfarvirus and Iridovirus Conference. Salamanca, Spain. June 24-28, 2012.  288. Lorenzo M.M., Caceres A., Sanchez-Puig J.M., Esteban M., Fraile-Ramos A, and Blasco R (2012). Study on the involvement of the cellular ESCRT machinery in vaccinia virus infection. XIX International Poxvirus, Asfarvirus and Iridovirus Conference. Salamanca, Spain. June 24-28, 2012.  289. Gonzalez-Santamaria J., Campagna M., Garcia M.A., Marcos-Villar L., Gonzalez D., Gallego P., Cruz-Herrera C.F., Guerra S., Rodriguez M., Esteban M, and Rivas C (2012). Regulation of vaccinia virus E3 by SUMO. XIX International Poxvirus, Asfarvirus and Iridovirus Conference. Salamanca, Spain. June 24-28, 2012.  290. Eduardo-Correia B., Versteeg G., Ketscher L., Knobeloch K.P., Garcia-Sastre A., Esteban M, and Guerra S (2012). Role of ISG-15 and isogylation in poxvirus infection. XIX International Poxvirus, Asfarvirus and Iridovirus Conference. Salamanca, Spain. June 24-28, 2012.  291. Gomez C.E., Perdiguero B., Najera J.L., Sorzano C.O.S., Jimenez V., Gonzalez-Sanz R, and Esteban M ( 2 0 1 2 ) .  R e m o v a l  o f  v a c c i n i a  v i r u s  g e nes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. XIX International Poxvirus, Asfarvirus and Iridovirus Conference. Salamanca, Spain. June 24-28, 2012.  292. Sanchez-Sampedro L., Gomez C.E., Mejias-Perez E, and Esteban M (2012). High quality long-term CD4+ and CD8+ effector memory populations stimulated by the vaccination protocol DNA-LACK/MVA-LACK in Leishmania major Balb/c model of infection. XIX International Poxvirus, Asfarvirus and Iridovirus Conference. Salamanca, Spain. June 24-28, 2012.  293. Chichon, F.J., Rodr\u00edguez, M.J., Pereiro, E.; Chiappi, M., Perdiguero, B., Guttmann, P., Werner, S., Rehbein, S., Schneider, G., Esteban, M. And Carrascosa, J.L. Cryo-X-ray Tomography: an  58 alternative microscopy for cellular approaches. International Congress of the Spanish Biophysical Society (SBE). Barcelona, 3 - 6 July, 2012.   294. Pereiro, E.; Chichon, F.J.; Ferrer S.; Rodr\u00edguez, M.J.; Chiappi M.; Guttmann, P.; S.; Schneider, G.; Esteban, M. and Carrascosa, J.L. Cryo-X-ray nanotomography. 18th User\u2019s Meeting & Workshops on X-ray Bio-imaging and Powder Diffraction. Hsinchu, Taiw\u00e1n. 29 - 30 August 2012.  295. McKay, P.F., Cope A.V., Swales J., Joseph S., Esteban M., Tatoud R., Carter D., Weber J, a n d  Shattock R.J (2012). Antigen-specific T lymphocyte responses elicited by a DNA_MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA. AIDS Vaccine 2012. Boston, USA. 9-12 Sept.  296. Hulot S.L., Korber B.T., Pantaleo, G., Tartaglia J., Jacobs, B., Perdiguero B., Gomez C.E., Esteban M., Letvin N., Seaman M.S., Haynes B, and Santra S (2012). Comparison of the depth of vaccine-icited HIV-1 Env epitope-specific CD8+ T lymphocyte responses. AIDS Vaccine 2012. Boston, USA. 9-12 Sept.  297. Garcia-Arriaza, J., Arnaez P., Gomez C.E, and Esteban M (2012). Immune responses triggered by HIV/AIDS vaccine candidates derived from MVA-B with deletions in several immune regulatory genes. AIDS Vaccine 2012. Boston, USA. 9-12 Sept.  298. Gomez C.E., Perdiguero B., Jimenez V., Filali-Mouhim., Ghneim K., Haddad E., Quakkerlaar E., Delaloye J., Harari A., Roger T., Durhem T., Sekaly R., Melief C., Calandra T., Sallusto F., Lanzavecchia A., Wagnner R., Pantaleo G, and Esteban M ( 2 0 1 2 ) .  S y s t e m s  a n \u00e1 l i s i s  o f  MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. AIDS Vaccine 2012. Boston, USA. 9-12 Sept.   299. Chichon, F.J.; Rodr\u00edguez, M.J.; Pereiro, E.; Chiappi, M.; Perdiguero, B.; Guttmann, P.; Werner, S.; Rehbein, S.; Schneider, G.; Esteban, M. And Carrascosa, J.L. Analysis of Vaccinia virus infection by cryo-X-ray nanotomography. The 15th European Microscopy Congress. Manchester, 16 \u2013 2 1 September 2012.  300. Caceres A., Perdiguero B., Gomez C.E., Cepeda V., Sorzano C.O., Caelles, C and Esteban M (2013). Role of the cellular phosphatase DUSP1 in vaccinia virus infection. XII Congreso Nacional de Virolog\u00eda, Burgos, Spain, June 2-12.  301. Herrera C.F., Campagna M., Marcos-Villar, L., Garcia M.A., Lang V., Vidal A., Rodriguez M.S., Esteban M, and Rivas C (2013). Regulation of PKR activity by SUMO. XII Congreso Nacional de Virolog\u00eda, Burgos, Spain, June 2-12.  302. Garcia-Arriaza J., Arnaez P., Gomez C.E., Sorzano C.O and Esteban M (2013). Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. XII Congreso Nacional de Virolog\u00eda, Burgos, Spain, June 2-12.  303. Lorenzo M.M., Caceres A., Sanchez-Puig J.M., Esteban M., Fraile-Ramos A, and Blasco R ( 2013). Study of the involvement of the cellular ESCRT machinery in vaccinia virus infection. XII Congreso Nacional de Virolog\u00eda, Burgos, Spain, June 2-12.  304. Y\u00e1ng\u00fcez E., Frau A ., Garcia-Culebras A., Esteban M., Garc\u00eda-Sastre, A., N i e t o A , and Guerra S (2013). ISG15 regulates peritoneal macrophages functionality against viral infection. XII Congreso Nacional de Virolog\u00eda, Burgos, Spain, June 2-12.   305. Chich\u00f3n, F.J.; Rodr\u00edguez, M.J.; Pereiro, E.; Chiappi, M.; Perdiguero, B.; Guttmann, P.; Werner, S.; Henzler, E.K.; Schneider, G.; Esteban, M. and Carrascosa, J.L. Vaccinia virus (VACV) development inside infected cells by SOFT X-ray tomographic reconstruction. MICROSCOPY AT THE  59 FRONTIERS OF SCIENCE 2013 , 3rd Joint Congress of the Portuguese and Spanish Microscopy Societies and Israel Society for Microscopy, Tarragona, 17 \u2013 20 september 2013   306. J.L Heeney, B. Jacobs, M. Esteban, R. Wagner, K. Foulds, M. Roderer, S. Self, S. Barnet, J. Tartaglia, D. Montefioru, G. Tomaras, and G. Pantaleo (2013). Increased HIV-1 immunogenicity of replication competent NYVAC. AIDS Vaccine 2013. Barcelona, Spain, 7-9 October.  307. J.L Heeney, R. Wagner, M. Esteban, B. Jacobs, K. Foulds, M. Roderer, S. Self, S. Phogat, D. Montefiori, G. Tomaras and G. Pantaleo (2013). Rapid appearance of vaccine-induced protective anti-Env antibody responses with early co-administration of gp120 and NYVAC or DNA. AIDS Vaccine 2013. Barcelona, Spain, 7-9 October.  308. B. Mothe, S. S\u00e1nchez, S. Corral, N. Climent, A.C Guardo, L. Leal, B. Torres, J.L Jimenez, J. Pich, J.A Arnaiz, A. Leon, M. Mu\u00f1oz-Fernandez, J.M Gatell, B. Clotet, M. Esteban, M. Plana, J. Lopez Bernaldo de Quiros, C. Brander, and F. Garcia (2013). Dynamics of viral load (VL) rebound alter cART interruption in chronic HIV infected patients receiving MVA-B plus disulfiram. AIDS Vaccine 2013. Barcelona, Spain, 7-9 October.  309. C.E Gomez, B. Perdiguero, J. Garcia-Arriaza, V. Cepeda, C.O Sanchez-Sorcano, B. Mothe, J.L Jimenez, M.A Mu\u00f1oz-Fernandez, J. Gatell, J.C Lopez Bernaldo de Quiros, C. Brander, F. Garcia, and  M. Esteban ( 2 0 1 3 ) .  I m m u n o g e n i c i t y  o f  M V A-B in HIV-infected volunteers. AIDS Vaccine 2013. Barcelona, Spain, 7-9 October.  310. B. Mothe, N. Climent, M. Plana, M. Rosas, J. Jimenez, M. Mu\u00f1oz-Fernandez, J. Pich, J. Arnaiz, J. Gatell, B. Clotet, M. Esteban, J.L Bernaldo de Quiros, F. Garcia, and C. Brander (2013). Safety, immunogenicity and dynamics of viral load rebound alter cART interruption inb chronic HIV infected patients receiving MVA-B vaccination. AIDS Vaccine 2013. Barcelona, Spain, 7-9 October.  311. B. Perdiguero, C.E Gomez, C.O.S. Sorzano, J. Delaloye, T. Roger, T. Calandra, G. Pantaleo, and M. Esteban (2013). Deletion of the VACV A46R gene encoding for a TPR signalling inhibitor enhances the immunogenicity of the HIV/AIDS vaccine candidate NYVAC-C. AIDS Vaccine 2013. Barcelona, Spain, 7-9 October.  312. J. Delaloye, A. Filali-Mouhim, M. Cameron, E. Haddad, A. Harari, J. Goulet, C.E Gomez, B. Perdiguero, M. Esteban, G. Pantaleo, T. Roger, R. Sekaly, and T. Calandra (2013). Dual deletion of type I and type II interferon binding proteins in NYVAC-HIV Env-Gag-Pol-Nef poxvirus vectors markedly improves vector immunogenicity. AIDS Vaccine 2013. Barcelona, Spain, 7-9 October.  313.  J. Garcia-Arriaza, and M. Esteban (2013). Modulation of immune responses to HIV Env and Gag-Pol-Nef antigens by selective deletion of a poxvirus gene. AIDS Vaccine 2013. Barcelona, Spain, 7-9 October.  314. C.E Gomez, B. Perdiguero, M.V Cepeda, L. Mingorance, J. Garcia-Arriaza, A. Vandermeeren, C.O. Sorzano, and M. Esteban (2013). High, broad, polyfunctional and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate base don MVA expressing the near full-lenght HCV genome.  7th VACCINE & ISV Congress. Sitges, Spain, 27-29 October.  315. M. Di Pilato, E. Mejias-Perez, C.E Gomez, B. Perdiguero, C.O Sorzano, and M. Esteban ( 2 0 1 3 ) .  New vaccinia virus promoter as candidate for future bacines. 7th VACCINE & ISV Congress. Sitges, Spain, 27-29 October  316. L. Sanchez-Sampedro, C.E Gomez, E. Mejias-Perez, E. Perez-Jimenez, J.C Oliveros and M. Esteban ( 2 0 1 3 ) .  M 6 5  a n d  M 1 0 1  r e p l i c a t i o n-competent vaccinia virases as vaccine candidates against leishmaniasis. 7th VACCINE & ISV Congress. Sitges, Spain, 27-29 October  317. A. Vijayan, C.E Gomez, E. Mejias-Perez, and M. Esteban (2013). A Vaccinia virus A27 protein fused  60 with plasmodium circumsporozoite as a potencial malaria vaccine candidate. 7th VACCINE & ISV Congress. Sitges, Spain, 27-29 October.  318. Mauro Di Pilato*, S\u00e1nchez-Sampedro L, Mejias-Perez E, Sorzano C O and Esteban M ( 2 0 1 4 ) .  Enhancement of antigen-specific CD4 T cell response through spacer modification in vaccinia virus promoters. 4th International Conference on Vaccines & Vaccination. Valencia, 24-26, September.  319. Di Pilato M*, Mej\u00edas-P\u00e9rez E*, Zonca M, Perdiguero B, G\u00f3mez CE, Trakala M, Nieto J, N\u00e1jera JL, Sorzano CO, Planelles L, Esteban M. (2014). Vaccinia Virus with Selective Deletions Enhances T Cell Response to HIV Antigens by Specific    Neutrophil Recruitment.  HIV Research for Prevention  2014. Cape Town, South Africa, 28-31, October.  320. Perdiguero B, G\u00f3mez CE, Cepeda MV, S\u00e1nchez-Sampedro L, Garc\u00eda-Arriaza J, Mej\u00edas-P\u00e9rez  E, Jim\u00e9nez V, S\u00e1nchez C, Sorzano CO, Delaloye J, Roger T, Calandra T, Wagner R, Asbach B, Kibler KV, Jacobs BL, Pantaleo G, Esteban M (2014). Bivalent NYVAC-based Vaccine Candidates against HIV/AIDS Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs. HIV Research for Prevention 2014. Cape Town, South Africa, 28-31, October.  321. Yanguez E, Garcia-Culebras, A, Frau A, Garcia-Sastre A, Esteban M, Nieto A, and Guerra S (2014). ISG15 regulates peritoneal macrophages functionality against viral infection. XX International Poxvirus, Asfarvirus & Iridovirus Conference. Victoria BC, Canada, September 26-30.  322. Garcia-Arriaza J, Cepeda V, Halleng\u00e4rd D, Sorzano C O, K\u00fcmmerer M K, Liljestr\u00f6m P, and Esteban M (2014). A novel poxvirus-based vaccine (MVA-CHIKV) is highly immunogenic and protects mice against chikungunya infection. XX International Poxvirus, Asfarvirus & Iridovirus Conference. Victoria BC, Canada, September 26-30.  323.  Di Pilato M, Mej\u00edas-P\u00e9rez E, Zonca M, Perdiguero B, G\u00f3mez C, Trakala M, Nieto J, N\u00e1jera JL, Sorzano CO, Combadiere C, Pantaleo G, Planelles L a n d  Esteban M. (2015).Neutrophil migration via NFKB activation by modified Vaccinia virus as a novel mechanism to enhance HIV-specific T cell responses. XIII Congreso Nacional de Virolog\u00eda 2015. Madrid, 7-10, June.  324.  Garcia-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori D, Labranche C, Yates N, Shen X, Tomaras G, Ferrari G, Foulds K.E, Mcdermott A, Kao S, Roederer M, Hawkins N, Self S, Yao J, Farrell P, Phogat S, Tartaglia J, Barnett S.W, Burke B, Cristillo A, Weiss D, Lee C, Kibler K, Jacobs B, Asbach B, Warner R, Ding S, Pantaleo G and Esteban M (2015). Head-to-head comparison of Poxvirus Nyvac and Alvac vectors expressing identical HIV-1 clade C inmunogens in prime/boost combination with env protein in non-human primates. X I I I  C o n g r e s o  N a c i o n a l  d e  V i r o l o g \u00ed a  2 0 1 5 .   Madrid, 7-10, June.  325. Di Pilato M, S\u00e1nchez-Sampedro L, Mej\u00edas- P \u00e9 r e z  E ,  S o r z a n o  C . O . S  a n d  Esteban M ( 2 0 1 5 ) .  Modification of promoter spacer length in Vaccinia Virus as astrategy to control the antigen expression. XIII Congreso Nacional de Virolog\u00eda 2015.  Madrid, 7-10, June.  326. De la Cruz-Herrera C.F, Baz-Martinez, Lang V, El Motiam A, Barbaz\u00e1n J, Couceiro R, Abal M, Vidal A, Esteban M, Mu\u00f1oz-Fontela C, Nieto A, Rodr\u00edguez MS, Collado M, Rivas C (2015). Modulation of P85\u03b2 activity by sumo. XIII Congreso Nacional de Virolog\u00eda 2015.  Madrid, 7-10, June.  327. G\u00f3mez C.E, Perdiguero B, Garc\u00eda- Arriaza J, Cepeda V, S\u00e1nchez-Sorzano C.O, Mothe B, Jimenez J L, Mu\u00f1oz-Fern\u00e1ndez M.A, Gatell J.M, L\u00f3pez Bernaldo de Quir\u00f3s C, Brander C, Garc\u00eda F and Esteban M ( 2 0 1 5 ) .  Therapeutic MVA-B Vaccine improves the m a g n i t u d e  a n d  q u a l i t y  o f  t h e  T  c e l l  inmune responses in HIV-1 infected subjects on haart. X I I I  C o n g r e s o  N a c i o n a l  d e  V i r o l o g \u00ed a  2 0 1 5 .   Madrid, 7-10, June.  328. Rodr\u00edguez M.J, Chich\u00f3n S, Guti\u00e9rrez-Erlandsson S, Conesa J.J, Esteban M, Carrascosa Jos\u00e9 L (2015). Role of vimentin filaments in Vaccinia Virus assembly and maturation. XIII Congreso Nacional  61 de Virolog\u00eda 2015.  Madrid, 7-10, June.  329. Vijayan A, Garc\u00eda- A r r i a z a  J ,  R a m a n  S . C ,  C o n e s a  J . J ,  C h i c h \u00f3 n  F . J ,  S a n t i a g o  C ,  S o r z a n o  O . S ,  Carrascosa J.L and Esteban M (2015). A chimeric HIV-1 GP120 fused with Vaccinia Virus 14K (A27) protein as an HIV inmunogen. XIII Congreso Nacional de Virolog\u00eda 2015.  Madrid, 7-10, June.  330. Perdiguero B, G\u00f3mez C.E, Cepeda V, S\u00e1nchez-Sampedro L, Garc\u00eda-Arriaza J, Mej\u00edas-P\u00e9rez E, Jimenez V, S\u00e1nchez C, Sorzano C.O.S, Oliveros J.C, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler V, Jacobs B.L, Pantaleo G and Esteban M (2015). Virological and immunological characterization of novel NYVAC-based HIV/AIDS Vaccine candidates expressing clade C trimeric soluble GP140 (ZM96) and GAG (ZM96)-POL-NEF(CN54) as virus- l i k e  p a r t i c l e s .  X I I I  C o n g r e s o  Nacional de Virolog\u00eda 2015.  Madrid, 7-10, June.  331. Mej\u00edas- P \u00e9 r e z  E ,  S \u00e1 n c h e z-Sampedro L, Sorzano C.O S, Esteban M ( 2 0 1 5 ) .  Head-to-head comparison of Vaccinia Virus-based vectors NYVAC and MVA expressing Leishmania activated C-kinase in mice. XIII Congreso Nacional de Virolog\u00eda 2015.  Madrid, 7-10, June.  332. Quir\u00f3s M, Garc\u00eda-Arriaza J, G\u00f3mez C.E, Sorzano C.O.S and Esteban M (2015). Characterization of a novel Hepatitis C Virus (HCV) Vaccine candidate base on MVA expressing the nearly full-length HCV genome and lacking C6L Vaccine Virus immunomodulatory gene. XIII Congreso Nacional de Virolog\u00eda 2015.  Madrid, 7-10, June.  333. De la Cruz-Herrera C.F, Baz-Mart\u00ednez M, Vidal A, Lang V, Motiam A.E, Rodr\u00edguez M.S, Esteban M, Rivas C (2015). Non-covalent interaction with sumo is necessary for full activation of PKR. XIII Congreso Nacional de Virolog\u00eda 2015.  Madrid, 7-10, June.  334. Liljestr\u00f6m P, Roques, P, Ljungberg K, K\u00fcmmerer B.M, Gosse L, Deureuddre-Bosquet N, Halleng\u00e4rd D, Garcia-Arriaza J, Esteban M, Merits A, and Le Grant R (2015). The making of a Chikungunya vaccine: comparing attenuated and vectored vaccine platforms. 9th Vaccine and ISV Congress, October 18-20. Seoul, South Corea.  335. Kibler K, Gomez C, Denzler K, Perdiguero B, Huynh T, Sanchez L, Fukushima N, Esteban M, Pantaleo G, and Jacobs B (2016). Pre-clinical safety studies demonstrate attenuation of the replication-competent NYVAC-KC as a vaccine candidate vector. X X I  I n t e r n a t i o n a l  P o x v i r u s  Asfarvirus and Iridovirus Conference. July 1-5, Strasbourg, France.   336. Esteban M, Garcia-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori D, Labranche C, Yates N, Shen X, Tomaras G, Ferrari, G, Foulds K, Mvdermott A, Kao S-F, Roederer M, Hawkins N, Self S, Yao J, Farrel P, Phogat S, Tartaglia J, Barnett S, Burke B, Cristillo A, Weis D, Lee C, Kibler K, Jacobs B, Wagner R, Ding S, and Pantaleo G (2016). A replication-competent NYVAC vector expressing HIV-1 clade C immunogens ( N Y V A C-C-KC) is more immunogenic than NYVAC-C in prime/boost combination with ENV protein in non-human primates. XXI International Poxvirus Asfarvirus and Iridovirus Conference. July 1-5, Strasbourg, France.  337. Alberto C. Guardo, Vicens D\u00edaz-Brito, Judit Pich, Joan Albert Arnaiz, Beatriz Perdiguero, Jos\u00e9 M Gatell, Mariano Esteban, Juan Carlos L\u00f3pez Bernaldo de Quir\u00f3s, Felipe Garc\u00eda, Montserrat Plana, for the RISVAC02boost study. Boosting MVA-B dose in healthy volunteers 4 years after a first immunization (2016) . HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P). October 17-21, 2016. Chicago, USA.  338. Vicens D\u00edaz-Brito, Alberto C. Guardo, Montserrat Plana, Judit P i c h ,  J o a n  A l b e r t  A r n a i z ,  B e a t r i z  Perdiguero, Jos\u00e9 M Gatell, Mariano Esteban, Juan Carlos L\u00f3pez Bernaldo de Quir\u00f3s, Felipe Garc\u00eda, for the RISVAC02 and RISVAC03 study. Comparison of safety and immunogenicity of MVA-B in HIV-uninfected and HIV-infected volunteers ( 2 0 1 6 ). HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P). October 17-21, 2016. Chicago, USA.   62 339. Gomez CE, Perdiguero B, Garc\u00eda-Arriaza J, Sanchez-Sorzano CO, Guardo A, Diaz-Brito V, Pich J, Arnaiz JA, Jimenez JL, Mu\u00f1oz-Fernandez MA, Gatell JM, Bernaldo de Quiros JC, Garcia F, Plana M, and Esteban M (2017). Long-term immune responses induced by the prophylactic MVA-B HIV/AIDS vaccine. XIV Congreso Nacional de Virologia. Cadiz, 11-14 junio.  340. Perez P, Marin MQ, Gomez CE, Sanchez-Sorzano CO, Esteban M, a n d  G a r c i a-Arriaza J (2017). Deletion of the vaccinia virus gene A40R improves adaptive and memory immune responses of the HIV/AIDS vaccine candidate MVA-B (2017). XIV Congreso Nacional de Virologia. Cadiz, 11-14 junio.  341. Marin MQ, Perez P, Gomez CE, Sanchez-Sorzano CO, Esteban M, and Garcia-Arriaza, J (2017). Characterization of novel hepatitis C virus vaccine candidate base don MVA expressing the nearly full-length HCV genome and lacking 6L vaccinia virus gene. XIV Congreso Nacional de Virologia. Cadiz, 11-14 junio.   342. Di Pilato M, Mejias-Perez E, Sanchez-Sorzano CO, and Esteban M (2017). Role of vaccinia virus NF-kB inhibitor protein A52, B15 and K7 in immunity. XIV Congreso Nacional de Virologia. Cadiz, 11-14 junio.  343. Garcia-Arriaza J, Perdiguero B, Heeney J ,  S e a m a n  M S ,  M o n t e f i o r i  D C ,  Y a t e s  N L ,  T o m a r a s  G D ,  Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnet SW, Burke B, Cristillo AD, Weis DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, and Esteban M (2017). Replication competent poxvirus NYVAC-KC as HIV/AIDS vaccine candidate and role of the virus B19R gene in non-human primatesXIV Congreso Nacional de Virologia. Cadiz, 11-14 junio.  344. Esteban M ( 2 0 1 7 ) .  N e w  t r e n d s  i n  i m m u n o l o g y :  t o w a r d s  i m m u n o g e n i c  a n d  effective recombinant vaccines against HIV/AIDS and emerging viruses. XI Congreso anual de biotecnolog\u00eda. Le\u00f3n, 12-14 junio.    TESIS DOCTORALES DIRIGIDAS    1. Cabrera, Carlos V. (1978).  Studies on the structure and genetic expression of poxvirus.  Departments of Microbiology, Rutgers Medical School, CMDNJ, Piscataway, New Jersey and School of Pharmacy, Universidad de Santiago de Compostela, Espa\u00f1a.  2. Dallo, Shatha (1986).  Isolation and characterization of spontaneous deletion mutants of vaccinia virus.  Department of Microbiology and Immunology, SUNY Health Science Center at Brooklyn, NY. Premio extraordinario.  3. Maa, Juehn-Shin (1988).  Biochemical and genetic characterization of immunodominant proteins of vaccinia virus.  Department of Biochemistry, SUNY Health Science Center at Brooklyn, NY.  4. Kahn, Jeffrey S. (1990).  Structural and functional studies of the vaccinia virus nucleic acid-dependent ATPase.  Department of Microbiology and Immunology, SUNY Health Science Center at Brooklyn, NY.  5. Gong, Shiaoching (1990).  Genetic variability of the 14 KDa envelope protein of vaccinia virus and involvement of this protein in virus-induced cell fusion.  Department of Biochemistry, SUNY Health Science Center at Brooklyn, NY.  6. Chingfeng Lai (1990).  Structural and functional characterization of the vaccinia virus 14 KDa envelope  63 protein synthesized in Escherichia coli.  Department of Biochemistry, SUNY Health Science Center at Brooklyn, NY.  7. Walter E. Demkowicz (1991).  Identification and immunologic characterization of two antigenic core proteins of vaccinia virus.  Department of Microbiology and Immunology, SUNY Health Science Center at Brooklyn, NY.   8. Rodriguez, J-R (1992).  Characterization of attenuated variants of vaccinia virus as safe recombinant vaccines:  application as a vaccine against AIDS.  Department of Biochemistry, SUNY Health Science Center at Brooklyn, NY. Universidad Aut\u00f3noma de Madrid. Premio extraordinario.  9. Irvine, Martin (1993). Identification and characterization of mutants of vaccinia virus with increased sensitivity to interferon. Department of Microbiology and Immunology. SUNY, Health Science Center at Brooklyn, N.Y.   10. Lee, S.B (1994). Structure and function of the interferon-induced double-stranded RNA-dependent protein kinase. Department of Microbiology, SUNY Health Science Center at Brooklyn, N.Y. Premio extraordinario.  11. Melkov\u00e1, Zora (1995). Macrophage antiviral activity: Role of Interferon-gamma and nitric oxide in the inhibition of vaccinia virus growth in macrophages. State University of New York, Health Science Center at Brooklyn, N.Y. USA.  12. Pav\u00f3n, Miguel (1997). La proteina kinasa humana inducida por interfer\u00f3n y sensible a dsRNA (PKR): caracterizaci\u00f3n preliminar, proteinas de uni\u00f3n y algunas propiedades nuevas. Centro Nacional de Biotecnologia. Universidad Aut\u00f3noma de Madrid.  13. Collado, Manuel (1997). Modulaci\u00f3n de la respuesta inmunitaria frente a la proteina env del VIH-1, mediante su fusi\u00f3n a ant\u00edgenos del virus vaccinia. Centro Nacional de Biotecnologia. Universidad Aut\u00f3noma de Madrid.  14.  Vazquez, Isabel (1998). Caracterizaci\u00f3n de los dominios funcionales de la proteina de 14   kDa del virus vaccinia que juega un pap\u00e9l importante en la interacci\u00f3n virus-c\u00e9lula. Centro Nacional de Biotecnologia y Facultad de Farmacia de la Universidad de Santiago de Compostela.   15. Gonzalo, Rosa (1999). Desarrollo de estrategias de inmunizaci\u00f3n frente  a Leishmania basadas en virus vaccinia recombinantes en el modelo murino. Centro Nacional de Biotecnologia, Universidad Aut\u00f3noma de Madrid.   16. Moratilla, Marta (1999). An\u00e1lisis estructurales y funcionales del genoma del virus Molluscum contagiosum. Centro Nacional de Biotecnolog\u00eda. Universidad Aut\u00f3noma de Madrid.  17.  Gil, Jes\u00fas (2000). Mecanismo de inducci\u00f3n de apoptosis y activaci\u00f3n de NF-kB por la proteina quinasa dependiente de dsRNA, PKR.  Centro Nacional de Biotecnolog\u00eda, Universidad Aut\u00f3noma de Madrid. Premio extraordinario  18.  Abait\u00faa, Fernando (2001). Potenciaci\u00f3n de la respuesta inmune frente al ant\u00edgeno de la envuelta del virus de la inmunodeficiencia humana (VIH-1) por recombinantes atenuados del virus vaccinia que expressan citoquinas I   tipo Th1 (FN-gamma e IL-12). Universidad Aut\u00f3noma de Madrid. Sobresaliente cum laude.   19. Juan Carlos Gallego G\u00f3mez (2003). Biolog\u00eda celular de la infecci\u00f3n y morfog\u00e9nesis de mutantes atenuados del virus vaccinia. Universidad Aut\u00f3noma de Madrid. 11 Marzo. Sobresaliente cum laude.  64  20. Carmen E. G\u00f3mez (2003). Respuesta inmune generada por sistemas combinados de vacunaci\u00f3n frente a p\u00e9ptidos de la envuelta del VIH-1 incluidos en la prote\u00edna multiepit\u00f3pica TAB-13. Universidad Aut\u00f3noma de Madrid. 17 Diciembre. Sobresaliente cum laude  21. Maria Angel Garc\u00eda Chaves (2004). Mecanismo de acci\u00f3n y regulaci\u00f3n de la prote\u00edna quinasa inducida por interferon, PKR. Universidad Aut\u00f3noma de Madrid. 30 Abril de 2004. Sobresaliente cum laude. Premio Extraordinario de la UAM.  22. Soledad Blanco Chapinal (2005). Estrategias de modulaci\u00f3n de la respuesta inmune frente a malaria en el modelo murino de Plasmodium yoelii. Universidad Aut\u00f3noma de Madrid. 16 Diciembre de 2005. Sobresaliente Cum Laude.  23. Andrea Vandermeeren (2006). Study of the HCV polyprotein expresi\u00f3n from an inducible vaccinia virus recombinant and its implication in the host-cell responses. Universidad Aut\u00f3noma de Madrid. 30 de Marzo de 2006. Sobresaliente cum laude.  24. Eva P\u00e9rez Jim\u00e9nez (2006). Desarrollo de una vacuna frente a leishmaniasis. Universidad Aut\u00f3noma de Madrid. 29 Mayo. Sobresaliente cum laude.  25. Jos\u00e9 Luis N\u00e1jera (2007). Caracterizaci\u00f3n \u201cin vitro\u201d e \u201cin vivo\u201d de los vectores atenuados de poxvirus MVA y NYVAC como candidatos vacunales frente al VIH/SIDA. Universidad Aut\u00f3noma de Madrid. 23 de Noviembre. Sobresaliente \u201ccum laude\u201d.  26. Elena Domingo Gil (2008). Caracterizaci\u00f3n de la apoptosis inducida por el sistema 2-5A/RNasa L. Universidad Aut\u00f3noma de Madrid. 15 Febrero. Sobresaliente \u201ccum laude\u201d.  27. Lucas Sanchez Sampedro (2012). Mutantes replicativos y atenuados del virus vaccinia como candidatos vacunales frente a leishmaniasis. Universidad Aut\u00f3noma de Madrid. 19 Octubre.  Apto \u201ccum laude\u201d.  28. Ana C\u00e1ceres N\u00fa\u00f1ez (2013). Papel de la fosfatasa celular DUSP-1 en la infecci\u00f3n por el virus vaccinia. Universidad Aut\u00f3noma de Madrid. 19 Abril. Apto \u201ccum laude\u201d.  29. Aneesh Vijayan (2013). Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on circumsporozoite protein. Universidad Aut\u00f3noma de Madrid. 13 Junio.  Apto  30. Mauro di Pilato (2015). Poxvirus vaccine strategies to improve T cell responses: neutrophil immunomodulation and promoter modification. Universidad Aut\u00f3noma de Madrid. 3 Mayo. Sobresaliente \u201ccum laude\u201d.  31. Ernesto Mej\u00edas (2017). Vectores virales basados en poxvirus como agentes oncol\u00edticos. Universidad Aut\u00f3noma de Madrid. 27 enero. Sobresaliente \u201ccum laude\u201d    EXPERIENCIA DE GESTI\u00d3N DE I+D    T\u00edtulo: Centro Nacional de Biotecnolog\u00eda del CSIC.  Tipo de actividad: Director Fecha: 1992- 2003   65 T\u00edtulo: Presidente de la Real Academia Nacional de Farmacia (RANF) Fecha: 2012-    2  EXPERIENCIA EN ORGANIZACI\u00d3N DE ACTIVIDADES DE I+D  T\u00edtulo: Fith European Conference on Experimental Aids Research (ECEAR), Presidente. Tipo de actividad: Congreso, Madrid. Fecha: 16-19 de Junio 2000.  T\u00edtulo:  XI International Poxvirus and Iridovirus Meeting, Presidente. Tipo de actividad: Congreso, Toledo.  Fecha: 4-9 de mayo , 1996.  T\u00edtulo: II European Congress in Virology (EUROVIROLOGY-2004), Co-Presidente. Tipo de actividad: Congreso, Madrid. Fecha: Septiembre, 2004.  T\u00edtulo:  7the Vaccine Congres and ISV, Co-Chair Tipo de actividad: Congreso, Sitges, Spain Fecha: 27-29 October, 2013   EXPERIENCIA ACAD\u00c9MICA:  En Espa\u00f1a, Facultad de Farmacia, Universidad de Santiago de Compostela. Profesor Ayudante de Pr\u00e1cticas en Microbiolog\u00eda, 1968-1970.  En EE.UU, Rutgers Medical School, Piscataway, New Jersey. Instructor, Department of Microbiology, 1974-1977  En EE.UU (Health Science Center, Brooklyn, New York). Professor, Departments of Biochemistry and of Microbiology and Immunology. 1979-1992  l. Medical School Courses:          (a)  General Biochemistry    (b)  Nine-week selective course in General Biochemistry    (c)  Microbiology and Immunology  2. School of Graduate Studies            (a)  Molecular Genetics, GI l02, 4 credits            (b)  Animal Virology, G l03, 6 credits            (c)  Biochemistry, G l03, 8 credits            (d)  Microbial Genetics, G l02, 6 credits            (e)  Techniques in Molecular Cloning, G-507, 4 credits  Member of President's Advisory Committee on Research Allocation,  1984-1987. Member of Search Committee for Chairman of Microbiology and Immunology, 1981    Member of Search Committee for Chairman of Anatomy and Cell Biology, 1982-1984       Committee of the Graduate School Faculty, 1980       Co-Director of Molecular Genetics Course 1980-1986  Chairman, Recombinant Biohazards Committee, 1990-1992                                                                66  Group Leader, AIDS Research, 1990-1993  En Espa\u00f1a, Universidad Aut\u00f3noma de Madrid. Profesor Honorario, Departamento de Biolog\u00eda Molecular. 1992-actual. Curso Sistema Inmune y Agentes infecciosos. 4  cr\u00e9ditos. 1998-2008. Participaci\u00f3n en Masters de Virolog\u00eda, Universidades Aut\u00f3noma y Complutense de Madrid (2009-present)     MIEMBRO DE SOCIEDADES CIENTIFICAS  \u2022 Miembro Honorario de las siguientes Sociedades: \u2022 American Society of Microbiology \u2022 American Society of Virology \u2022 British Society of Microbiology \u2022 Spanish Society of Microbiology \u2022 Harvey Society \u2022 The Society of Sigma Xi \u2022 New York Academy of Sciences \u2022 American Association for the Advancement of Science    PARTICIPACION  EN  COMITES  EUROPEOS  - Member of the European Action Progamme Against AIDS. 1994-present  - Member of the COST /STD Initiative for a European Vaccine Program.     1994-97.  - Member of the European Concerted Action Against Malaria, 1996-98  - M e m b e r  o f  E x t e r n a l  A d v i s o r y  G r o u p  ( E A G )  o f  t h e  E u r o p e a n  C o m m i s s i o n ,  k e y  a c t i o n  2 ,  C ontrol of Infectious Diseases, Fifth Framework Programme.1998-2002   - Member of WHO Advisory Committee on Variola Virus Reseach, 1998-present  - Member of Strategic Advisory Group of Experts (SAGE) for Immunization, Vaccines and Biologicals, WHO, 2002-2007  - Member of Advisory Group for the Sciende Foundation of Ireland, 2000-2004  - Member of European Science Foundation (ESF) Group for Research Infraestructures on Biomedical Sciences, 2003-2008  - Member of Scientific Advisory Group, Novartis, Spain. 2002-2008  -Founder and Board Member of the European Foundation Against AIDS (EuroVacc) 2002-present  Member of Scientific Advisory Group, CSIC, 2012-2017     67 EVALUACION DE TRABAJOS CIENTIFICOS  1) Revistas cient\u00edficas: Science; EMBO J.  ; J. Virol. ; Virology. ; J. Gen. Virol. ; Arch. Virology; Virus Research; J. Biol. Chem. ; J. Interferon and Cytokine Research; ONCOGENE; Molecular Therapy; Vaccine. FEBS Lett. Apoptosis  2)  Proyectos: National Science Foundation (NSF), USA; American Cancer Society, USA; Natural Sciences and Engineering Research Council of Canada (NSERC); Human Frontiers, EU; Austrian Science Fund; National Science Foundation of Ireland; Research Grants Council, Hong Kong; Medical Research Council of South Africa; Israel Science Foundation;  Agencia Nacional de Evaluaci\u00f3n y Prospectiva (ANEP); Fondo de Investigaciones Sanitarias (FIS); Comunidad Aut\u00f3noma de Madrid (UAM); Fundaci\u00f3n para la Investigaci\u00f3n sobre el Sida (FIPSE). Fundaci\u00f3n Marcelino Bot\u00edn; Foundation Bill and Melinda Gates  3)   Centros de investigaci\u00f3n:  Miembro del Comit\u00e9 Externo de Evaluacion de los centros: Centro Nacional de Ingenier\u00eda y de Industria Tecnol\u00f3gica (INETI) del Ministerio de Ciencia y Tecnolog\u00eda de Portugal; Instituto de Investigaciones Bioqu\u00edmicas, Fundaci\u00f3n Campomar, Buenos Aires, Argentina (Abril, 2 0 0 1 )  .Molecular Virology Institut, Munich (2002).   LOGROS CIENTIFICOS:  El objetivo de mi investigaci\u00f3n es entender la biolog\u00eda molecular de agentes infecciosos para desarrollar estrategias que permitan su control. Los resultados mas significativos obtenidos en las l\u00edneas de investigaci\u00f3n del laboratorio han sido los siguientes:   LINEA: BIOLOG\u00cdA DE LA INFECCI\u00d3N VIRAL. Estos estudios nos han permitido identificar procesos de entrada del virus en la c\u00e9lula, su transcripci\u00f3n en RNA mensajeros, control de la s\u00edntesis de prote\u00ednas, procesos de replicaci\u00f3n del DNA, y ensamblaje viral.  -Establecimiento de la entrada del virus vaccinia en c\u00e9lulas por fusion de membranes (ref. 31, 61, 80)  -Descubrimiento de que la cara basolateral de la c\u00e9lula est\u00e1 implicada en la entrada del virus vaccinia (ref. 85)  -Descubrimiento de la prote\u00edna p14 (A27L) del virus vaccinia  como mediador de la entrada del virus en la c\u00e9lula por fusi\u00f3n e identificaci\u00f3n de los dominios de union y de neutralizaci\u00f3n (ref. 54, 62, 66, 74, 78, 80, 95, 136, 140)  -Descubrimiento de la prote\u00edna p32 (D8L) como mediador de la union del virus vaccinia a la membrana cellular (ref. 79, 84, 91)  -Establecimiento de un sistema libre de c\u00e9lulas para la traducci\u00f3n de los RNA mensajeros virales (ref. 3,4,7)  -Demostraci\u00f3n in vitro de la traducci\u00f3n completa del genoma del virus de la encefalomiocarditis (ref. 9)  -Demostraci\u00f3n de la regulaci\u00f3n diferencial de la s\u00edntesis de prote\u00ednas por el virus vaccinia y de la existencia de una r\u00e1pida inhibici\u00f3n traduccional (ref. 2,5, 6)  -Descubrimiento de los mecanismos de replicaci\u00f3n (iniciaci\u00f3n, elongaci\u00f3n y terminaci\u00f3n) del DNA del virus vaccinia (ref. 13 a 21, 26, 27, 28)  -Establecimiento de un sistema de purificaci\u00f3n del DNA intacto del virus vaccinia (ref. 20)  -Identificaci\u00f3n de prote\u00ednas de union al DNA del virus vaccinia (ref. 21, 27)  68  -Primer mapa transcripcional del virus vaccinia (ref. 22, 23)  -Descubrimiento de RNAs virales de bajo peso molecular que act\u00faan como reguladores de la traducci\u00f3n de los RNA mensajeros celulares (ref. 30, 71, 87, 99)   -Identificaci\u00f3n de las prote\u00ednas del virus vaccinia que inducen protecci\u00f3n frente a la infecci\u00f3n y son inmunodominantes en individuos vacunados contra viruela (67, 79, 81, 84)  -Primera generaci\u00f3n de una vacuna contra viruela basada en prote\u00ednas purificadas (88, 90, 172)  -Caracterizaci\u00f3n de las prote\u00ednas que son necesarias para el correcto ensamblaje del virus vaccinia y del reclutamiento de membranes en distintos compartimentos celulares (ref. 107, 113, 120, 124, 129, 130, 143, 161, 166)  -Demostraci\u00f3n de que la forma inmadura del virus vaccinia contiene una doble membrana (ref. 170)  -Primera definici\u00f3n por microscop\u00eda electr\u00f3nica y por tomograf\u00eda de la estructura del virus vaccinia a una resoluci\u00f3n de 4-6 nm (199), del proceso de ensamblaje de membranas (240) y del proceso de morfog\u00e9nesis por crio-Rayos X (244).  -Secuenciaci\u00f3n parcial del genoma del poxvirus  Molluscum contagiosum, su mapeo e identificaci\u00f3n de genes con organizaci\u00f3n \u00fanica (115, 118, 123, 174)  -Demostraci\u00f3n de que las prote\u00ednas A27-A17 de vaccinia participan en el proceso de fusi\u00f3n del virus con la membrana celular y mapeo del dominio de fusi\u00f3n (ref. 229).   LINEA: MECANISMO DE ACCION DE LOS INTERFERONES (IFN). Estos estudios nos han permitido demostrar el papel de  los interferones como inhibidores de la replicaci\u00f3n viral y como reguladores del crecimiento celular.  .-Descubrimiento de que los interferones (IFN) inhiben la replicaci\u00f3n viral a niv\u00e9l traduccional. Este trabajo (ref. 2) publicado en Nature mereci\u00f3 la distinci\u00f3n en la secci\u00f3n News and Views y fue pionero en el desciframiento de mecanismos de acci\u00f3n (ref. 1-12;43,47) e inter\u00e9s por el uso del IFN como droga en tratamiento de enfermedades infecciosas y c\u00e1ncer.  - Descubrimiento de que los virus animales contienen genes que interfieren con la acci\u00f3n de los interferones (ref.44,45,56, 98)   -Descubrimiento de que los interferones inhiben la transformai\u00f3n gen\u00e9tica y oncog\u00e9nica por genes virales y celulares, as\u00ed como procesos de recombinaci\u00f3n viral (ref.48-52)   -Descubrimiento del modo de acci\u00f3n antiviral de la prostaglandina PGA1 y su relaci\u00f3n con los interferones (ref.33,37,39,40,60,73)   -Descubrimiento de la proteina quinasa PKR dependiente de RNA bicatenario e inducida por los interferones como activador del proceso de muerte celular por apoptosis (ref.101), lo que explica la acci\u00f3n antitumoral de IFN. En una serie extensa de trabajos se caracteriz\u00f3 el modo de acci\u00f3n antiviral y anticelular de la PKR y su se\u00f1alizaci\u00f3n molecular (ref. 92,93,102,117,122, 125,138,139,144,148-151,160,178,192).  -Identificaci\u00f3n de genes virales (en poxvirus, herpesvirus, reovirus) y celulares cuyos productos controlan la acci\u00f3n de la prote\u00edna quinasa PKR (ref. 116,156, 169,185,187)  -Descubrimiento de la prote\u00edna RNasaL inducida por IFN como inductor de apoptosis (ref.128)    69 -Identificaci\u00f3n de la prote\u00edna E3L como inhibidor de la apoptosis inducida por el  sistema de defensa 2-5A  sintetasa/RNasa L (ref. 132, 176)   -Demostraci\u00f3n del efecto antiviral y apopt\u00f3tico de la prote\u00edna \u00f3xido n\u00edtrico sintetasa inducida por IFN (ref. 109, 126,154)  -Demostraci\u00f3n de un nuevo mecanismo de acci\u00f3n de evasi\u00f3n viral (familia de flavivirus) que eluden a la acci\u00f3n de la prote\u00edna quinasa PKR  por mediaci\u00f3n de una estructura (hairpin-loop) en el extremo 5\u00b4de la forma subgen\u00f3mica viral que codifica para las prote\u00ednas estructurales (ref. 207)  -Demostraci\u00f3n de que la expresi\u00f3n del genoma del virus de la hepatitis C induce apoptosis por activaci\u00f3n de las rutas de muerte, prote\u00edna quinasa PKR y sistema 2-5 A sintetasa/RNasa L (ref. 202).  -Demostraci\u00f3n del papel de la mitocondria en la apoptosis mediada por el el sistema 2-5A sintetasa/RNasa L inducido por los interferones (ref. 211)  -Primera generaci\u00f3n de un rat\u00f3n transg\u00e9nico que al expresar la prote\u00edna E3 del virus vaccinia confiere mayor sensibilidad de los animales a la infecci\u00f3n con virus y par\u00e1sitos, ejerciendo estos efectos por interferencia con el sistema de los interferones y respuesta inmune (ref. 230)  -Demostraci\u00f3n de que hay genes supresores de tumores que tambi\u00e9n act\u00faan como inhibidores de la replicaci\u00f3n de los virus (ref. 217, 220, 227,243,262)  -Hemos escrito una revisi\u00f3n extensa sobre el modo de acci\u00f3n de la prote\u00edna PKR inducida por los interferones (ref. 216, 221)  LINEA: INTERACCION VIRUS-CELULA. Estos estudios tienen como objetivo definir el impacto que la infecci\u00f3n tiene sobre el hospedador, as\u00ed como identificar los genes celulares y sus productos que se inducen o reprimen durante el proceso de infecci\u00f3n viral y que juegan un pap\u00e9l importante en la patog\u00e9nesis v\u00edrica.  -Demostraci\u00f3n del reclutamiento de ribosomas por los RNA mensajeros virales y formaci\u00f3n del complejo de iniciaci\u00f3n en la traducci\u00f3n (ref. 11)  -Identificaci\u00f3n y demostraci\u00f3n de la enzima ATPasa-dependiente de DNA en la regulaci\u00f3n de la expresi\u00f3n g\u00e9nica viral (ref. 57, 83)  -Establecimiento de un sistema de expresi\u00f3n regulada de genes celulares por la polimerasa del bacteri\u00f3fago T3 (ref. 82).  -Identificaci\u00f3n por microarrays de los genes celulares que se inducen y reprimen durante la infecci\u00f3n de c\u00e9lulas HeLa con el virus vaccinia, estirpes salvaje WR y atenuadas MVA y NYVAC (ref. 183, 192, 208), as\u00ed como en c\u00e9lulas dendr\u00edticas humanas (ref. 223).   -Identificaci\u00f3n de los genes celulares inducidos por la activaci\u00f3n del sistema de interferon, OAS/RNasaL (253)  -Identificaci\u00f3n de los genes celulares inducidos en c\u00e9lulas dendr\u00edticas humanas por los candidatos vacunales frente al VIH, los vectores MVA-B (255) y MVA-C (281).  -Descubrimiento del gen humano ATF-3 como necesario para la inducci\u00f3n de apoptosis por activaci\u00f3n de la prote\u00edna quinasa PKR (ref. 215).  -Demostraci\u00f3n de que genes supresores de tumores tienen capacidad antiviral y que este efecto es ejercido, en el caso de ARF, por supresi\u00f3n de la acci\u00f3n de la proteina quinasa PKR (216, 217,220,221,227)   70 -Identificaci\u00f3n del gen celular ISG15 como inhibidor de la replicaci\u00f3n del virus vaccinia y demostraci\u00f3n del gen viral E3L que al interaccionar con ISG15 modula su capacidad antiviral (237, 298)   LINEA: PATOGENESIS DE LA INFECCION VIRAL. Estos estudios tienen como objetivo definir los mecanismos que utilizan  los virus animales para provocar la muerte del hospedador  -Demostraci\u00f3n de que el efecto citop\u00e1tico inducido por el virus vaccinia es dependiente de la expresi\u00f3n g\u00e9nica viral (ref. 24,25, 29)  -Demostraci\u00f3n de que las drogas antiinflamatorias aumentan la patogenicidad v\u00edrica (ref. 60)  -Establecimiento del primer sistema de seguimiento de la infecci\u00f3n viral en tejidos animales con un marcador fluorescente (ref. 69)  -Establecimiento de una infecci\u00f3n v\u00edrica persistente, demostraci\u00f3n de mutaciones y de su papel en patog\u00e9nesis (51,63-65,70,77,78)   -Descubrimiento del gen humano Wiskott-Aldrich (WASP) como necesario para la patog\u00e9nesis del virus vaccinia (ref. 198)   -Identificaci\u00f3n del gen de vaccinia C7L como regulador traduccional y de  apoptosis (ref. 212)  -Establecimiento de un sistema de imagen in vivo para el seguimiento de la infecci\u00f3n en tejidos de ratones inoculados con poxvirus virulentos y atenuados (ref. 222)  --Demostraci\u00f3n de un gen viral E3L capaz de revertir las defensas del hospedador y producir mayor sensibilidad a infecciones virales y parasitarias en modelo de rat\u00f3n transg\u00e9nico (230)   LINEA: DESARROLLO DE VACUNAS CONTRA ENFERMEDADES PREVALENTES. Estos estudios, pioneros en el campo de las vacunas,  han permitido establecer protocolos de inmunizaci\u00f3n combinada de vectores que inducen una fuerte respuesta inmune celular y protecci\u00f3n frente a distintos pat\u00f3genos. Estos protocolos se estan aplicando en ensayos cl\u00ednicos. El objetivo es modular el sistema inmune para provocar un mayor control de pat\u00f3genos y tumores.  -Descubrimiento de que la inmunizaci\u00f3n combinada con dos vectores distintos (prime/booster) aumenta consider\u00e1blemente la respuesta inmune celular frente a un ant\u00edgeno, dando lugar a una alta protecci\u00f3n contra un pat\u00f3geno que expresa dicho ant\u00edgeno(ref. 103)  -Establecimiento del ensayo ELISPOT para cuantificar a los linfocitos CD8+ que son espec\u00edficamnte activados en procesos de vacunaci\u00f3n (ref. 105).   -Establecimiento de protocolos de inmunizaci\u00f3n combinada que inducen protecci\u00f3n frente a malaria y caracterizaci\u00f3n de la respuesta inmune humoral y celular (ref. 103, 112,131,147,158,189)  -Establecimiento de protocolos de inmunizaci\u00f3n combinada que inducen protecci\u00f3n frente a leishmaniasis y caracterizaci\u00f3n de la respuesta inmune (ref. 94, 159, 176, 180, 183, 286)  -Desarrollo de una vacuna contra leishmania infantum (ref. 203, 209, 234; Solicitud de invenci\u00f3n N\u00ba 200501886)  -Demostraci\u00f3n del incremento de c\u00e9lulas memoria y protecci\u00f3n frente a leishmaniasis por activaci\u00f3n intradermal de c\u00e9lulas NFKTi en inmunizaci\u00f3n conjunta de vectores virales y adyuvantes (234)   71 -Establecimiento de protocolos de inmunizaci\u00f3n combinada que inducen una fuerte respuesta celular sist\u00e9mica y de mucosas espec\u00edfica frente a ant\u00edgenos del VIH-1 con valor progn\u00f3stico en protecci\u00f3n contra el Sida ( ref. 133,142,182,194)  -Demostraci\u00f3n del papel de las citoquinas IL-12, IL-18, GM-CSF e IFN-\u03b3  en la respuesta inmune frente a distintos ant\u00edgenos y su efecto en protecci\u00f3n contra pat\u00f3genos (ref. 135,141,154,180, 186,191)  -Generaci\u00f3n de vectores recombinantes con potencial cl\u00ednico frente al sida, malaria y leishmania (ref 51,75,86,146,151,171,183,189)   -Desarrollo de dos vacunas contra el VIH/SIDA basadas en MVA frente a los subtipos B y C, que representan el 80% de los casos de SIDA en el mundo (Patent US 8,871,219 B2, 28/10/2014; ref. 218, 219)  -Demostraci\u00f3n en ensayos precl\u00ednicos en monos, que los vectores MVA y NYVAC inducen distinto tipo de respuestas celulares frente a ant\u00edgenos del VIH/SIV y confieren una alta protecci\u00f3n frente al virus pat\u00f3geno SHIV89.6p (ref. 232).  -Demostraci\u00f3n en monos de que se pueden administrar los vectores MVA y NYVAC por via respiratoria y conseguir niveles semejantes de activaci\u00f3n de la respuesta inmune que por inyecci\u00f3n de los mismos vectores. Esta aplicaci\u00f3n facilida vacunar frente a SIDA  a una gran poblaci\u00f3n en paises pobres (ref. 231).  -Demostraci\u00f3n en ensayo cl\u00ednico profil\u00e1ctico en fase I que el protocolo DNA/NYVAC induce una alta inmunogenicidad (mas del 90% de los vacunados) frente a los ant\u00edgenos del VIH, manteni\u00e9ndose esta respuesta inmune durante m\u00e1s de un a\u00f1o con activaci\u00f3n polifuncional de la poblaci\u00f3n de c\u00e9lulas T CD4 y CD8+ (ref. 233, 236).    -Demostraci\u00f3n que el vector MVA-B en c\u00e9lulas dendr\u00edticas humanas activa la expresi\u00f3n de genes inmunomoduladores con actividad polifuncional (255, 268).  -Demostraci\u00f3n en ensayo cl\u00ednico en fase I con el vector MVA-B administrado en tres dosis a individuos sanos, que esta vacuna induce una potente respuesta inmune en la mayor parte de los voluntarios, siendo polifuncional y duradera ( 269, 270).  -Generaci\u00f3n de nuevos vectores de NYVAC ( 266, 276, 283) y MVA (256, 259, 271, 280, 281) con mayor capacidad para activar respuesta inmunes de amplio rango y duraderas frente al VIH.  -Desarrollo de protocolos de inmunizaci\u00f3n con mayor capacidad para activar c\u00e9lulas dendr\u00edticas (241, 260, 264).  -Desarrollo de una candidato vacunal frente a c\u00e1ncer de pr\u00f3stata (263) y vectores oncol\u00edticos (345).  -Desarrollo de un candidato vacunal frente a gripe (275).  -Desarrollo de un candidato vacunal frente a malaria con inducci\u00f3n de esterilidad (284; patente solicitud P201131854).  -Identificaci\u00f3n del gen C6L de vaccinia como inhibidor del interferon beta y su aplicaci\u00f3n en vacunas de poxvirus (271; solicitud de patente P201131230).  -Desarrollo de un candidato vacunal frente al virus de la hepatitis C (295): patente solicitud P201330467  -Desarrollo de un candidato vacunal frente al virus Chikungunya con 100% de protecci\u00f3n: patente solicitud PCT/EP2014/076310, 2 Dic 2014 (303, 309, 310, 320, 333, 340).  -Identificado un nuevo mecanismo de activaci\u00f3n de la respuesta immune por poxvirus (317, 321).  72  -Modificaci\u00f3n de promotores del virus vaccinia con mayor capacidad para expresar ant\u00edgenos heter\u00f3logos e incrementar la respuesta immune (299, 322)  -Generado un prototipo vacunal frente al VIH basado en el vector NYVAC que expresa la protein Gp140 en forma trim\u00e9rica y Gag como VLPs junto con Pol-Nef del subtipo C del VIH y demonstraci\u00f3n de su capacidad inmunog\u00e9nica en modelos de rat\u00f3n y de monos (314, 324).  -Demostraci\u00f3n en ensayo cl\u00ednico terap\u00e9utico en fase I con el vector MVA-B administrado en tres dosis a individuos infectados por VIH y en terapia antirretroviral (cART), que la vacunaci\u00f3n induce activaci\u00f3n de c\u00e9lulas T CD4 y reduce de forma transitoria la viremia despu\u00e9s de la retirada de cART (315).   \u2013Demonstraci\u00f3n de marcadores inmunes, celulares y humorales, que se correlacionan con protecci\u00f3n frente al VIH en modelo de macacos tratados con la vacuna basada en NYVAC-KC replicativo (336).  -Desarrollo de candidatos vacunales frente al virus de ebola con protecci\u00f3n del 80% (347)    Resumen de Investigaci\u00f3n del grupo POXVIRUS Y VACUNAS  Los objetivos fundamentales de nuestro laboratorio van dirigidos a comprender las bases moleculares en la patogenia de agentes infecciosos y su relaci\u00f3n con el huesped, as\u00ed como utilizar estos conocimientos para desarrollar vacunas que puedan ser efectivas en el control de enfermedades prevalentes con gran impacto en la poblaci\u00f3n. Como sistema modelo de agente infeccioso y como vector de expresi\u00f3n, utilizamos  el virus vaccinia que pertenece a la familia de los poxvirus. Las l\u00edneas de investigaci\u00f3n  son:   1. Mecanismo de ensamblaje del virus vaccinia.   El ensamblaje del virus vaccinia, y en general de los poxvirus, es un proceso complejo en el que intervienen mas de 100 prote\u00ednas y cuyo estudio puede aportar conocimientos relevantes en biolog\u00eda. Nuestros trabajos van dirigidos a conocer a nivel molecular y celular c\u00f3mo se forman las membranas y los cores virales para dar lugar a part\u00edculas infectivas. Utilizando mutantes condicionales para determinados genes virales y su estudio ultraestructural por microscopia electr\u00f3nica de c\u00e9lulas infectadas, llevado a cabo en colaboraci\u00f3n con C.Risco y J.L.Carrascosa (CNB), hemos demostrado el pap\u00e9l que  distintas prote\u00ednas del core (A4L, A10L) y de la membrana (A14L, A17L, A27L) viral ejercen en los procesos morfogen\u00e9ticos. El objetivo a largo plazo es identificar todos los estad\u00edos de morfog\u00e9nesis, el pap\u00e9l de las prote\u00ednas de membrana en ensamblaje, su modo de interacci\u00f3n y definir por t\u00e9cnicas de alta resoluci\u00f3n la organizaci\u00f3n estructural del virion y la estructura tridimensional de algunas de estas prote\u00ednas.    2. Mecanismos de acci\u00f3n antiviral y  antitumoral de los interferones  Durante a\u00f1os, nuestro grupo viene trabajando sobre el mecanismo de acci\u00f3n de los interferones (IFN), debido al  papel tan importante que este tipo de mol\u00e9culas biol\u00f3gicas juegan como primera l\u00ednea de defensa del organismo frente a infecciones, como inhibidores del crecimiento celular con efecto antitumoral y como reguladores del sistema inmune. Hemos estudiado, en sistemas inducibles, el papel que enzimas inducidas por IFN pueden tener como antivirales y antitumorales: proteinas 2-5A sintetasa/RNasa L, \u00f3xido n\u00edtrico sintetasa (iNOS) y proteina quinasa p68 (PKR). Nuestros estudios futuros van dirigidos a conocer el receptor que activa la se\u00f1alizaci\u00f3n de PKR, todas las prote\u00ednas con las que interacciona formando un complejo, su papel en la regulaci\u00f3n de la s\u00edntesis de prote\u00ednas, as\u00ed como los genes celulares que son activados, aplicando las tecnolog\u00edas de gen\u00f3mica, prote\u00f3mica y modelos celulares y animales. Tambi\u00e9n estamos estudiando el papel de varios genes virales (E3L de VV, MC159L de molluscum contagiosum, sigma 2 de reovirus aviar, LANA3 de herpesvirus 8 y E2-NS5A de HCV), as\u00ed como celulares (PACT, p67, NF90, ISG15) como reguladores del proceso antiviral y de apoptosis inducido por IFN. Esta investigaci\u00f3n puede beneficiar la aplicaci\u00f3n  cl\u00ednica del IFN en terapia antiviral y antitumoral   73 3. Interacci\u00f3n virus-c\u00e9lula    Por microarrays de DNA hemos identificando genes celulares inducidos en respuesta a la infecci\u00f3n por VV (estirpe salvaje y mutantes) y por acci\u00f3n de est\u00edmulos apopt\u00f3ticos. Nuestro objetivo es identificar genes celulares importantes en el proceso infectivo y apopt\u00f3tico y desarrollar modelos celulares y  animales para su estudio funcional. Estos estudios ayudar\u00e1n a entender los mecanismos de patog\u00e9nesis viral y c\u00f3mo el hu\u00e9sped responde a la infecci\u00f3n. Recientemente hemos descubierto la prote\u00edna celular WASP como responsable de la transmisi\u00f3n del virus en animales y la proteina ISG15 como inhibidor de la replicaci\u00f3n viral.    4. Desarrollo de vacunas contra enfermedades prevalentes.    Nuestro laboratorio est\u00e1 desarrollando estrategias de inmunizaci\u00f3n contra VIH, hepatitis C, chikungunya, malaria, leishmania, ebola y c\u00e1ncer de pr\u00f3stata basadas en la utilizaci\u00f3n de recombinantes del virus vaccinia, estirpes MVA y NYVAC. Nuestro grupo ha sido pionero en el establecimiento de protocolos de inmunizaci\u00f3n combinada de vectores que inducen una fuerte respuesta inmune y protecci\u00f3n frente a pat\u00f3genos en modelo murino de malaria (Plasmodium yoelii) y  leishmania (L. major y L.infantum). Estos estudios han permitido definir par\u00e1metros b\u00e1sicos para conseguir la inducci\u00f3n primaria de linfocitos T CD8+ y las condiciones para generar una fuerte respuesta secundaria, lo que puede tener inter\u00e9s para el desarrollo de estrategias profil\u00e1cticas y terap\u00e9uticas para prevenir enfermedades infecciosas y tumorales. Con el fin de modular la respuesta inmune frente a ant\u00edgenos de inter\u00e9s, estamos evaluando el efecto sobre dicha respuesta (sist\u00e9mica y de mucosas) de la coexpresi\u00f3n de diversas citoquinas (IL-12, IFN-\u03b3, GM-CSF, IL-18, IL-15) y de adyuvantes como mega CD40L. En colaboraci\u00f3n con otros grupos, hemos llevado a cabo con alguna de las vacunas generadas por nosotros, ensayos de protecci\u00f3n en perro frente a leishmaniasis y frente al SIV en macacos, que han demostrao su eficacia. Tambi\u00e9n  formamos parte del grupo europeo de desarrollo de una vacuna contra VIH/SIDA (EuroVacc), habiendo demostrado que la combinaci\u00f3n de vectores de DNA y de poxvirus (NYVAC) inducen una alta respuesta inmune frente al VIH con activaci\u00f3n de c\u00e9lulas T CD4+ y CD8+ en ratones, macacos y humanos. En 2009 iniciamos en Espa\u00f1a el primer e n s a y o  c l \u00ed n i c o  e n  f a s e  I  c o n  l a  vacuna MVA-B generada por mi grupo en el CNB c o n  r e s u l t a d o s  m u y  p o s i t i v o s  d e  i n m u n o g e n i c i d a d  y  e n  2012 iniciamos otro ensayo cl\u00ednico fase I con individuos VIH positivos, con resultados prometedores. Como parte de proyectos de colaboraci\u00f3n con la Fundaci\u00f3n Bill y Melinda Gates, as\u00ed como junto con consorcios europeosx financiados en el programam H2020, llevaremos a cabo varios ensayos en macacos y en humanos para determinar el protocolo \u00f3ptimo de inmunizaci\u00f3n y su eficacia frente al VIH. Estamos mejorando la capacidad de los vectores de poxvirus por modificaci\u00f3n gen\u00e9tica mediante deleciones espec\u00edficas en genes que bloquean la respuesta inmune del hospedador para futuros ensayos cl\u00ednicos, as\u00ed como la combinaci\u00f3n de inmun\u00f3genos con el objetivo de eliminar los reservorios del VIH en el organismo.  5. Desarrollo de vacunas contra hepatitis C, chikungunya, ebola y c\u00e1ncer de pr\u00f3stata.  Nuestro objetivo es desarrollar una vacuna basada en un procedimiento de inmunizaci\u00f3n combinada de vectores (\u201cprime/boost\u201d), que expresan la poliproteina del virus de la hepatitis C (VHC). Hemos conseguido un virus recombinante de vaccinia, estirpe MVA, que expresa todas las prote\u00ednas del VHC-1a de forma constitutiva y que induce respuestas inmunes amplias frente a HCV en modelos animales. Estamos optimizando el vector por deleci\u00f3n de genes inmunomoduladores para conseguir una mayor potenciaci\u00f3n de la respuesta inmune humoral y celular.  Reci\u00e9ntemente hemos generado un vector de MVA-CHIKV que expresa todas las prote\u00ednas estructurales del virus chikungunya y demostrado su capacidad protectiva esterilizante en modelo murino. Estos estudios se han extendido al modelo de macaco con resultados semejantes al modelo murino y queremos llevar  esta vacuna a fases cl\u00ednicas. Tambien hemos generado un vector de MVA-ebola que expresa los ant\u00edgenos GP y VP40 del virus ebola y que en modelo de rat\u00f3n protege en un 80% frente a la infecci\u00f3n por el virus mortal de ebola, estirpe Zaire.  Recientemente hemos iniciado un proyecto de dise\u00f1o de vacunas contra c\u00e1ncer de pr\u00f3stata y hemos clonado varios genes que se expresan selectivamente en tumores prost\u00e1ticos. Disponemos de modelos de rat\u00f3n que  74 producen tumores de pr\u00f3stata y que son de utilidad para establecer procedimientos de inmunizaci\u00f3n que generen protecci\u00f3n frente la aparici\u00f3n de tumores en dichos animales. Se han obtenido resultados de reducci\u00f3n de tumores prost\u00e1ticos mediante vacunaci\u00f3n con nuestros vectores. Para mejorar la eficacia antitumoral estamos desarrollando nuevos vectores con capacidad oncol\u00edtica. Es predecible que la combinaci\u00f3n de la capacidad oncol\u00edtica e inmunog\u00e9nica de vectores de poxvirus sea la mas eficaz para el control tumoral.        Research:  The main objectives of our laboratory are geared to understand the molecular basis in the pathogenesis of infectious agents and their interaction with the host, as well as to use this knowledge in the development of vaccines that might be effective against prevalent diseases like HIV/AIDS, hepatitis C, chikungunya, malaria, leishmaniasis and prostate cancer. As a model system of infectious agent and as a delivery vector for expression of genes of interest, we used vaccinia virus (VV) a member of the poxvirus family. The research areas of our lab are.  1. Vaccinia virus (VV) assembly.  VV assembly is a complex process in which more than 100 proteins participate, and by studying this process we might also provide important insights in cell biology. Our objectives are to understand, at the molecular and cellular levels, how viral membranes and cores are formed, and what are the viral proteins involved in these events that lead to virion assembly  2.  Mechanism of antiviral and anticellular action of interferons.   For years, our laboratory has been investigating the mechanism of action of interferons (IFN), since these molecules play major roles as a first-line host defense against viral infections, tumor cell growth and regulation of the immune system. We have provided important insights into the mechanism of apoptosis action by the IFN-induced ds-RNA dependent protein kinase (PKR), and we have identified the inhibitory effects exerted over PKR by some viral genes. The role of these proteins in defense, particularly on innate immune responses is being investigated.  3. Virus-host cell interactions  How poxviruses alter host cell responses following virus infection is a poorly characterized process. Our objective is to know the impact of vaccinia virus on host cell gene expression profiling in order to identify cellular genes relevant for VV replication as well as for host cell defense, and to develop cell culture and animal models for functional gene studies. To this aim, we used microarrays to identify cellular genes specifically induced in the course of virus infection using virulent and attenuated VV strains with potential as human vaccines. A number of host genes have been identified and their role in virus pathogenesis is being investigated using animal model systems.  5. Developmen of vaccines against prevalent diseases. Our laboratory has been developing immunization strategies against HIV, malaria and leishmania based on the use of VV recombinants. We have pioneered the development of protocols based on heterologous immunization approaches (prime/booster) with vectors that induced enhanced cellular immune responses, leading to protection in murine models against malaria (Plasmodium yoelii) and leishmania (L. major and L. infantum). These studies have defined immunological parameters to expand CD8+ T cells during primary and secondary immunizations, with significance in the development of prophylactic and therapeutic strategies against infectious agents and tumor diseases. We have engineered potential vaccines against HIV/AIDS and phase I clinical studies are underway. Novel vaccines with enhanced immunogenicity against HIV are being developed in our lab for testing in non-human primate models, as well as we are producing new vaccines against hepatitis C, chikungunya, ebola, leishmania and cancer.   75  Scientific, technological and socioeconomic impact   In spite of the spectacular scientific advances provided by the new technologies, genomics, proteomics and bioinformatics, and the elucidation of the human genome, the genomes of other species and of many microorganisms, we find ourselves in the XXI century with major diseases for which there is no cure, like AIDS (25 million (M) deaths and 40M infections), malaria (300 M infections and 0.5M deaths/year mostly childrem), tuberculosis (1.5 M deaths/year), hepatitis C (300 M infections), leishmaniasis (12 M infections), and cancer (the second leading cause of human deaths). WHO considers a priority to develop  prophylactic and therapeutic vaccines against these different deathly diseases. Our group at the CNB has developed two prototype vaccines against HIV/AIDS based on subtypes B (MVA-B) and C (MVA-C) that account for nearly 80% of all HIV infections wordlwide (patent PCT/ES2006/070114).  In preclinical studies in mice and in macaques the prototype vaccines  expressing four HIV antigens (Env/Gag-Pol-Nef) have fulfilled the expected characteristics of a potential good vaccine, ie, high immunogenicity, elicit in monkeys protection after challenge with pathogenic simian immunodeficiency virus, the vaccines can be safely delivered by aerosol which facilitates their easy administration specially in poor countries, and when given to human healthy volunteers triggered HIV-specific T-cell immune responses in over 90% of volunteers, being the immune response polyfunctional and durable. With the vaccine prototype MVA-B,  we have performed in Spain two phase I clinical trials in healthy and HIV-infected individuals, that has received wide attention by the media. Both trials showed good immunological for HIV-specific CD4 and CD8 T cells. We are improving the poxvirus vectors and combination of immunogens to obtain stronger immune responses, humoral and celular, with broad specificities.  Our group has also generated potential vaccines agains leishmaniasis (patent  PCT/ES2006/070122), malaria,  hepatitis C (patent PCT/ES2014/070246), chikungunya (patent PCT/EP2014/076310), ebola and prostate cancer, all of which are now under preclinical and patent evaluation. Our current studies are focus in the development of optimized vaccines, understanding the role of immune cells in protection against human diseases and use of these vaccines in human clinical trials.    GRUPO DE INVESTIGACI\u00d3N   Mariano Esteban- Profesor de Investigaci\u00f3n del CSIC Carmen E. G\u00f3mez-contrato postdoctoral Beatriz Perdiguero-contrato postdoctoral Juan F. Garcia-contrato postdoctoral Liliana Carre\u00f1o-postdoctoral Mauro di Pilato, predoctoral Ernesto Mej\u00edas, predoctoral Suresh Chithathur, predoctoral Mar\u00eda Quir\u00f3s-predoctoral Patricia P\u00e9rez, predoctoral   Mar\u00eda Victoria Jim\u00e9nez-T\u00e9cnico especialista Cristina S\u00e1nchez, T\u00e9cnico    Breve C.V (espa\u00f1ol):  MARIANO ESTEBAN RODRIGUEZ  Centro Nacional de Biotecnologia, CSIC, Campus Universidad Aut\u00f3noma, Darwin 3, 28049 Madrid. Tel:34-91-585-4553; Fax:34-91-585-4506; Email:mesteban@cnb.csic.es.   Mariano Esteban, es Presidente de la Real Academia Nacional de Farmacia (RANF), Presidente del Instituto de Espa\u00f1a, Profesor de Investigaci\u00f3n vinculado Ad Honorem del Centro Nacional de Biotecnolog\u00eda (CNB) del  76 CSIC y Jefe del grupo de Poxvirus y Vacunas del CNB. Es natural e hijo predilecto de Villal\u00f3n de Campos (Valladolid), se licenci\u00f3 en Farmacia (1967) y en Ciencias Biol\u00f3gicas (1972), obteniendo el t\u00edtulo de Doctor en 1970  en la especialidad de Microbiolog\u00eda por la Facultad de Farmacia, Universidad de Santiago de Compostela.  Entre 1970-74 trabaj\u00f3 como postdoctoral en el Centro Nacional de Investigaciones M\u00e9dicas de Londres (MRC) con David Metz e Ian Kerr s o b r e  m e c a n i s m o  d e  a c c i \u00f3 n  d e  l o s  i n t e r f e r o n e s  y  s \u00ed n t e s i s  d e  p r o t e \u00ed n a s, siendo contratado posteriormente, 1974-77, como Instructor en el Departamento de Microbiolog\u00eda de la Facultad de Medicina de la Universidad de Rutgers en Nueva Jersey, Estados Unidos de Am\u00e9rica, con John Holowzack sobre replicaci\u00f3n del DNA. Tras una breve estancia en 1978 en el Centro de Biolog\u00eda Molecular de Gante en B\u00e9lgica con Walter Fiers s o b r e  s e c u e n c i a c i \u00f3 n  d e l  g e n o ma  d e  v i r u s, le fue concedida en 1979 una plaza de Profesor Titular en el Departamento de Bioqu\u00edmica de la Facultad de Medicina en la Universidad del Estado de Nueva York (SUNY), pasando luego a ser nombrado en 1982 Profesor Asociado con nivel funcionario y en 1985 Profesor (Catedr\u00e1tico) de los Departamentos de Bioqu\u00edmica y de Microbiolog\u00eda e Inmunolog\u00eda de la mencionada Facultad de Medicina, donde trabaj\u00f3 sobre acci\u00f3n de los interferones y vacunas.  En 1987  fue nombrado Profesor de Investigaci\u00f3n del Consejo Superior de Investigaciones Cient\u00edficas. En 1992, tras una estancia de 22 a\u00f1os en el extranjero, regresa a Espa\u00f1a para dirigir el nuevo Centro Nacional de Biotecnolog\u00eda (CNB) del CSIC, cargo que ocup\u00f3 d u r a n t e  1 1  a \u00f1 o s .  E n  u n  p e r \u00ed o d o  c o r t o  r e c l u t \u00f3  e x c e l e n t e s  l\u00edderes cient\u00edficos y el Centro adquiri\u00f3 credibilidad internacional como lugar de excelencia en investigaci\u00f3n biotecnol\u00f3gica en las \u00e1reas de salud humana y animal, agricultura y medio ambiente. Adem\u00e1s, el CNB fue un polo de atracci\u00f3n de empresas estableciendo modelos de colaboraci\u00f3n con compa\u00f1\u00edas nacionales e internacionales. El CNB ha sido evaluado varias veces por C o m i t \u00e9s C i e n t \u00ed f i c os I n t e r n a c i o n a les que lo consideran c o m o  \u201c c e n t r o  de excelencia en biotecnolog\u00eda\u201d, siendo actualmente Centro de Excelencia Severo Ochoa.   El inter\u00e9s de las investigaciones de Mariano Esteban se han centrado en el conocimiento de la biolog\u00eda molecular de agentes pat\u00f3genos como los virus, para de esta forma desarrollar procedimientos que permitan el control de enfermedades infecciosas. Sus descubrimientos sobre la biolog\u00eda del virus vacunal, que fue utilizado como vacuna para erradicar la viruela, le ha servido para generar n u e v a s  vacunas contra enfermedades prevalentes como el sida, hepatitis C, virus chikungunya, malaria y leishmania, habiendo sido pionero en el campo de la vacunas al desarrollar procedimientos de inmunizaci\u00f3n combinada de vectores (prime/boost) que incrementan la respuesta inmune celular y confieren protecci\u00f3n frente a distintos pat\u00f3genos. Estos protocolos de vacunaci\u00f3n est\u00e1n siendo experimentados en ensayos cl\u00ednicos de fase  I/II contra pat\u00f3genos y c\u00e1ncer. Su grupo est\u00e1 participando en el programa EuroVacc y de la Fundaci\u00f3n Bill y Melinda Gates para el desarrollo de una vacuna contra el SIDA habiendo generado dos vacunas contra el VIH, subtipos B y C, que han sido analizadas en ensayos clinicos en fase I/II en Espa\u00f1a y Reino Unido con buenos resultados inmunol\u00f3gicos y otros prototipos vacunales con la estirpe NYVAC que se est\u00e1n ensayando en Europa y EE.UU y pr\u00f3ximamente en \u00c1frica. A c t u a l m e n t e  h a  i n i c i a d o  e l  d e s a r r o l l o  d e  n u e v a s  v a c u n a s  c o n t r a  enfermedades emergentes (chikungunya, ebola, zika), neurodegenerativas (Alzheimer) y c\u00e1ncer de pr\u00f3stata, as\u00ed como una nueva generaci\u00f3n de vectores con mayor capacidad inmunog\u00e9nica y oncol\u00edtica.  Las contribuciones cient\u00edficas de Esteban sobre el modo de acci\u00f3n de los interferones han sido pioneras, potenciando el inter\u00e9s cl\u00ednico de estos f\u00e1rmacos como agentes antivirales y antitumorales. Estudios recientes en su laboratorio han demostrado el papel que varios de los genes inducidos por los interferones tienen como reguladores de la muerte celular programada (apoptosis), lo que servir\u00e1 para establecer pautas terap\u00e9uticas m\u00e1s eficaces en el uso de los interferones en pacientes con tumores y en terapia g\u00e9nica.  Estas contribuciones cient\u00edficas representan m\u00e1s de 340 t r a b a j o s  p u b l i c a d o s  e n  r e v istas internacionales de impacto, 10 patentes y mas de 330 comunicaciones en congresos nacionales e  internacionales.   Sus investigaciones en Estados Unidos de Am\u00e9rica fueron financiadas por los Institutos Nacionales de Salud (NIH) y la Fundaci\u00f3n Nacional de las Ciencias (NSF). Desde su regreso a Espa\u00f1a, sus investigaciones est\u00e1n siendo financiadas por la Uni\u00f3n Europea, NIH, el Plan Nacional de Investigaci\u00f3n y Desarrollo, Fondo de Investigaci\u00f3n Sanitaria, Comunidad Aut\u00f3noma de Madrid, Fundaci\u00f3n para la Investigaci\u00f3n sobre el Sida  77 (FIPSE)  y varias empresas. En el a\u00f1o 2005 obtuvo un acuerdo de colaboraci\u00f3n con la Fundaci\u00f3n Bot\u00edn para realizar investigaciones en vacunas contra enfermedades prevalentes y tambi\u00e9n su grupo fue galardonado en 2006 con un proyecto por la Fundaci\u00f3n Bill y Melinda Gates para la generaci\u00f3n de una vacuna contra el VIH/SIDA, que contin\u00faa hasta el 2017. Participa en la Red de Sida y en dos proyectos europeos H2020 con duraci\u00f3n hasta el a\u00f1o 2021.   En su laboratorio se han formado estudiantes de varias nacionalidades y recibe peri\u00f3dicamente Profesores visitantes. Ha dirigido 30 T e s i s  D o c t o r a l e s  y  a c t u a l m e nte trabajan en su laboratorio 12 p e r s o n a s ,  p r e  y  posdoctorales de distintas nacionalidades. Participa en actividades acad\u00e9micas de Master con la Universidad Aut\u00f3noma de Madrid, (UAM), de la que es Profesor Honor\u00edfico, habiendo coordinado el curso de Enfermedades Infecciosas y Sistema inmune.   Mariano Esteban ha sido y es m i e m b r o  d e  p r e s t i g i o s a s  s o c i e d a d e s  i n t e r n a c i o n a l e s  ( A m e r i c a n  S o c i e t y  o f  Microbiology; American Society of Virology; British Society of Microbiology; Spanish Society of Microbiology; Harvey Society; The Society of Sigma Xi; New York Academy of Sciences; American Association for the Advancement of Science). Miembro Editorial, y evaluador de art\u00edculos de revistas prestigiosas y de proyectos nacionales e internacionales. Ha participado en varios Comites Europeos (Member of the European Action Programme Against AIDS. 1994-1997; Member of the COST /STD Initiative for a European Vaccine Program,1994-97; Member of the European Concerted Action Against Malaria, 1996-98; Member of External Advisory Group (EAG) of the European Commission, key action 2, Control of Infectious Diseases, Fifth Framework Programme,(1998-2002). Member of WHO Advisory Committee on Variola Virus Reseach, 1998-actual. Member of Strategic Advisory Group of Experts (SAGE) for Vaccines and Biologicals, WHO, 2003-2007. Member of Advisory Group for the Science Foundation of Ireland, 2000. Member of European Science Foundation (ESF) Group for Research Infraestructures on Biomedical Sciences, 2003, y nacionales (ANEP; Grandes Instalaciones Cient\u00edficas, 2003-2013). En 2013 fue nombrado miembro del Comit\u00e9 Cient\u00edfico Asesor del CSIC.   Ha impartido un gran n\u00famero de conferencias en varios pa\u00edses, organizado cursos, workshops. Ha organizado congresos internacionales: Presidente, XI International Poxvirus and Iridovirus Meeting, Toledo, 1996; Presidente, Fifth European Conference on Experimental AIDS Research (ECEAR-2000), Madrid, Co-Presidente II European Virology Congress (EuroVirology-2004) en Madrid y Co-Chair  del 7th Vaccine & ISV congress- 2013 in Sitges, Spain.  Ha obtenido varias distinciones cient\u00edficas, entre ellas, el premio del Consejo de Salud de Nueva York, premio de la Universidad del Estado de Nueva York, Farmac\u00e9utico del A\u00f1o. Premio IBERDROLA de Ciencia para Profesores visitantes. Premio de la Sociedad Espa\u00f1ola de Virolog\u00eda. Ha sido fundador y Presidente de la primera asociaci\u00f3n de profesionales espa\u00f1oles en el extranjero, Asociaci\u00f3n de Licenciados y Doctores Espa\u00f1oles en Estados Unidos (ALDEEU), habiendo recibido en 2012 el medall\u00f3n de ALDEEU. Es fundador y miembro de la Fundaci\u00f3n Europea contra el Sida (EuroVacc). En 2006 fue nombrado Acad\u00e9mico de N\u00famero de la Real Academia Nacional de Farmacia (RANF) de Espa\u00f1a y en Diciembre de 2012 fue elegido Presidente de la RANF, habiendo sido reelegido de su cargo en 2015. En octubre de 2017 fue nombrado Presidente del Instituto de Espa\u00f1a, instituci\u00f3n que integra a las diez Reales Academias.  Actualmente el grupo de Mariano Esteban tiene dirigida la investigaci\u00f3n hacia la traslaci\u00f3n de la investigaci\u00f3n b\u00e1sica a la cl\u00ednica, basado en la generaci\u00f3n de nuevas vacunas contra enfermedades emergentes, optimizaci\u00f3n de vectores de poxvirus MVA y NYVAC como vacunas, identificaci\u00f3n de los mecanismos inmunes y su correlaci\u00f3n con protecci\u00f3n frente a pat\u00f3genos. El objetivo final es obtener vacunas seguras y eficaces contra distintas enfermedades humanas como el sida, hepatitis C, chikungunya, ebola, zika, malaria, leishmania, Alzheimer y c\u00e1ncer.   GRUPO DE INVESTIGACI\u00d3N   Mariano Esteban- Profesor de Investigaci\u00f3n del CSIC Carmen E. G\u00f3mez-Contrato postdoctoral  78 Beatriz Perdiguero-Contrato postdoctoral Juan F. Garcia-contrato postdoctoral FIS Liliana Carre\u00f1o-postdoctoral Mauro di Pilato, becario predoctoral Ernesto Mej\u00edas, predoctoral Suresh Chithathur, predoctoral Mar\u00eda Quir\u00f3s, predoctoral Patricia P\u00e9rez, predoctoral   Mar\u00eda Victoria Jim\u00e9nez-T\u00e9cnico especialista Cristina S\u00e1nchez, T\u00e9cnico      SHORT CV (English): MARIANO ESTEBAN  Centro Nacional de Biotecnologia, CSIC, Campus Universidad Aut\u00f3noma, Darwin 3, 28049 Madrid, Spain; Tel:34-91-585-4553; Fax:34-91-585-4506; Email:mesteban@cnb.csic.es.    Mariano Esteban is Professor of the Spanish Research Council (CSIC) at the National Center of Biotechnology (CNB) in Madrid, Spain and Head of the Poxvirus and Vaccines Group. He obtained his PhD at the School of Pharmacy, University of Santiago de Compostela and spent 22 years abroad in various centers; postdoctoral (1970-74) at the National Institute for Medical Research, Mill Hill (London); Instructor (1974-77) at the Department of Microbiology, Rutgers Medical School, Piscataway, New Jersey, USA; research scientist (1978) at the Molecular Biology Institute, Ghent, Belgium; Assistant (1979-82), Associate (1982-85) and full Professor (1985-92) of SUNY at the Department of Biochemistry, Downstate Medical Center, Broklyn, New York. In 1987 he was appointed Professor of Science by the Spanish Research Council of Spain (CSIC), and Director (1992-2003) of the newly created National Center for Biotechnology (CNB) in Madrid. Within a short time, he recruited excellent Group Leaders and the CNB won international credibility, as a place of excellence for basic and applied science in biotechnology in the areas of health, agriculture and environment.   Prof. Esteban is a well-recognised scientist with a long experience in molecular basis of pathogenesis by infectious agents and in translational research. In particular, his group in Spain has made major contributions on the biology of vaccinia virus, the mechanism of action of interferons and development of vaccines against major diseases like HIV/Aids, hepatitis C, chikungunya, malaria and leishmaniasis, some of which have advanced to phase I clinical trials (HIV). His research is supported by grants from national (MICINN; FIS; FIPSE, Foundation Bot\u00edn), international agencies (NIH, USA; Bill y Melinda Gates, European Union) and industries.  Prof. Esteban has published 347 articles in prestigious journals, 10 patents, directed 31 PhD thesis,  presented over 300 communications to international meetings and has given many seminars worldwide. He is a Member of a number of prestigious scientific international societies, Member of Editorial Boards and peer-review in major journals. He is also a Member of European and Spanish organizations.  He has organized international scientific meetings: President of XI International Poxvirus and Iridovirus Meeting, Toledo, 1996; President of the Fifth European Conference on Experimental AIDS Research (ECEAR-2000), Madrid; Vice-president of the European Virology meeting in Madrid, in 2004; Co-Chair of the 7Th Vaccine and ISV Congress-2013, Sitges, Spain. He participates in academic activities at the Autonomous University of Madrid, is founder of EuroVacc and of Spanish Professionals in the USA, member of the Royal Academy of Pharmacy of Spain (RANF), in 2012 was elected President, and in 2017 he became President of the Royal Society of Spain.   Vaccine achivements  79 Development of a vaccine against HIV/AIDS remains a major challenge in the control of this pandemic that has produced more than 30 m i l l i o n  d e a t h s  s i n c e  i t  w a s  f i r s t  d i a g n o s e d  i n  1 9 8 1  a n d  c o n t i n u e s  u n a b a t e d  worldwide. The group of Prof. Esteban at the CNB-CSIC has developed candidate vaccines against HIV/AIDS based on poxvirus vectors (MVA and NYVAC) that have shown excellent immunological profiles in animal models (mouse and macaques) and efficacy against simian immunodeficiency virus in macaques.  Moreover, some of these vectors have entered phase I clinical trials, both prophylactic and therapeutic, giving good HIV-specific immune responses in most of the volunteers. Further improvement of the immunization protocols has been achieved in monkeys. The aim is to enter phase II/III clinical trials with some of the Esteban\u00b4s developed candidate vaccines in the next few y e a r s .  P r o f .  E s t e b a n  H I V  r e s e a r c h  i s  s u p p o r t e d  b y  n a t i o n a l  a n d  international grants (i.e, Bill and Melinda Gates, EU) and collaborates actively with international teams in both Europe and USA. R e c e n t l y ,  h i s  g r o u p  h a s  d i s c o v e r e d  a  n e w  role of NF-kB and of neutrophils in immune responses to poxvirus vector vaccines and the full protective efficacy of a vaccine against chikungunya virus.  Our current studies are focus in the development of optimized vaccines against emerging human diseases, understanding the role of activated immune cells in protection against pathogens and the application of these vaccines in human clinical trials.  ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}